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ABSTRACT 
The effect of vaccination dose on the immune response of mice to Mycobacteriwn 
bovis B a d e  Calme~e Guerin (BCG) was examined. To assess T helper cell-type 1 
(Thl) and -type 2 (Th2) responses, a very sensitive ELISPOT assay was developed. 
Using this assay, the numbers of BCG-specific interferon y- and interleukin Cproducing 
spleen cells were used as indicators of the Thl md Th2 responses, respectively. IgGl and 
IgG2a serum antibody titers were also assessed. Mice were immunized with different 
doses of BCG, and their immune response to BCG antigen was determined at various 
times after vaccination. Low dose immunized mice developed predominantly Thl 
responses and tittle antibody, while those given higher numbers of bacilli generated a 
mixed Th l m  response and had signifcant antibody titers. Furthermore, mice given the 
lower doses of BCG developed an immune imprint that enabled them to resist 
development of a Th2 response on subsequent challenge with a higher dose of BCG, 
which generates a Th2 response in previously unexposed mice. The immune response of 
mice immunized with recombinant BCG (rBCG) expressing Escherichia coli P- 
galactosidase was also characterized. Thl cells predominated in the immune response to 
BCG antigen as well as to the expressed p-galactosidase antigen in low dose vaccinated 
mice. Moreover, the Thl response to both antigens was stable after high dose challenge 
of low dose vaccinated animals indicating that immune imprinting bad been established 
both to BCG and to the recombinant pgalactosidase antigen. 
The results indicate that the immune state that develops in mice upon vaccination 
with BCG depends on the initial dose of antigen administered, with low amounts of 
antigen leading to Thl immunity, and relatively high amaunts of antigen leading to Th2 
immune responses. Mycobacterium tuberculosis is only controlled effectively by a cell- 
mediated immune response. Immuni7ation with a relalively low dose of BCG, rather 
than the current standard dose, may provide greater immune protection against M. 
tuberculosis. Moreover. low dose vaccination with rBCG expressing proteins of 
leishmania or HlV promises to be an e&ctive means of vaccination against diseases 
caused by these pathogens, which can only be contained by a Thl response. 
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1 INTRODUCTION 
1.1 Law Dose Antigen Vaccination 
In 1958, Salvin demonstrated that guinea pigs immunized with ovalbumin or 
diptheria tuxoid in such a way that they developed an Arthus-type reaction, went through 
a period m which they displayed a delayed type hypersensitivity (DTH) response to the 
antigen (Salvin, 1958). After an initial latent period, the animals developed DTH hat was 
replaced several days iater by Arthus-type hypersensitivity. The time required to convert 
tiom the DTH to Arthus response was inversdy proportional to the sensitizing dose of 
antigen. Furthermore, when very Iow sensitizing doses of antigen were administered, 
only DTH responses deveIoped (Sdvin, 1958). The r d t s  suggested that the immune 
response follows a particular pattern of development. The initial, and often the only 
response to deveIop is of the cell-mediated type, followed th& by a humoraI 
response if the immunizing conditions are appropriate. I believe this to be a general 
principle of the immune system, that cell-mediated immune responses d l  always precede 
a n t i i y  responses in the deveIoping immune response. Recent studies by Lederer et al. 
(1996) and Bird (1998) suggest that indeed interferon y(lFNy) preceeds interleukin 4 (IL- 
4) in the deveIoping immune response. The studies of Salvin (1958) and Parish (1972) 
demonstrated that the dose of antigen administered has a significant impact on the type of 
immunity that is induced, with low doses favouring DTH and high doses favouring 
progression to an anti'body response- 
Asherson and Stone (1962) demonstrated that the devdopment of an mn'body 
response inhliited the abiiity of mice to develop DTH response to the same antigen, a 
state r e f d  to as humoral immune deviation. The work of Parish suggested that the 
inverse was also true. Rats immunized with low doses of antigen administered repeatedly 
over a number of days developed an exclusive and stable DTH response, and were unable 
to develop a sign8cant antibody response (Parish, 1972). These observations suggested 
that reciprocal control exists over the two arms of the immune response. Immunization in 
a manner that induces a stable all-mediated immune response could prevent the 
subsequent development of an a n t i i y  response and vice versa. Cells capable of 
suppressing DTH (TPTH) and antibody (TAb) responses were identified (in modem 
terminology) as CD4' and CD8' cells, respectively (Ramshaw et al., 1976; 1977). 
T helper (Th) cells are the choreographers of the immune response, involved in 
directing and controlling almost all aspects of immunity. In a simplified classification 
system, they are divided into two distinct groups based on the cytokines they produce 
(Mosrnann and Coffinann, 1987). Type 1 T helper cells (Thl cells) mediate DTH and 
help to activate cytotoxic T cells. They are charactaized by production of IFNy. 
interleukin 2 (IL-2), lymphotoxin and tumor necrosis factor (TNF) (Abbas et ai.. 1996; 
O'Garra, 1998). Type 2 T helper ceUs (Th2 cells) produce IL-4 and also interleukin 5 
(IL-5), interleukin 6 (IL-6) and interleukin I3 (IL-13) (Abbas et al., 19%; O'Garra, 
1998) and are important for anh'body production and immunity to parasitic infections. No 
doubt there are many subgroups within this classification, with cells producing various 
combinations of these cytokines. For the purpose of this discussion, cells that produce 
IFNy are dassed as Thl cells, whereas those that produce LL-4 are termed Th2 cells. This 
terminology will serve as IL-4 and IFNy represent cytokines that are dominant in 
regulating responses at opposite ends of the immune spectnnn. 
Some infectious agents can be controUed by an antibody (Th2) response while 
others are only effectively eliminated by a cell-mediated 0 1 )  immune response. The 
induction of an inappropriate response will be ineffective at preventing or curing disease 
and may even be exacerbating (Sher et al., 1992). It is therefore imperative that the 
appropriate immune response be generated with vaccinatio~ Leishmania parasites are an 
exampIe of a disease for which a cell-mediated response is required to provide effective 
immunity ( Lockley and Scott, 1991; Lacksley et al., 1999). Inbted mouse strains can 
be classified as susceptible or resistant to leishmania infection depending on the type of T 
helper cells that they generate upon infection with a relativeIy large number of parasites. 
Those strains that develop a Thl response resist the infection and cure the lesion, while 
the infection progresses in those that mount a Tb2 response, In an interesting set of 
experiments, Bretscher et al. demonstrated that BALB/c mice, the prototypic susceptible 
strain, were able to resist an infection with a low number of parasites and, in time, 
became immune to a Iarger, normaIIy pathogenic dose, Analysis of the immune response 
showed that the low dose infection induced a ThI response, which was maintained even 
after the high dose exposure (Bretscher, I992a; Menon and Bretscher, 1996; 1998). This 
work not ody demonstrated the efficacy of low dose infection for inducing ThI cells, but 
also demonstrated that immune deviation or imprinting can be achieved by this method. 
This is an important aspect for vaccine research as it demonstrates that a polarized 
response can be achieved and also maintained upon subsequent challenge. 
Mycobacteria are similar to leishmania in that they are both slow growing 
intraceUular organisms that infect cells of the monocyte lineage, and a Thl response is 
necessary to provide protection fkom both pathogens. In this thesis, I have chamcterized 
the immune response of mice after vaccination with Bacille CaIrnette Guerin (BCG), an 
attenuated strain of Mycobacterium bovis, and recombinant BCG (rBCG). The 
implications of the observations are discussed in the context of immune regulation and 
vaccination against tuberculosis (lB) and other diseases. 
1.2 Tnberculosis 
1.2.1 Mycobrcterir 
The genus Mycobacterium represents a group of over seventy organisms that are 
grouped together based upon acid alcohol fastness, properties of mycolic acids in their 
cell wall and DNA guanine and cytosine content of 61-71 mol % (Shinnick and Good, 
1994). The genus is firrtber divided into two groups based on growth rate; slow growers 
require more than seven days to form visiile colonies on solid medium and fast growers 
that form colonies in less than seven days. In humans and other animals, the slow 
growing group is responsible for most mycobactd disease, whereas the fast growing 
species are g e n d y  non-pathogenic. Members of the Mycobacterium tuberculosis 
complex are the etiologic agents of TB (reviewed in Shinnick and Good, 1994). The 
complex includes three species: M. tuberculosis, M. bovis and M. africanum, which 
share >95% DNA homology with each other. The M. complex (M. miurn and M. 
intracellulare) also causes pulmonary and non-pulmonary infections, primarily in 
irnmunocompromised individuals. 
1.2.2 Epidemiology 
Tuberculosis has been afnicting humans since before the beginning of recorded 
history. Evidence of the disease has been identified in skeletal remains as old as 8000 
years (Stead and Dutt, 1994) and the disease continues to be the most prevalent infectious 
cause of human morbidity and mortality in the world today. Developing countries where 
propermedid care and access to antibiotics is limited currently account for the majority 
of cases. The W d d  Health Orgaaization (WHO) estimates that 8 million new cases of 
TB arise each year and 3 million peopIe die annually due to the disease (World Health 
Organization, 1994). 
When a disease @demic £irst afBicts a popufation, morbidity and mortality rates 
follow a typical curve over time- This curve rises reIativeIy rapidly, reaching a peak 
foHowed by a much slower and longer descenk, as the pool of susceptiile individds m 
the population is reduced either through acquisition of immImity or through death. 
Tuberculosis, like other contagious diseases, follows this typical pattern when introduced 
into a particular environment. In TB epidemics, this pattern of disease is explained by 
natural selection and the elimination of susceptible individuals h m  the population 
(Grigg, 1958; Stead and Dutt, 1994). However, TB is a slow disease, with patients o h  
living many years between the time of infection and death. Because of this, the epidemic 
wave of TI3 is much longer than for most diseases. The time for a TB epidemic to run its 
course is estimated at 300 years or more (Grigg, 1958). lo most western countries, the 
current TB epidemic is in the late stages and TB rates have fallen significantly over the last 
century. As the infection moves through a community, those who are more susceptible to 
the disease are affected and eventually killed by the disease, while the resistant individuals 
remain alive to pass on their resktance genes to their children. As the pool of susceptible 
individuals is depleted, fewer people became ill following infection and eventually the 
epidemic becomes self-limiting. In some countries in Aliica and Asia, the epidemic is in 
an early stage (Cummins, 1920), and morbidity and mortaIity rates are curre~ltiy higher. 
In these communities, the current epidemic wave started at a much later time. Dramatic 
evidence of the early part of the TB wave was observed in North American Indians after 
they had settled on reserves in the 1880s. Ferguson (1955) reported that the death rate 
h m  TB rose from approximately 1000 deaths per 100,000 people in I88 1 to 9000 per 
100,000 in 1886, almost a ten-fold increase in a span of five years. This was at the peak 
of the TB epidemic in this group. The severe annual death rate was most probably a 
result of a population that had Iittle previous exposure to TB being placed in conditions 
ideal for TB spread. TB rates among the native people of Saskatchewan have continued 
to fdl over the past century, but remain higher than among the general population 
(Hoeppner, 1991; Hoeppner and Marciniuk, 2000). Other examples of high TB mortality 
as a resuit of introduction of the pathogen into a popdation come fhm the reports of 
Cummins (1920) that have compared TB rates in British troops to those of troops 
d t e d  into British military h m  o t h e r ~ ~ ~ t r i e s .  
TB patients caa be divided into two groups: those with progressive primary 
dkwx (early progressive) aud those with reactivation disease (ramdescent) (Modding 
1994; Stead and Dutt, 1994). Individuals with progressive primary disease arc i n f i  
with M. tubermlosis and develop disease as a result of the primary infection. Those with 
reactivation disease initially control the infection, but eventually develop disease, d l y  
years after the initial exposure, as a result of a failure of the immune system to continue to 
control that iafection. With regards to the epidemic wave, primary infection is more 
interesting, as disease is a direct result of susceptibility to infection, rather than the result 
of a iater event that subsequently undermines an initial protective response. In endemic 
areas, the type of disease seen in chiIdhood TB is quite different h m  that seen in adults, 
being more generalized and progressive. interestingly, TB m those who are exposed for 
the first time as adults is often similar to the chiIdhood form (Cumrnins. 1920). 
In the early stages of a TB epidemic, disease occurs more often in chiIdren as 
susceptible individuals develop disease as a direct resdt of primary infection (Grigg, 
1958). In the later stages of the epidemic wave, as natural selection works to eIimiaate 
those susceptible to progressive primary disease, the majority of cases of TB occur m 
adults, often as a resuit of reactivation. Reactivation disease occurs in individuals whose 
infection ocamed at a time when TB was more prevalent, often years previously, (Stead 
and Dutt, 1994) and hence it contributes to the prominence of adult TB at the end of the 
epidemic wave. This etioIogy is common in non-endemic areas. Alternatively, in endemic 
areas, adults may develop disease as a consequence of reinfection or reactivation. 
The pattens of a TB epidemic has particular si~ficance for the situation here m 
Caaada In this cormtry, the TB rate is W a r  to that in other deveIoped countries among 
the g a d  population. However, among the indigenous people, the rate of TB cases is 
umsiderab1y higher than in Caucasians (Hoeppner, 1991; 1998). One possible 
explanation for this is that the m i r e  people are at an d e r  stage in the epidemic wave 
than Caucasians, having only begun the recent *demic wave in the last 150 years 
(Ferguson, 1955; Hoeppner and Marciniuk, 2000). If more individuals in these Native 
communities are suscephile to progessive primary infections, a higher rate of TB is 
expected in children among the Native populatioa than in individuals of European 
descent, This is certainly the trend in Saskatchewan as the majority of TB cases in Native 
People occur in children under five years of age while in the Caucasian population most 
cases occur in the elderly (Hoeppner, 2000). 
1.2.3 Tubercutosis Pathology 
Since the tubercie bacillus was identified in 1882 (Koch, 1932), scientists have 
attempted to understand the relationship of the organism with the infected host, After 
more than one hundred yean of research, t h a  are still many questions to be answered, 
and the disease mains somewhat of an enigma. Understanding the disease pathology 
and progress in an individual requires an understanding of the immune response 
generated in that individual to M. ~~(betcuiosis and perhaps to other mycobacted 
species. 
The majority of individuaIs who are infected with M. tuberculosis do not become 
ill with TB. In fact, 90-95% of individuals who have been infected with M. tuberculosis. 
as assessed by a positive skin tesq do not develop disease (Sheffield, 1994). In these 
individuals, the immune system is able to respond to the organism, generating an immune 
response which is capabk of controlling the growth and spread of the organism, and 
preventing clinical disease fnnn developing. In the ranaining individuals, the immune 
system somehow fds  to generate either sufEcient or appropriate immunity to control the 
organism and these individuals deveIop some form of clinical disease. 
Understanding the pathology in tubemIosis infections is fbrther complic~ted 
by the many forms of disease which deveIop: primary vs. secondary, multibacilliary vs. 
pauciibacilIiary, pulmonary vs. extrapulmonary, and the many variations and gradations 
which are seen within each group. To better understand the immune response to M. 
rubercuiosis and its role in development of disease, it will be necessary to understand the 
distinctions between these p u p s .  Most importantly, it is essential to distinguish 
between primary progressive disease and secondary or reactivation disease, as these 
different forms are likely the result of very different mechanisms. In the fonner case, the 
disease r d t s  as an initial failure of the immune system to respond appropriately to the 
M. ruberculosis. In the latter, the disease occurs as a subsequent filure of the immune 
system to continue to contain the primary infection, often as a result of immune 
suppression of some kind. The reason for the immune system's fgilure to continue to 
control the infection is known in m y  of these cases, whether it is h m  circumstances 
associated with immunosuppressive d h s e s  such as human immunodeficiency virus 
(HIV), malnutrition, alcoholism or concomitant inf i ion  ( Stead, 1967; Sheffield, 1994). 
Therefore, the discussion presented here will focus mainly on why patients fail to contain 
a M. hiberculosis infection upon primary exposure. I feel that this is a much more 
interesting question from the imrnunoIogical standpoint and that answering tbis question 
will lead to a fx greater understanding of the pathogenhost relationship and of the disease 
itself. 
TubercuIosis can affect virtually any body tissue, but initiai infection in humans is 
almost invariably by the respiratory route, fhm which it subsequently spreads to other 
areas (Stead, 1967; Dannenberg, 1994). [n order to be infective, aerosol particles 
containing mycobacteria must k very small to ensure that they remain suspended m air 
long enough to reach the alvwti of the Irmg where the infection takes place (Ferguson, 
1955; Damenberg, 1994). It has been estimated that aerosols of one to three bacteria will 
stay suspended Iong enough to reach the alveoli while larger particles will generally settle 
on mucod surfaces before reaching the alveoli and be cleared by cilia (Dannenberg, 
1994). Bacilli that lodge in the alvmli will be taken up by alveolar macrophages that are 
resident in the lung. Many of the bacilli will be dead upon inhalation or will be killed by 
the action of non-specifically activated maaophages. If the macrophage does not possess 
the capacity to kiU the engulfed tubercle bacillus, then the bacteria can grow 
intracellularly, and the initial lesion may be established (Damenberg, 1994). Evidence 
suggests that in the majority of cases, a TB infection is the result of a single infectious 
particle as most infections start at a single focus (Ferguson, 1955). If this is true, then the 
degree of exposure will increase the likelihood of infection, but not the eventual outcome. 
In other words, individuals who live in endemic areas are more likely to become infected, 
but the probability of developing disease once infected, or the severity of disease, 
depends on other factors. Epidemiological evidence supports this theory as the rate, type 
and severity of TB in recently converted skin test-positive individuals who are at a high 
risk of infection does not differ siguificantly h m  simiIar individuals who are at a low 
risk of infection (Ferguson, 1955; Hoeppner, 2000). 
I propose that the development of tuberculous disease in any individual is the 
result of an inability of the immune system to control the infection. The reasons for 
failure of the immune system will not be the same in all  patients. Defining the reason for 
such failure in any individual will require knowledge of the history of exposure to certain 
predisposing factors a s  well as an understanding of the ongoing immune response in that 
patient, 
1.2.4 Facton that Influence Susceptibility to Tnberculosis 
1.2.4.1 Genetic factors 
Susceptiiity to TB is a muhigenic trait At present, few genes have been 
identified that are related to TB susceptiiiIity/resistance. However, major 
histocompabbility complex- (MHC) genes and the bcg gene have been studied exte~l~ivey 
in this context. 
1.2.4.1.1 Major Eistocompatability Complex Genes 
Numerous studies have shown that susceptiiilitylresistance to TB is parhdly 
attniutable to MHC-proteins, both in animals and humans. This is not surprising as 
these proteins play such an integral role in T cell responses. In mouse models of 
intracellular infections, susceptiiility and resistance are associated with particular MHC- 
(H-2) haplotypes (reviewed in Buschman et al., 1990). Studies in mice have shown that 
during inf'ections with M. tuberculosis, H-2b appears to be associated with increased 
IFNy production in response to mycobacterial antigens while H-2d is associated with 
lower IFNy responses (Buschman et al., 1990). In a study using C57BU6 mice (H-29, 
BALWc (H-2d) and MHC-congenic BALB.B 10 (H-2b) mice infected with M. bovis 
BCG, dramatic Wdependent differences in cytokine production by T cells were 
observed. Type 1 cyolcines dominated the response of T cells of the H-2b mice, while 
type 2 cytokines, particularly IL-4, were produced in greater amounts by the cells of H-2* 
mice (Huygen et al., 1992). On the basis of median survival time after infection with M. 
tuberculosis, I -A~ and D~ alleles were associated with susceptibility while I -A~ and Dd 
alleles provided more resistance, establishing a role for both MHC-class I- and class II- 
restricted T cells (Apt et al., 1993). Finally, preliminary experiments suggest that MHC 
may be a significant haor in determining the dose response to BCG in MHC-congenic 
mice (Power and Bretscber, 1996). 
Studies in humans have indicated a correlation of susceptibiIity or resistance to 
TB with particular MHC-alleles. Human lymphocyte antigen (HLA) -DR2 has been 
associated with an increased susceptiiility to TB in several studies (Khomenko et al., 
1990; Brahmajothi et al., I99 1; Hill, 1998). In one study, HLA-B 15 was also associated 
with increitsed incidence of TB, while HL,A-B27 and -DM were associated with 
increased resistance (Khomenko et aI., 1990). HLA-DR4 has been linked with increased 
induration in response to skin test (Ottenhoff et aI., l986), indicating that this allele may 
be associated with enhanced cell-mediated responses. 
1.2.4.1.2 Nramp 
A gene which is expressed excIusively in macrophages has been identified as a 
factor in detecminiag resistance to several intraceilulrn organisms including BCG (Potter 
et d., 1983). Leirhmania sp. (Potter et d., 1983), Toxoplarma gondii (Blackwell et al., 
1994b) and Salmonella typhymun'um (Potter et al., 1983); hence, the gene has been 
given the various names kg ,  krh, and iry . Expression of this gene product is associated 
with an activated phenotype in the macrophage, d t i n g  in a greater capacity to kill 
intracellular pathogens. The protein product of this gene is called the nanrtai resisrance- 
ussociared macrophuge protein (Nramp) (VidaI et al., 1993). The gene was identified 
originally in inbred strains of mice. Diffaent strains varied greatly in their ability to 
control an infection after intravenous (i.v.) injection of I@ BCG mycobactecia (Pelletier et 
al., 1982). In some strains, the bacteria grew IogarittnrucaIly in the spleen, liver and 
lungs of the infected mice whiIe in other strains designated B C G  the number of BCG 
never rises higher than it is immediately af ta  the initial infection. This 100- to 1000-fold 
diffefe~lce in bacterial load was traced to a single autosoma1 gene mapping to the 
centromeric part of chromosome 1 (Skamene, 1 994). Although the mechanism remains 
unclear, Nramp appears to be pleiotropic in its effects on macrophages, enhancing many 
aspects of their activation thereby enabling them to kill intraceilular pathogens more 
&dveIy (Denis et d., 1988; Blackwell et al., I994a). The protein associates with the 
phagosomal membrane and may be involved in traasport of divalent cations. Although 
the direct ~ 0 1 1 s  of Nramp are exezted upon macrophages rather than T cells, the 
outcome of its effects can strongly influence acquired immunity, partieddy in view of 
the effect of dose on the immune response. Human homologues of the k g  gene have 
been identified and alleles are being tested for Iinkage to TI3 and leprosy (Skamene et al., 
1998). 
Of course the question of whether this gene controls susceptibility to virulent M. 
rubercuIosi(r is of more interest than its control over an avirulent strain such as BCG. In 
a study using BCGs and BCGr mice, only infections with fewer than 10' M. tuberculosis 
showed a detectable difference in mycobtiderial growth in the lungs and spleens between 
the two strains of mice infected, with the lungs showing a more pronounced differe~lce 
(Brown et al., 1995). 
I .2 -4.1.3 Other Genes 
Recessive mutations m type 1 cytokine genes that block their immune function 
have been associated with a high msqtiIbility to mycobacterial infections (Altare et ai., 
1998a; 1998b). Although these mutations are rare, they emphasize the importance of this 
pathway in providing immunity to M. ruberculosis. Thus, less dramatic alielic variations 
m genes that affect the ability of an individual to produce, or respond to type I cytokines 
are likely to influence susceptibility to TI3 infection. Such allelic variations have not been 
identified to date, but they most certainly exist. 
1.2.4.2 Environment 
The environment in which one lives has the potential to affect ones susceptibility 
to TB. Factors such as the rate of TB in the community, the presence of TB patients in 
the houschoid, and crowded l a g  conditions within the household or cOmmzmity have 
the potential to increase the l d  of exposure and thus infection with TB. However, as 
discussed previously, these factors are unlikely to determine whether an individual 
develops disease after infection. 
One environmental factor that does affect the potential to develop disease upon 
infection is previous exposure to other mycobacteria, either those that exist in the 
environment or the BCG vaccine. As exposure to these cross-reacting bacteria has the 
potential to influence the subsequent immune response upon infection with M. 
tuberculosis, environmental bacteria can predetermine the effectiveness of the immune 
response to M. tubeculosis infection. This subject is discussed in greater detail in section 
1.2 .S Immunology of Tuberculosis 
The immunology of rnycobacterial infection continues to be the subject of much 
research. In the majority of individuals who are infected, the immune system is able to 
contain the primary infixtion, and the patient remains asymptomatic, most often for their 
entire life. In the remaining individuals, the disease progresses, presumably because the 
immune system fails to contain if and the patient becomes symptomatic. 
The question ''what is effective immuaity to M. tuberculosis?" is not easily 
auswered. M. ruberculosis is a facultative intracelldar organism, which spends most of 
its in vivo life within iafected macrophages. Controlling intracellular pathogens such as 
M. lu&rculosis is accomplished through the cellular am of the immune system and both 
CD4' and CD8' cells are involved 
1.2.5.1 Humoral Response 
Many researchers have looked at the a u t i i y  response to rnycobacterial infections 
in an effort to d e h e  the significance of this aspect of the immune response in immunity to 
mycobacteria Although some earIy controversy existed, there is now little doubt that 
a n t i i  does not play a  role in protecting against such infections (reviewed in Rosenthal, 
I980b). This is because the organisms of the M. tuberculosis complex are intracellulslr 
organisms tbat live and grow witbin the protected environment of infected macrophages 
and are therefore not susceptible to the neutralizing effect of antibodies. Although some 
peptides of mywbactaial proteins may be expressed on the surface of infected cells in 
association with MHC-molecules, a n t i i e s  against these peptide/MHC-complexes 
probabiy would not be effective as there would Likely be far too few a n h i e s  bound to a 
cell to have an effect (Humphrey and Dourmashkin, 1969). 
1.2.5.2 Cell-Mediated Responses 
1.2.5.2.1 Delayed Type Hypersensitivity 
Antigen-specific CD4+ c d s  producing type 1 cytokines mediate DTH which is 
considered an important immune mechanism for clearing intraceUuIar pathogens including 
intracellularmycobacteria DTH responses to mywbacterial antigens have been used for 
many years as an indicator of exposure to mycobacteria In particular, skin tests 
performed with purified protein derivative (PPD) have been used as a diagnostic tool to 
determine if an individual has been exposed to M. tuberculosis. DTH responses to PPD 
have also been used to asses the effectiveness of BCG vaccination, and individuals who 
receive BCG are often given a skin test to determine if they have developed an immune 
response to the vaccine. Unfortunately, a positive skin test does not distinguish between 
exposure to M. tuberculosis, M. bows BCG or another species of mywbacteria (WHO 
Tuberculosis Research Office, 1955a; 19531). In animal studies, a positive skin test a f k  
vaccination with BCG is associated with increased protection against challenge with 
virulent M. hcberculosis, and there is a correlation in some studies between the degree of 
positivity (mm of induration) and resistance to disease (Tuberculosis Program - U. S. 
Public Health Service, 1955; Siebenrnann and Barbara, 1974). However, in human trials 
of BCG vaccination, such a wrreIation does not exist (Tubercuiosis Research Centre, 
1999). Therefore, for humans, a more complete uaderstanding of what constitutes 
effective immunity to M. tuberculosis is necessary, as a simple evaluation of DTH 
tespomes by skin testing is not a predictor of protection. 
1.2.5.2.2 T helper Cells 
Thl ceUs play a dominant role in immunity to slow-growing intracellular 
organisms such as leishmania and mywbacteria, which selectively infect phagocytic ceh 
of the macrophage lineage. These T cells produce the type 1 pro-idammatory cytokines 
IFNy and TNF. IFNy and poss~ily TNF activate macrophages to enable them to kill 
intracelldar mywbacteria (Nathan, 1986; Kaufmann, 1999;). These cytokines are also 
muid for granuloma formation (Flynn et a]., 1993; 1995; Kaufmann, 1999). Thus, 
induction of Thl cells is critical in ensuring an effective immune response to 
mywbactaial infections. Th2 cells, on the other haad, are not important in conferring 
protection against these slowIy replicating, predominantly intracellular pathogens. 
Moreover, induction of Th2 cells can be detrimental to the development of a protective 
response (Kaufinann, 1999). 
1.2.5.2.3 Cytotoxic T cells 
Most research on the immunology of TB has focused on the CD4' T helper (Th) 
cell, although in recent years some &den= has suggested a prominent role for CD8' T 
cells. Studies in MHC-class Ideficient mice have shown an increased susceptiiility to 
mywbacterial infection indicating that class I-restricted CD8+ cells have a role to play in 
TB immunity (Flynu et al., 1992). The effector mechanisms of these cells are two-fold. 
They can produce immunostimulatq cytokines that stimulate phagocytic cell activation 
and they are also capable of recopking and d l y  kiUing infected cells through various 
mechanisms. The relative importance of these various mechanisms in confening 
immunity to TB is being investigated. In a mouse model of M. tuberculosis infection, 
both CD4+ and CDC M. tuberculosis-specific T cells were found in the lung very early 
after i.v. infection with 2xId M. trrberculosis. Although CD4' cells dominated the 
response, a significant number of IFNy-producing CD8+ cells (approximately half the 
number of CD4' cells) were identified after in vitro stimulation with M. tuberculosis 
infected antigen-presenting cells (Serbina and F l p ,  1999). AAer aerosol infection of 
mice with M. tuberculosis, IFNyproducing C W  and CDS' T cells peaked in the lung 
tissue at 8 wk post infection (pi) and 4 wk pi in the lymph nodes draining the lung (Feng 
et aI., 1999b). IFNypmducing CDS+ ceIls have also been isolated in peripheral blood 
mononuclear cells (PBMC) after in& infection of cattle with M. bovis (Liebana et 
al., 1999). 
The studies of Serbina, Fen& and Liebana have not examined the cytotoxic 
capabilities of the CDb cells, but a previous shldy has shown a direct correlation between 
IFNyproduction and cytolytic activity in CD8+ cells (Fabio et al., 1994). However, the 
relevance of the various cytoiytic mechanisms of CD8' cells to protection against 
mycobacterial disease is ambiguous, at least in the early stages of infection. Perforia- and 
granzyme-knockout mice were found to be no more susceptible to M. tuberculosis in 
early stages of infection than normal mice (Cooper et al., 1997). Therefore, CD8' cells 
may be exerting their effects more though type 1 cytokine production than through d k c t  
Iysis of infected ceUs in mycabacmiai infections. 
1.2.6 Immunologic Spectrum of Disease 
Attempts have been made to define a spectrum of disease that correIates to immuue 
function in TB patients. Tubercuiosis patients were classified into two polar groups based 
upon the clinical presentation of the disease and radiological data (Lenzini et aI., 1977). 
Patients classified as reactive (RR) had the least severe forms of disease while those with 
acute miliay TB were designated as unreactive (UU). Two other intermediate groups 
were also defined, reactive intermediate (RI), and unreactive intermediate (UI). The 
groups were tested for various immmological, bactaiological, and histobgical 
parameters. AIl of the patients in the RR group were skin test-positive to PPD. In 
addition, these patients had no anti-PPD serum a n h i e s ,  reacted strongly in leukocyte 
migration-inhi'bition tests and had no mycobacteria present in either their sputum or their 
tissues. These patients had a response typical of that induced by Thl cells, which seemed 
to confer some degree of protectioa The patients classified as UU, however, were skin 
test-negative, leukocyte migration inhiition-negative and they had large numbers of 
mycobacteria both in their sputum and tissues as well as anti-PPD antibodies in their 
s e m .  The response in these patients was more typical of a Th2 response and appears to 
have given little protection fiom the disease. The RI and WI patients were between these 
two polar groups in a continuous immune spectnrm as assessed by these parameters 
(Lenzini et al., 1977). 
Bhatnagar et al. (1 977) also proposed tbat a spectmm of immune responses a f h  
exposure to M. hcbercuIosis correlates with disease severity. Healthy, skin test-positive 
(presumably M. tuberculosis-exposed individuals) were included in this study. The 
results indicated a spectrum of disease, with healthy contacts demonstrating strong cell- 
mediated immunity (CMI), but lide humoral response, seriousIy ill miliary TB patients 
exhiiiting little cell-mediated immunity and increased humoral responses, and those with 
less severe forms of pulmonary TB lying midway in between the two extremes 
(Bhamagar et al., 1977). 
These studies suggested that individuak who develop a humoral response upon 
exposure to M. rubercuIosis are more likely to develop disease and that the severity of the 
disease correlates with the prominence of the humoral response. These interpretations 
were reasonable based on what was known about effective immunity to mycobacteria. 
The subsequent discovery of distinct CD4+ subsets mediating distinct immune functions 
and the understanding that these Tht and Th2 subsets are cross- regulated provided an 
explanation of why the immune spctmm cmeIates with disease pathology. Individuals 
who generate a Thl response upaa infection with M. tuberculosis might be expected to 
contain the disease, whereas those who develop a Th2 response upon exposure would be 
expected to have severe disease because they would not be able to contain the organism. 
Patients who develop a mixed ThllTh2 response wodd have varying degrees of disease 
depending on the relative strength of the Thl component versus the Th2 component. A 
mixed ThlRh2 response wouid be less effectual for clearing infm-on because the two 
arms of the immune mpnse are cross regulated, and the Th2 cytokines such as L4 can 
iuhiiit the production and function of type 1 cytokines ( Mosmann and Co- 1987; 
Lehn et al., 1989; Sher et al., 1991; 1992). In addition, IL-4 has been shown to act in 
TB Iesions to increase the necrotic effkct of TNF, thereby increasing damage and 
preventing healing of the lesion (Hernandez-Pando and Rook, 1994). This model 
suggests that TB patients with more severe disease shouid have a more prominent Th2 
response, while those with less severe disease should have a more prominent Thl 
response. Healthy individuals who have been infied with M. mberculosis would have 
a Thl response that protects them fhm disease. 
In support of this model, SufceI et aI. (1994) found a significant Merence 
between the mean number of M- fuberc11Iosi.s-specific IL4pmducing ceIls in the 
peripheral blood lymphocytes of a group of TI3 patients compared to the numbers in 
sensitized healthy controls. However, there was considerable variation among the patients 
with respect to this parameter, and so the diffaence between the groups was only 
apparent at the population level. Similarly in leprosy patients, IL-2 and lFNy messenger 
RNA (dlNA) were generally higher in tuberculoid leprosy lesions, while mRNA for IL- 
4, L-5 and interleukin 10 (IL-10) predomioated in lepromatous leprosy Iesions 
(Yamamura, 199 1). 
1.2.7 Histologic Spectrum- of Disease 
The idea of a histologicaI spectrum of disease in TB patients stems Grom 
observations in leprosy patients (Ridley, 1974). Ridley compared the histological 
appearance of leprosy lesions with immunoIo@cal pztrameters. The results indicated a 
spectmm of disease with two clearly defined poles. At one e r n e  are patients with 
lesions characterized by well defined epithelioid cell granulomas containing a significant 
number of lymphocytes and few, if any, acid-f&t bacilli (AFB). At the other end of the 
spectrum are patients with loosely formed macrophage granulomas containing no 
epithelioid cells, few lymphocytes and very high numbers of AFB (Ridley, 1974). It is 
important to note that epitheiioid c e h  are highly developed and activated cells of the 
macrophage lineage which are crucial for proper grandma formation. Patients with the 
former type of disease, often caIIed tuberculous leprosy, have a much better prognosis 
than those with the latter form, leptomatous leprosy. 
A similar histological spectrum has been defined in TB patients (Ridley and 
Ridley, 1987). Upon histoIogical examination of lesions, patients were divided into six 
groups based on the cell types, organization, and necrosis observed in tuberculous 
granuloma The lesions of individuals at one pole consisted of highly organized 
granuloma in which mature epithetioid ceh predominated and in which there was tittle or 
no sign of necrosis and few bacilli Tbis type of lesion is seen predominantly in the 
cutaneous form of TB known as lupus vulgaris. These lesions correspond histologically 
to those seen in the tuberculous leprosy patients d e s c n i  previously. At the other end of 
the spectrum were patients with fatal di sseminated disease. The lesions in these cases 
showed extensive basophilic or eosinophilic necrosis with many AFB present. In lesions 
of this group, macrophages represented the predominant granuloma ten type, but these 
were few in number and the gnmdoma lacked defined structure (Ridley and Ridley, 
1987). The majority of patients, however, were f o d  to be between the two poIes, 
having varying degrees of illness that axrefated with the ability of the immune response 
to contain the bacilli within the granuloma 
It appears that there is a qectnm of disease ranging ftom healthy sensitized 
contacts who have a strong Thl response and are able to contain the pathogen to those 
individuals with severe disseminated disease who have a purely Th2 response and are, 
therefore, unable to control the pathogen. However, in TB patients, this pattern does not 
take into 8ccouut a l l  individuals since, in some studies, not all of the patients fit into a 
spectnrm so defined and an association between a Th2 response and disease is only 
apparent as a trend in the populatioa In particular, in some patients with TB, the immune 
response does not show a Th2 component. Consider the lupus vulgaris patients in the 
study by Ridley and Ridley (1987). These patients mounted classical Thl responses 
against the organism, with welldefined granuloma containing few bacilli, and yet they 
were unable to control the W o n  M v e l y  as clinical manifestations of the disease 
continued. These individuals do not fit into the proposed immunological spectrum as it is 
currently defined. 
1.2.8 A Model Explaining Tuberculosis Immunopathology 
1.2.8.1 Two Types of lmmunopathology in TubercuIosis 
One model of TB immun0pathoIogy suggests that the disease is the d t  of an 
individual developing a Th2 response upon expome to M. tuberculosis. I feel that 
although this model is colrect in many respects, it is insufficient to d e s m i  the cause of 
progression of TB in many patients, specifidy, those who do not fit into the 
immunologieaYdisease spednrm as it is cutrently perceived. Dr. Bretscher, m y l f  and 
some of the other members of the Saskatchewan Research Centre for Elimination of 
Tuberculosis propose a new spectnm as shown in Figure 1 -I. According to this model 
M. tuberdosis infected individuals develop disease as a result of two distinct types of 
Type I Tuberculosis 
Death to 
recovery 
I 
I Little or No Th2 I Little or No Th: 
Component Component 
No Antibody No Antibody or 
Low IgG1:IgGZ Low IgGkIgG2 
Genetic Factors Genetic Factors 
Environrnentd Environmental 
priming Priming 
Malnutrition Low dose BCG 
~mmunosuppression 
M e  II Tuberculosis 
Chronic to 
pmgressive 
Genetic Factors 
Environmental 
Priming 
High dose BCG 
Figure 1-1 A model hr immunopathology of tuberculosis. Tuberculosis is the result 
of an idktive immune response against M. ru6erculosis. Disease may result if the 
immune response is an app@ate Thl response but of insufficient strength to oontroi the 
infection (Type I tuberculosis) or if the immune tespoase has a Th2 component that 
interferes with the ThI response (Type II -0sis). The predicted immune response 
of the respective groups as well as some of the predisposing facbrs for each type of 
disease are shown. 
failure of the immune system which lead to -distinct immunopathological states. The 
majority of natural infections will result in the induction of an appropriate Thl lcell- 
mediated immune response that is able to contain the pathogen without development of 
clinical disease (Figure 1.1, center). In a small pacentage of infections, a Thl response 
develops, but for some reason this immune response is i d c i e n t  to contain the 
infection and clinical disease d t s  (Figure 1 .l, left). In these individuals, the severity of 
the disease depends entirely on the strength of the Thl response. We expect that these 
individuals have Thl responses to mywkkriaI antigen, but responses will not have a 
significant Th.2 component. If anti-rnycobacte'al ~ f l t i i e s  are generated, the 
immunoglobulin-y-2 (IgG2) subclass which are associated with a Thl response (Kitani 
and Strober, 1993; Kawano and Yata, 1994), will be prominent. We refer to such 
individuals as Type I TB patients. In another small group of infections, the immune 
response is not entirely a Thl response, having a significant Th2 component (Figure 1.1, 
right). In these individuals, ?he severity of the disease depends upon the relative 
proportions of the ThlflM components. These people will have varying numbers of Th2 
type cells. We refer to these individuals as Type II TB patients. Discriminating between 
these two types of patients will be ctucial to understanding the relationship between the 
pathogen and the host immune response in TB as well as in other diseases. Measuring 
levels of various immuuogfobulin subclasses may provide a means of discriminating 
between these groups. 
It is important to clarifL the diffetence between hsuflicient Thl immunity to 
control the TB infection and an immune response that has a detrimental Th2 component. I 
have previously discussed the clinical and immunological evidence that some TB patients 
may have developed the disease because they have an immune response that has a 'Ih2 
component, i.e, Type iI patients. The patients that we wodd classify as Type I patients 
have an ongoing immune response to M. ttikculosb and we maintain that they have the 
appropriate type of immune response. then are they unable to clear the infection? I 
hypothesize that either the bactaial load in the ongoing infection is too great to be cleared 
by the established immune respollse, even though the same irnmuue response wuld clear 
a lesser infection, or alternatively, that prior exposure to environmental mywbactaia 
results in immune suppression that prevents a strong Th I response fiom developing. 
The Koch phenomenon (Koch, 1890) represents an experimental model of the 
former mechanism. Guinea pigs injected on one flank with virulent M. tuberculosis 
develop a lesion. However, after several wk, if these same animals are given a second 
injection of an equal number of bacteria on the other flank, they are able to wall off and 
heaI the infkdon at the second site, while the infiction at the primary site progresses. 
This suggests that these animals have sufficient immunity to control an infection with the 
relatively large number of organisms given in the secondary infection, but that this 
immunity is insufficient to control an estabIished infdon. Similar observations have 
been reported in models of tumor growth (North, 1985). In mice injected with a given 
number of P8 15 tumor cells on one flank, a solid tumor develops; however, while the 
primary tumor continues to grow, the mice are able to eliminate a second injection of the 
same given number of tumor cells at another site. The initial inoculum induces sufficient 
immunity to eliminate the second inoculum, but not the established tumor. This is referred 
to as concomitant immunity (North, 1985). Why can't the immune system clear the 
infection at the primary site? One obvious reason is that in the time it takes to establish the 
immune response, the organrrganrsm (or tumor cell inoculum) grows uninhibited and by tbe 
time the immune response is instituted, the tumor or infection is too large to be effectively 
cleared. However, a solid tumor is very different fiom an intraceHular organism infecting 
many individual cells. In TB infections, there are at least two explanations for why the 
immune response is not effective despite concomitazlt immunity. 
1. M. tuberculosis has been shown to have several inhibibxy affects on the 
response of immune cells (Hussain et d., 1999; Tmg et al., f999). Thus, in the time 
te~uired to establish an imune tesponse to the organism, immune ceUs responding 
locally to the i d i o n  may become subject to suppressive actions of the bacteria before 
they can be fully activated. Cells induced at a distance from the site of infection would 
mi1 be functional and thus capable of inbiiiting infeEtion at a second site. 
2. The immune response itself may be patially responsible for its 
ineffectiveness in cIearing a TB infection. The immune response to TB o h  results in 
granuloma formation. The function of the granuloma is to sunound mycobacteria 
infkted cells and trap them within to contain the infkction. However, the formation of a 
granuloma may actually prevent eficient immune clearance of the pathogen as it may 
remain viabIe within the caseous center of the granuloma for many years. 
Immune suppression generated after exposure to environmental mywbacteria 
offers an alternative reason why an appropriate Thl response to M. tuberculosis is 
induced but mains ineffective in controffhg the disease. l'El patients who have positive 
skin sensitivity to M. tlcberculosis can have reduced or absent responses to enviromnental 
saprophytic mycabacteria (kudjito et al., 1986). One m@t consider that the immune 
response to the environmental saprophytic mycobacteria in these patients is a predominant 
Th2 response and so no skin reactivity to these bacteria is observed. However, as 
demonstrated here with BCG and as Rook has reponed with killed M. vuccue 
(Hernandez-Pando et al., 1997), mycubactaid immunization usually r d t s  in either a 
Thl response or a mixed Thlm response dependiag on the dose administered. 
Thetefore, it seems d e I y  that there would be a large number of individuals with a 
pred~minautly Th2 response to environmental mycobacteria, and a mixed ThITTh2 
response to M. tu6ercufosis as there is considerable cross-reactivity between 
mywbacterid species. It is perhaps reasonable to assume that the individuals who have 
reduced or absent skin-test sensitivity to enviromnentd mycobaderia have a suppressed 
response to the eovironmental mymbacteria and that the reactivity observed on skin tests 
with M. tuberculosis PPD is directed against hrberculosis-specific antigens. The lack 
of immunity to environmental mycobactaia observed in some individuals could be 
explained by a mechanism of oral tolerance. Exposure to mycobacteria in the gut may 
induce T cells tbat produce such factors as transforming growth factor /3 (TGF-P) that 
suppress the systemic immune response to mycobacteria Studies in leprosy patients and 
their contacts support such a mechanim of active suppression. In the leprosy patients, 
sonicates of fast growing mycobacteria suppressed the local response to slow growing 
mycobacteria (Nye et al., 1983). 
If there is some degree of unresponsiveness to environmental mycobacteria due to 
environmental priming, then it is reasonable to assume that the responsible mechanisms 
will affect the subsequent response to M. tuberculosis due to cross-reactivity between the 
mycobacterial species. Thus, a down-regulated response to environmental mycobacteria 
may prevent these individuals f h m  mounting an optimal immune response to M. 
tuberculosis. This may represent a mechanism through which the immune system of 
some individuals is prevented h m  mounting an optimal Thl response upon exposure to 
M. tu6ercuIosis and thus these individuals would develop 'Type I" tuberculosis. 
1 .2.8.2 Predictions from the Model 
The model makes several predictions. Firstly, the model predicts that some 
individuals who are infected with TB and who develop clinical disease will recover 
without the aid of chemotherapeutic agents. These individuals are expected to be those 
with an initially insufficient Thl response that increases with time so that it can eventually 
contain the infection. EpidemioIogical studies conducted in the pre-chemothaapeutic era 
indicate that this is indeed the case. Many of the patients who were admitted to sanatoria 
with TB eventually recovered Illy firom the disease without the benefit of antibi0tiCs 
(Brown, 1919; Rutledge and Crouch, 1919). Presumably, the immune system of these 
individuals was eventually able to oontrol the infection. 
Secondly, some TB patients are expected to benefit h m  immune interventions 
designed to boost their immune response to TB. Such treatment could be a valuable 
adjunct to antibiotic treatment. The patients benetiting h m  such interventious would be 
those suffering fiom Type 1 TB, in which boosting the immune response would lead to an 
increase in the appropriate Thl response required to clear the infection. Those with a Th2 
response would not benefit from a d m i n i d g  antigen as immunothefapy as this would 
be expected to only lead to a stronger Th2 component that would not help in clearing the 
infxtion and may actually exacerbate the disease due to increased immune-mediated tissue 
damage and necrosis. Immunotherapy for TB has not been attempted kquently as 
history records that Robert Koch's initial attempts at hunotherapy were disastrous in 
some cases. Koch used crude tubaculin preparations to treat patients suffixkg h m  
various forms of tuberdous disease and also provided this material to other physicians 
for similar trials (Koch, 18W, Koch, 1891). Historical discussions of these studies 
indicate that the treatment was an utter fiiiure as many individuals died rapidly as a result 
of the tuberculin tealmen& (v'ihow, 1891). However, what is not discussed in 
historical references to this work is the fkt that, af&r tuberculin treatment, many TB 
patients recovered fully (Coghill, 1891). 
I predict that the latter were most likely those with the Trpe form of the disease, 
while the former suffered fnnn Type ll t u b d o s i s .  There is no direct prwf h m  these 
studies that the patients who b e n M  from the tubedin therapy had Thl immunity 
while those patients whose conditions worsened had Th2 immunity, but descriptions of 
the individual cases support this hypothesis. Patients with one clinical form of the disease 
were almost invariably cured after treatment with tuberculin (Koch, 1890; Hospital for 
Diseases of the Chest, 1891). These dered  f'rom a cutaneous form of M. 
tuberculosis iafecton commonly refaced ta as lupus vulgaris. Modern histological 
examination of lupus vulgaris cases demonstrate that the lesions observed in these patients 
are associated with a Thl response. These lesions are characterized by weil-structured 
granuloma containing predominantly epithelioid cds (Ridley and Ridley, 1987). It seems 
likely in retrospect tbat these patients suf5ered h m  the disease because their immune 
response was not strong enough to control the infection even though they mounted an 
appropriate type of immune response. This surmise explains why boosting the imme 
response led to clearance of the infection. Lupus vulgaris patients were not the only ones 
that benefited h m  the treatment as numerous pulmonary TI3 patients also recovered after 
tuberculin injections (Coghill, 1891). The patients who benefited from treatment were 
those with less severe f o m  of disease and it is likely that some of these patients wouId 
have recovered eventually even without treatment or perhaps they wouId have lived for 
many years with chronic disease. Many other patients suffered greatly as a result of the 
treatment with tuberculin (Viichow, 1891; Coghill, 1895). Because of this and a lack of 
understanding of the pathology of the disease, all tuberculin treatments were discontinued 
and the idea of immuuotherapy for TB has become stigmatized. It is interesting to note 
that many of the patients suffered as a resdt of improper use of tuberculin therapy - the 
use of very high doses and use in patients with severe disease (Coghill, 1895) - practices 
contraindicated by Koch himself (Koch, 1890). 
If this model of TB in humans is correct, there wiIl be considerable implications 
for vaccination against and treatment of the disease. For vaccination purposes, an 
immunizing regimen that induces only Thl responses will be beneficial to individuals 
prone to develop either Type I or Type II tuberculosis. For individuals who wouId 
develop Type I TB upon exposure to M. tubermtosis, any immunization which boosts 
Thl immunity would be beneficiaI as it may allow them to clear the infection more 
readily. For those patients who would deveIop a Th2 response and thus Type EI 
tuberculosis when exposed to M. tubercutosis, a vacch&~n strategy that allows them to 
develop a Thl imprint and hence a Thl response upon exposure probably would prevent 
the disease. 
For treatment of disease, understanding the implications for patients with different 
types of TB is important. As 1 have suggested previously, early treatments with 
tuberculin may have helped patients with Type I TB by boosting their Thl response. 
Therefore, patients with this type of disease may h e f i t  from immunotherapy as an 
adjunct to chemotherapy. Those with a Th2 response would not benefit fiom antigen 
therapy as it would probably boost their Th2 bmmity and perhaps exacerbate disease. 
Defining parameters that can distinguish between these two groups is a priority for the 
Saskatchewan Research Centre for the Himination of Tuberculosis. 
1.3 Bacille Caimette Guerin (BCG) 
1.3.1 Early History 
BCG is an attenuated strain of M. bovis that was developed over a period of 13 
years ( 1908- 192 1) by two French scientists, Alain Calmate and C d e  Guerin working 
at the Pasteur Institute in Lille, France (Guerin, 1980). Using bovine bile as an emulsifier 
to prevent clumping of the K G ,  they soon discovered that this treatment reduced the 
virulence of the bacillus. They continued to passage this bacillus every three weeks, 
checking its virulence in animals until, after 13 years and 23 1 passages, it was completely 
non-pathogenic in animals. 
On July 18, 1921, the first dose of BCG was administered to a human infant by 
Dr. Benjamin Weill-Halle in cohboration with Calmette and Guerin (Weill-Halle and 
Rosenthal, 1980). The child was chosen for this trial because he was to be raised by his 
tuberculous grandmother as his mother hi died of TB in child-birth It was felt that the 
child was also doomed to die of tk disease. The infant was fed b e e  doses of the 
vaccine in his first two weeks and remained fke h m  TB for life. This first human trial 
did not demonstrate the efficacy of the BCG vaccine as the child may have never 
developed TB without it; rather its significance is that it demonsbated the safety of the 
vaccine for humans. Since the League of Nations certified BCG as safe for human use in 
1928, more than 2.5 billion people have been vaccinated with the BCG vaccine (Stover et 
al., 1991). 
1.3.2 Efficacy studies in Humans 
By 1948, more than 10 million peopIe had been vaccinated with BCG. Despite 
this, reports of the protection provided by the vaccine were almost entirely anecdotal. It 
was not until the late 1940s that reports of proper1y controlled studies became available. 
An extensive and excellent review of the results of BCG vaccination trials conducted 
before 1980 is included in BCG Vaccine: Tuberculosis-Cancer (Rosenthal, 1980a). 
There has been tremendous variability in the outcome of BCG vaccination trials. Early 
studies in North American Indians conducted by Ferguson in Canada (1928) and Aronson 
in the United States (1958) found a similar rate of protection of approximately 80%. 
Ferguson also found a high rate of protection among nursing students in Saskatchewan 
(1955). A study conducted by Hart and Sutherland (1977) found a protection rate of 78% 
among British schoolchildren. However, many other studies have shown far lower Iw& 
of protection with the BCG d e  (Comstock and Webster, 1969; Comstock et al., 
1976). The Madras ~ a i  conducted in South India by the WHO, reported no overall efflect 
of BCG vaccination (Tubercuiosis Prevention Trial, 1980; TubercuIosis Research Centre, 
1999). A meta-analysis of the published studies on BCG eflicacy reported an overall 
protective effect of 50% (Colditz et al., 1994), dthough this number is rather meaningless 
as it does not predict the potential efficacy of vaccination against the disease in any one 
population. The variability in 6 c a c y  of the BCG vaccine found in various trials is W y  
to reflect a number of factors that affect the immune response to BCG. A description of 
these hctors and their probable effkct on the outcome of BCG vaccination follow. 
1.3.3 Variables Affecting the Efficacy of BCG in Humans 
1.3.3.1 Genetic Factors 
In general, Caucasians appear to be more resistant to TB than AEicans, Asians 
and North American Indians. This observation is thought to be due to the fkt that 
Caucasians have been exposed to the bacterium for many generations and, therefore, this 
population has developed a relatively high level of resistance due to the process of natural 
selection (Cummins, 1920; Ferguson, 1955). Ebination of individuals f?om a 
population who have genes or alleles which predispose them to developing disease or 
more serious f o m  of disease, results in a more resistant population. The longer the 
population has been exposed to M. tuberculosis, the greater the resistance to TB. This 
selection process is likely to affect the response to the closely related M. bovis BCG. 
This topic is discussed in tixther detail in section 1.2.4.1. 
1.3.3.2 Environment 
The primary environmental factor that is likely to affect the outcome of BCG 
vaccination is the presence of other mycobacted species Iiving in the environment. The 
mycobacteria represent a diverse group of organisms. Many species are commonly found 
in soil or water, or as non-pathogenic organisms in animals and in man. Most individuals 
living in areas where such mycobactaia are present, will have positive skin-test responses 
to tuberculins made h m  these organisms, indicating that the organisms are capable of 
inducing an immune response in humans. These organisms have been shown to confer 
some degree of iIrxnuae protection h m  virulent mycobactaia in animal studies (Palmer 
and Long, 1966). Originally, Palmer and Long (1966) suggested that exposure to 
environmental mycobacteria is one reason why some BCG studies indicate a much lower 
efficacy level than others. They hypothesized that if a population exposed to cross- 
reactiug e n m e n t a l  mywbacteria is subsequently given BCG, then the level of 
protection detected in the study would be only the additional protection provided by the 
BCG vaaht ioa The additional level of protection provided by BCG vaccination in 
areas where environmental myabacteria are prevalent will  be somewhat less than that in 
areas where BCG v&on is the only means of protection. Accordingly, studies 
conducted in areas where environmental mycobacteria are prevalent, may seriously 
rmdefestimate the protective value of the vaccine. In one study, montlcytes fhm 
Maatow-negative patients h m  the Chingleput region of India inhibited intracelldar 
growth of M. microti more efficiently than monocytes h m  children in London. After 
BCG vaccination, monocytes h m  the London population had increased bacteriostatic 
activity, wWe those hrn ChingIeput did not (Cheng et al., 1993). The authors suggest 
that exposure of the subjects from India to atypical mycobacteria may be responsiile for 
the observed results. 
Stanford et al. (1 98 1) cartied this hypothesis one step further. They proposed that 
the intluence of environmentaI mycobacteria may not dways be beneficial and suggested 
that the immune response generated by exposure to such mycobacteria will vary 
depending on the species to which one is exposed and pahaps on the conditions of 
exposure. In some cases, a protective immune response may be generated, while in other 
cases a detrimentaf immune reqwnse is the result Thus, in locations where enviromnental 
mycobacteria are prevalent a bene6cid or detrimental immune response may be generated 
before BCG vaccination and subsequent exposure to BCG simply boosts the established 
response. Once again, according to this model, there will be tide effect of BCG 
vaccination m areas where environmental mycobacteria are common. 
Subsequent expahnents suggested that a beneficial response was a purely Thl 
response, while the de!rimentaI response was one with a Th2 component (Hernandez- 
Pando and Rook, 1994; Hemandez-Pando et al., 1997). The evidence suggested t b t  in a 
purely Thl response, TNF acts as a pro-idammatory, Thl cytokine, but if even a small 
amount of IL-4 is present, then the lesion becomes necrotic Hemaudez-Pando et al. 
(1994, 1997) hypothesized that iL-4 in the lesion sensitizes the tissue to the necrotizing 
effects of TNF, thereby leading to destruction of surrounding tissue and chronic disease 
(Hernandez-Pando and Rook, 1994; Hernandez-Pando et aI., f 997). 
1.3.3.3 Vaccination Parameters 
Vaccination parameters such as route of injection, dose of BCG administd and 
the strain of BCG used to vaccinate are also determiaants of the immune response to BCG 
vaccination. However, the influence of varying these parameters can be determined 
experimentally and controlled in vaccination procedures so that the response is optimal. 
1.3.3 -3.1 Route of Injection 
The three routes of administration that have been most commonly used for 
vaccinating humans with BCG are oral, intradermal (i.d.) and transcutaneous. The oral 
route of administration was the first method used to administer BCG, in the belief that in 
the first two weeks of infancy? the intestinal mucosa were more permissive to the 
trahsport of microbes, allowing for more effectve vaccination (Weill-Halle and 
Rosenthal, 1980). It appears that the organism is able to gain access to the blood in 
infants who are i m m d  orally (Weill-Halle and Rosenthal, 1980). Indeed, using the 
oral method of administration, younger chiidren had higher tuberculin reactivity than 
those who were older at the time of vaccination (Weill-We and Rosenthal, 1980). The 
oral route continued to be used in many countries for some time. In particular, Brazil had 
used the oral mute for many years and advocated the use of higher doses and multiple 
administrations. However, the oral method has baa repiaced by the i.d. route even m 
Brad for reasons of ef5cacy and the desire to vaccinate individuals who were beyond 
infancy. Furthermore, with this method, disaimination of individuals who have been 
vaccinated h n  those who have been exposed to M. tuberculosis is not possible, due to 
the lack of the BCG scar after oral vaccination. 
The transcldaneous method of v a a m t m  . includes the multiple puncture method 
and the scarification method. The multiple puncture method consists of applying a 
suspension of BCG vaccine to the skin surface and inserting a needle or multiple needles 
through the suspension to a depth of 2-3 mm into the skin. This method was pioneered 
by Rosenthal and is thought to be as effective as i.d. injection with less serious side 
effects (Weill-Halle and Rosenthal, 1980). It is the onIy method that is licensed fm use m 
the United States (Lowry et al., 1998). A modification of this method, commonly 
teferred to as scarification, involves placing a drop of BCG vaccine on the skin of the 
patient and scratching the d c e  of the skin with the point of a lancet. Because the 
vaccine is applied to the d a c e  of the skin by the transcutaneous method and a n&e is 
passed through the applied vaccine, only a small hction of the vaccine will effectively 
induce an immune response, Estimating the exact number of organisms in the vaccine 
dose is impossible. 
The i.d. route of administration of BCG is the most commonly used method and 
is recommended by the World Health r on, In Canada, BCG vaccination is 
carried out using reconstituted heze-dried preparations of BCG given intradermaIIy. 
Approximately lo7 colony forming units (ch) is administered to adults and half that 
number to i n h t s  in 100 p.l and 50 pl volumes, @vely (Hoeppner, 2000). This is 
the prefeffed method of vaccination because of its &cacy and reproduciiility in inducing 
an immune response as assessed by positive skin test. 
1.3.3.3.2 Strain of BCG Used for Vaccination 
The strain of BCG that is used has a significant impact on the outcome of the 
immune response andlor the degree of protection after vaccination. Lagrandaie et al. 
(1996) chataderized the immune response and ptotective activity of five BCG strains. 
They report significant differences between the various strains in their ability to induce an 
irmmme response and provide protection fhm challenge in mice. All these strains came 
h m  the same source initially, but repeated passage and different handling conditions 
have no doubt resulted in substrains with different growth properties. Behr and Small 
(1999) have charactecized the genetic makeup of various strains and have found great 
diffezences between strains that probably account for the differences in &cacy between 
strains 
1.3.3.3.3 Age at Time of Vaccination 
The age of the patient at the time of vaccination has an influence on the eff- of 
BCG vaccination. Individuals who live in areas where they are likely to be exposed to 
environmental mycobacteria are more likely to be sensitized to environmental 
mycobacteria as they age (WHO Tuberculosis Research Office, 1955~). In some cases, 
this exposure may have an immuuizing effect similar to BCG vaccination whereas in 
others, such exposure will result in an inappropriate response (see section 1.3.3.2). As 
this exposure occurs in an uncontrolled manner, the outcome of such exposure will vary 
from area to area and individual to individuaI, and certainly a desirable immune response 
will not occur in all individuals who are exposed Vaccination with BCG at an early age, 
prefmbly in the neonate before the detrimental effects of environmental exposure occur, 
will be more likely to give a desirable response to BCG. 
1.3.3.3.4 Dose of  Vaccine 
Rarely has the effm of BCG dose been examined in human studies. Animal 
studies have often reported that higher doses of BCG provide more effective protection 
against subsequent chailenge (discussed below), therefore, the highest tolerable dose is 
used for human vaccination When more than one dose of BCG has been employed in 
vaccination studies, the dose range has been small, within ten fold of the highest dose 
used (Tuberculosis Prevention Trial, 1980; Tuberculosis Research Centre, 1999). ln the 
context of the proposed model, such a dose may be still too high to discern a significant 
diffarnce firom the standard dose. In one study which purports to look at low dose 
vaccination in humans (Lowry et al., 1998), a dose of BCG which is 1000-fold lower 
than the standard dose was admmskd - .  to human subjects and compared with the 
standard dose. The authors found little evidence of an immune response to the low dose 
of BCG as assessed by IFNyproduction or proliferation by peripheral blood 
mononuc1enr celis at 16 wk and 1 yr pi. However, such responses were rmnimal in the 
individuals who received the higher doses, and as the vaccine was administered by the 
multiple puncture method, only a small portion of the dose would have gained enhy into 
the tissue. By this method, even at the highest dose, the actual number of bacilli that 
interact with the immune system is relatively low. It has been reported that the multiple 
puncture method is far less effective at inducing IFNy production in PBMC than the i.d. 
route of vaccination (Kmp et al., 1996), even when the "dose" used Cbr transcutaneous 
immunization was 50 times that used for immmimtion by the i.d. route. It is interesting 
in this regard that proponents of this method of vaccination purport that it is highly 
e f f d v e  at inducing tuberculin conversion, but with fewer side effects (Weill-Halle and 
Rosenthal, 1980). Perhaps in the study by Lowry et a]. (1998), the few BCG bacilli 
introduced into the skin at the lowest doses administered, were cleared by the innate 
immune system before inducing an immune response. Alternatively, the immune 
response may have taken longer than 16 weeks to develop after immunization with the 
lower dose. 
1.3.4 Animal studies with BCG 
A large number of animal studies have examined the eflicacy of BCG vaccination 
using challenge with virdent strains of M. tubercdosis to assess protection (reviewed m 
Rosenthal, 1980c; Smith, 1985)- Trying to make sense of the vast amount of literature on 
the subject is difficult primarily due to the lack of continuity in experimental appmach 
between the various studies. I will not attempt .to give a review of the results reported in 
the various papers on the subject, This has been done previously and in an extensive 
manner that I am sure I could not improve upon (Rosenthaf, 1980~; Smitb, 1985). 
However, one thing is apparent Etom reading the literature - BCG vaccination can provide 
protection to animals against subsequent challenge with virulent mycobacteria None the 
less, there are a very large number of variables that must be considered in such studies, all 
of which may have si@cant impact on the outcome, or the conclusions dram h m  
these studies. Without taking all of these variables into consideration, it is possible to 
draw incorrect conclusions about the potential for a candidate vaccine. For this reason, I 
feel that it is beneficial to be aware of the importance of these variables to consider and 
how they may affect the outcome of the BCG trials. 
1.3.4.1 The Strain of Animal 
Some strains of mice are more resistant to certain infections than others and this 
correlates to the type of immune response which is generated. BALBIc mice are more 
prone to develop Th2 responses to most antigens than other strains such as C57BL. 
Therefore, they are more likely to develop disease when i n f i i  with organisms which 
are only cleared effectively by a Thl response. These differences are due to genetic 
variations within species, many of which influence the immune response that the aaimal 
develops upon exposure to the organism. Thus, it is important to understand the chosen 
animal modeI, its relative susceptibility to the infecting orgauism and the immune 
mechanisms that determine this susceptiiility, for what constitutes protection in one strain 
of mouse may not lead to protection in another strain, 
1.3.4.2 TheStrainofBCG 
As discussed previously, the strain of BCG that is used may have profound 
effects on the outcome of any such study, whether in humans or in animals. 
1.3.4.3 The Route of  Vaccination 
Numerous routes of vaccination have been employed in animal studies, including 
oral, subcutaneous (s.c.), intraperitoneal (Lp.), i.d., i.v., transcutaneous and aerosot It 
is ceaain that the route of adminisbation will affect ?he outcome of vaccination, under a 
single set of conditions. Antigens are certainly more effective immunogens by some 
routes af administration than others (Lagrange et al., 1974). However, I believe tbat it is 
psslile to achieve a 111 range of immune respouses, regardless of the parentera1 route of 
anministration, simpIy by varying the conditions of immunization. 
1.3.4.4 The Interval between Vaccination and Challenge 
In experiments that compare protection rates of various vaccines, it is important to 
take this variable into account. Most studies of protection have looked at the protective 
efficacy of a BCG vaccine by Menging relatively shortly after vaccination. In such 
cases, it may be possiile that the immune response has not reached its peak, or that the 
challenge could interfere with the developing immune response. In both cases, protdon 
could be greater if the challenge took place at a later time point To ensure that these 
problems do not occur, it is important to perform kinetic studies that look at both the 
immune response to the taccine as we11 as the protective effect 
1.3.4.5 The Dose of Vaccine Administered 
Previous studies examined the effect of dose on the protective e5cacy of BCG 
vaccination. In g e n d ,  these studies are k k b g  in that they have not taken into 
consideration many of the variables discussed above- For instance, in studies b t  
compare various doses of ECG, the higher doses may induce a more rapid response than 
lower doses, however, the lower doses, in time, may genaate a more appropriate and 
hence moe effective response as observed in other systems (Sdvin, 19%; Pan'sh, f 972; 
Bretscher et al., 1992). If the interval between vaccination and challenge is too short, i.e., 
before the lower dose can establish its peak response, then the lower dose will appear less 
effectve than its potential (Smith, 1985). This situation has been seen in studies of 
leishmania infection (Bretscher et al., 1992). Once again, kinetic studies that examine the 
immune response at various time points after infection are important to distinguish the 
effectiveness of various vaccine doses. 
1.3.4.6 Other Factors 
Other factors that will inauence the outcome of the protection assays include the 
virulence of the challenge strain, the challenge dose administered and route of 
administration, as well as the method used to assess protection, i.e., sunrival time, 
bacterial burden or pathology. 
1.3.5 The Immune Response to BCG Vaccination 
Surpnurpnsingly, there is scant information on the immune response induced by BCG 
vaccination considering the degree to which it has been studied as a vaccine for TB. Most 
studies of BCG vaccination have looked at the protective effect of vaccination in 
preventing TB morbidity and mortality. Few have assessed classical measures of the 
immune response, and most of these have assessed only one aspect of the immune 
response generated, i.e., antibody or cytotoxic T lymphocyte (CTL) responses. 
1.3.5.1 The Cellular Immune Response to BCG Vaccination 
In South India, where BCG vaccination Med in the Iast WHO BCG txial 
(Tuberculosis Prevention Trial, 1980; Tuberculosis Research Centre, 1999), various 
parameters of the immune response were evaluated both before and after intradermd 
vaccination with the standard dose of BCG. Individuals who were skin test- (Mantoux) 
negative before vaccination became skin test-positive; however, this did not correlate with 
an increase in INFy-production by PBMC @as et al., 1998). In another study, Kemp 
(1996) found that 2x106 BCG given by the i.d. route not only induced strong DTH 
responses at 2 months after vaccination, but M. ruberculosis-specific proliferation and 
IFNy-production by PBMC were also induced PBMC from healthy donors exposed to 
BCG in vitro demonstrated a sequential expression over time of cytokines from the Thl 
type to the Th2 type. Initial cytokine production in the first 4-5 days after stimulation 
included IFNy, TNF, and IL-2. At later times, Th2 cytokines including IL-4, IL-5, and 
IL-10 increased while Thl cytokines declined (Sander et al., 1995). Smith et al. (1999) 
looked at the CD8' T cell response in humans after vaccination with BCG. They found 
that these cells produced IFNy and TNF when stimulated with mycobacteriai antigen 
The cells also contained perforin granules and were capable of cytolytic activity. 
Mice deficient in CD4' or CD8' T cells had similar levels of Thl cytokines 
compared to normal controls, and were able to control pulmonary infection after 
intratracheal inoculation with 5x16 BCG. In contrast, interieukin 12"- mice bad an 
impaired ability to control the infection as assessed by histological examination of lung 
tissue (Xing et al., 1998). The results suggest that BCG induces both CD4+ and CD8+ 
cells and that they play an overlapping role in providing protection against BCG. The 
important role of 12 IL-12 in rnycobacterid immunity is also highlighted. Five different 
strains of BCG induced IFNy responses in lymph node cells of BALBic mice immunized 
by the S.C. route (Lagranderie ct al., 1996). IL-2 was also induced and the amount of 
both cytolcines produced varied with the strain of BCG used for immunization BCG 
changed the cytokine profile of CD4' nanaal killer T ceUs in the livers of mice immunkd 
with BCG. These cells tend to produce E-4, but after v a d a i o n  the ratio of IFNy- to 
IL4producing cells was greatly increased The authors suggested that BCG altered 
cytokine expression by CD4' T cells by IL-12 induction in macrophages (Emoto et al., 
1999). CD8' CTL specific for the 60 kDa myoobaEterial heat shock protein (hsp60) were 
induced in C57BU6 mice by i.v. immunization with 5x106 BCG (Zugel and Kaufmann, 
1997). CD8' T cells fiom BCG immunized donors have cytolytic activity against BCG- 
or PPD-pulsed autologous target cells (Smith et al., 1999). 
1.3.5.2 The Hamoral Response to BCC Vaccination 
Tumeer et d. (1998) looked at anti-PPD immunoglobuIin responses in BCG 
vaccinated individuals and TB patients. They found hit BCG vaccination (approx. loS 
BCG intradmally) induced slight ant i iy  responses in the majority of vaccinated 
individuals, and that the levels of antibody induced were similar to the levels seen in TB 
patients. Beyazova (1995) found that anti-PPD anti'body levels in infants immunized 
(route and dose unknown) with BCG in their first two months after birth showed a steady 
but gradual increase in anti-PPD ad'bodies until the end of the experiment at 15 months 
after immunization. No age-matched controls were included in this study, so there is no 
proof that the change in titer is actually due to BCG vaccination. SirniIarIy, antibodies to 
M. bovis BCG antigen A-60, the main component of old tuberculin, increased in infants 
over a six month post-vaccination period of obsavation (Rota et a]., 1994). Individuals 
vaccinated with 1-5x10' viable of BCG by the id. route demonstrated a 
smnvers ion rate of 6/21 to a purified protein antigen of BCG (P64) six wk after 
immunization @rowart et al., 1992). 
1.4 Recombinant BCG Vaccination 
The possibility of using recombinant BCG as a vehicle for immunizing individuaIs 
against a variety of infectious organisms has been an area of Interest for 
researchers for many reasons as d e s c n i  (Stover et al., 199 1): 
1. BCG is the most widely used vaccine in the world, with between 2.5 and 
3 billion people having received the vaccine since it was developed. 
2, It is a relatively safe vaccine with a low level of compIicatio11~. 
3. It can be administered any time after birth. 
4. It is a live vaccine so a single dose can provide long term immunity. 
5. Mycobacmia in general have immunopotentiating effects, which ensure a 
strong immune response. 
6. BCG vaccine is relatively stable. 
7. The vaccine is relatively inexpensive to produce. 
8. BCG has the capacity to carry a large amount of foreign DNA offering the 
opportunity to produce multivalent vaccines. 
The use of recombinant mywbacteria, particularly BCG, expressing foreign DNA 
as vaccine vectors is a relatively new concept- The first reports of mycobacteria 
expressing foreign DNA were made in 1987 (Jacobs et al., 1987). This group used 
chimeras containing bacteriophage DNA into which an E. coli cosmid had been inserted. 
This phasmid replicates as a plasmid in E. coli and as a phage in mycobacteria This 
shuttle vector permitted the introduction of foreign DNA into M. smegmuh and BCG. In 
1988, this group was able to express the kanamycin resistance gene as a selectable marker 
in a similar shuttle phasmid (Snapper et al., 1988). 
Since then, several other techniques have been developed to introduce foreign 
genes into mycobacteria These comprise the use of bacteriophages (Hatfbll et al., 1994; 
L,ee et al., 1991) and transposons (Gicquel, 1994), but the most common method is the 
use of hybrid pIasmids designed to replicate both in mywbacteria and also in E. coli. 
Such pIasmids allow gene insertion and mauipuiation to be  pertbmed using the fkt 
growing E. coli, before introducing the pIasmid into mycobacterial species by 
efectroporation. The M.fomihun plasmid pAI.5000 (Ranes et d., 1990; Rauzier et al., 
1988), a plasrnid capable of replicating in other mycobacterial species has been the center 
of much of this work. The intact plasmid contains 4837 base pairs with 65% G+C content 
and five open reading h e s  (ORFs). Further analysis identified the origin of 
replication, and that of the five ORFs, three ORFs (numbers 1,2 and 5) are necessary for 
replication of pAL5000 in M. smegnzafis (Rants et d., 1 WO), but apparently only ORF 
2 is required for replication in M./ortuitum (Villar and Benitez, 1994). 
Snapper et al. (1988) developed a plasmid d o r m a t i o n  system in mycobactaia 
using M. fortuitum / E. coli hybrid plaSmids. The hybrid plasmid @YUB 12) contained 
a mywbacteria repliwn h m  plasmid pAL5000 and an E. coli repliwn h m  pU666. The 
gene for kanamycin resistance (K') was also included in the plasmid. The plasrnid 
transformed both E. coli and mycobacterial species. Stable Kr expression was 
demonstrated. 
AIdovini and Young (1991) later modified this same plasmid to allow expression 
of other foreign proteins. They included the mywbacterial heat-shock protein, hsp60, 
promoter and translational start site to direct the expression of foreign genes. These 
regulatory elements were chosen because they are very strong promoters. Three new 
plasmids were produced, pY6029, pY6030 and pY6031 expressing the HIV gag, pol, 
and env genes, respectively (Aldovini and Young, 1991). These plasmids were 
introduced into BCG by electroporation and expression of the appropriate proteins was 
demonstrated by immunoblotting with HWpositive serum. BALB/c mice were 
inoculated with either 5 x lo6 BCG-HNgag or BCG-HIVenv intradermaUy or 
intravenously. The i.v. i n d a t e d  mice showed seroconversion rates of 3 6  to gag 
proteins and 115 to env proteins, 5 wk after immunization. None of the i.d. infected 
mouse sera were positive for HIV antibodies when assayed by ixxnmobIot at this time. 
Levels of a n t i i y  in mice that did semconvert were low. Cellmediated immunity 
against BCG-HIVgag as detamined by IFNy production and specific cytotoxic 
lymphocyte activity was also present (Aldovini and Young, 199 1). 
Karneoko et aI. (1994) used a hybrid shuttle plasmid of pIJ666-pAL5000 @IJK) 
to express an immunodominant domain of the HIV envelope V3 region, a 'T-cell 
epitope." Havmg imculated BALBlc mice S.C. with 1 x106 rBCG, they were able a 
demonstrate a specific CTL response two weeks after immunization. 
R a m  et al. (1990), after sequencing the pAL5000 plasmid, constructed pRR3, a 
''mini" mywbacteriai vector containing only those elements required for replication in M. 
smegmatis, BCG and E. coli as well as the genes for kaaamycin and ampicillin 
resistance. This plasmid replicates in E. coli and was introduced into BCG and M. 
smegmatis with relatively high efficiency. The Kr gene expression was confirmed by 
immunadetection. 
The expression of HIV nef gene in BCG was made possible by the inclusion of 
the groES/goELI operon h m  Streptomyces albtls and a synthetic ribosome binding 
site. Two new plasmids were constructed in this way, pWRIP17 and pWRIP19. Lymph 
node ceIls h m  mice immunized with BCG transformed with either of these plasmids 
prolifetated in response to Nef protein (Winter et al., 199 1). 
The lacZ gene was inserted into plasmid PEW under control of the promoter PAN 
from M. paruttrbercuIosis to produce the plasmid pAM320 (Lagranderie et al., 1993). 
BCG transformed with pAM320 produced bgalactosidase @gal). Guinea pigs 
immunized by i d ,  respiratory and oral routes showed specific cellular responses to @gal 
(as measured by proliferation of lymph node cells and induction of DTH) as well as 
gal-specific m t i i y  responses. It is worth noting that guinea pigs immunized by the o d  
and respiratory routes displayed stronger DTH than those immunized intradermally. 
Priming with non-recombinant BCG can d t  in potentiation of specific mhWy 
responses and somewhat reduced T-cell responses when mice are subsequently 
immunized with rBCG expressing the HIV nef gene or the lac2 gene (Gheorghiu et al., 
1 994). 
Stover and others deveioped another hndy of plasmid vectors used for 
transfming mywbactaia. They have idenlified a 1.8 Kb segment itom pALSOOO 
(oriM), which supports plasmid replication in mycobacteria (Stover et d., 1991). They 
included this segment dong with the E culi replicon from pUC 19, a gene for kanamycin 
resistance, and the regulatory sequences of the BCG 60 kDa heat shock protein hsp60 in 
the extrachromosomal plasmid vector pMV261. The regulatory sequence contains a 
mywbacterial promoter, a multiple cIoning site including ten unique restriction sites, and 
a transcriptional terminator rmABt, Using pMV261, several proteins were expressed at 
high levels including the E. coli lac2 gene, HIV pol, HIV gag, and HIV gp120. A 
mywbacterial gmme integrating vector was also constructed by replacing the oriM 
sequence of pMV261 with DNA encoding the attachment site and integrase gene of 
mycubacteriophage LS. Expression of the protein krn the integrative vector (pMV361) 
was less than that of the extrachromosomal vector, but increased in response to stress 
(Stover et al., 199 1 ). 
Using the plasmid pMV206 as a basis, various plasmids were constructed to 
express the pneumuccal d e  protein @spA) of Streptucoccus pneumoniae. Modified 
vectors allowed expression ofthe pspA as a cytopIasmic pmduct, a secreted product, or a 
membrane associated lipoprotein. A description of the plasmids and their construction 
foUows (Langermann et al, 1 994b). 
pMV206 contains a r n y a h c t e d  origin of repkcation, an E. coli origin of 
replication, a kmamycin resistance gene, and a mdtiple cIoning site. pMV26I includes 
everything in pMV206 as well as the promoter and n i d  binding site of the 
mycobacterid hsp60. Plasmid pPulV261-pspA contains the pspA antigen fused to the h t  
six d o n s  of the hsp60. Since no secretion signal is inciuded, the product is strictly 
cytoplasmic- 
pRB26 is composed of pMV206 plus the hs@O promoter only, allowing the 
inclusion of the nand pspA secretion signaI peptide and nisomal binding site in 
pBR26-pspA33. Thus, the expressed product is secreted. p2619 was constructed by 
including in pRB26 the n-bosomd binding site and the 5' lipoprotein signal sequence of 
the M. tuberculosis I9kD lipop~otein (Mtbi9) downstream h m  the hsp60 promoter. 
The pspA sequence is fUsed to Mtbl9 in the piasmid p2619-pspA33. Mycobacteria 
transformed with this plasmid express pspA as a d a c e  lipoprotein. 
All of these plasmids exist as multiwpy extrachromosomal plasmids in BCG and 
expression was very high (up to 15% of total BCG protein). All mice infected with BCG 
transformed with these plasmids produced au m'body response, however, protection 
frum an i.p. challenge with 104 S.pneumoniue (1 00 x LD50) was only observed in those 
animals infected with rBCG expressing pspA as a secreted product or as a d a c e  
glycoprotein (Langermam et al., 1994b). 
The outer surface protein (*A) of Bowelia burgdorferi was expressed using 
plasmids constructed in a similar way (Langermann et d., 1994a; Stover et al., 1993). In 
this experiment, only mice immunized with the rI3CG expressing OspA as a chimeric 
lipoprotein developed high a n t i i y  titers and showed protection h m  challenge with 
virulent B. burgdorferi. Neither of the preceding studies involved an examination of the 
cell-mediated response. 
pMV262 (identical to pMV261 but witb a different reading fbme) has been used 
to express the Leishmania mfb pteinase gp63 (Conneil et al., 1993; Flynn, 1994). 
Mice were irmnMized with 1p BCG containing this plasmid by i.v. route or lo6 by the 
s.c. route and then challenged with 104 L major promastigotes. CBNJ mice generally 
resolve Iesions spontaneously and unimrnunized mice did so, but lesion size was smaller 
in mice i m m d  with the rBCG prior to infection. BALB/c mice, however, do not 
spontaneously resolve their lesions and the lesions progressed even after immunization. 
Some protection h m  infection with L mexicana amastigotes was shown by 
immunization with BCG transformed with pMV262::gp63 (Connell et al., 1993). 
The pMV271 plasmid (identical to pMV261, except that it uses the hsp70 
promoter instead of hsp6O) has been used by Yasutomi to produce rBCG expressing the 
simian immunodifficiency virus (SIV) gag protein. This system was able to induce SIV- 
specific CTLs in rhesus monkeys ( L a  1993; Yasutomi, 1994). 
Table 1-1 lists some of the experiments that have used fec~mbinant BCG for 
immunization and the immune response elicited. In most cases, relatively high doses of 
rBCG have been administered. Two groups have looked at lower doses. Fuerst et al. 
(1 99 1) have examined the immune response in mice immunized by the i.v. route with 10' 
BCG expressing the E. coli fa& gene. They report production of anti-kgal-antriodies, 
although not as much as with higher doses, and a strong CfZ response at this dose. 
Intranasal immunization with l d  rBCG expressing B. butgdorsen' outer surface protein A 
(OspA) did not deve1op a significant a n t i i y  titer (approx. lo2), but the state of CMT 
was not examined (Langmann et d., 1994a). 
There is Me data available on the effect of dose on the immune response to a 
foreign protein expressed in BCG. Furthermore, there are no detailed studies of the helper 
T cell response to such proteins. I feel that the work presented here on the immune 
response to a wide range of doses of rBCG, including very low doses, and an 
examination of how the T h l m  balauce induced by such vaccination depends on dose, 
will have a significant impact on the future work in this area 
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1.5 Research Objectives: 
i. To establish a meehodology for accrtrately enumerating ex-vim antigen- 
spec& cytokine-producing cells for use in characterizing the immune 
response of immunized mice. 
ii, To characterize the BCG-specific Th cell response of mice after 
immunization with various doses of BCG administered by the i.d, and i.v. 
routes. The immune response to low doses of BCG antigen is of 
particular interest as low antigen doses in other systems have been shown 
to induce an almost exclusive Thl response. 
iii. To show that vaccination with low doses of BCG will establish a 
predominantly Thl response. It is believed that such a response would 
provide effective protection h m  M. tuberculosis infection. 
iv. To assess the hypothesis that low dose immunization will establish low 
zone immune deviation, by challenging low dose-immunized mice with 
high doses of BCG and examining the subsequent Th cell response to tfie 
challenge. 
v. To determine if low dose immunjzation with rBCG etcpressIng a foreign 
protein can establish low zone immune deviation to the expressed protein. 
Such deviation would be beneficial for immunizing against pathogens that 
are only controlIed by a cell-mediated immune response. 
2 MATERIALS AND METHODS 
2.1 Mice 
Female mice were used in all experiments. BALBIJ mice were obtained ffom the 
animal colony at the Department of Microbiology and Immunology, University of 
Saskatchewan. C57BW10 (B10) and B10.A mice were obtained h m  the Jackson 
Laboratory, Animal Resources Centre, Bar Harbor, ME, USA. All mice were housed at the 
animal care facility within the hparlment and were at least 6 wk old at the time of 
immunization. Animal care and treatment was in accordance with standards approved by the 
Canadian Council on Animal Care. 
2.2 Growth and Enumeration of BCG 
Dr. Emil Skamene of McGill University provided M. bovis strain BCG Montreal. 
The mycobacteria were propagated in Dubos medium containing 0.5% bovine senrm 
albumin and 0.05% Tween 80. Bacteria were enumerated by plating various dilutions on 
Dubos agar plates after sonication for five seconds at a power output of 5 and 50% duty 
cycle to break up clusters of bacteria. Colonies were counted fourteen days after plating, 
and consequently numbers of bacteria are expressed as cfu. 
2.3 Immmizations 
For BCG immunization, 14 day cultures of BCG were used. The cells were pelleted 
by centrifugation at 8000 g for 30 m h  and washed three times by repeated resupension m 
saline containing 0.05% Tween 80 followed by centrifugation at 8000 g for 20 min. After 
the final wash, the mywbacteria were resuspended in 11100 of the original volume of culture 
and serial dilutions were performed fiom this stock as needed. BCG immunizations were 
performed either by the i.d route or the i.v. route. For i.d, injection, hair was removed 
from the abdomen using a commercial depilatory (Neet) two days prior to injection. 
Injections were done using a I cc syringe with a 30 gauge needle attached. Mice were 
aaaesthetized with metafhe inhalation amsthetic. The skin of the abdomen was stretched 
overthe middle finger to prevent it h m  bunching up in h n t  of the needle. Wh the bevel 
of the needle facing upward, the needle was inserted several millimeters horizontally into the 
skin and 25-50 pl of the K G  fllspension containing the appropriate number of cfu was 
injected. For i,v. injection, mice were first w m e d  under a heat-lamp to induce 
vasodilation. The desired number of BCG cfu were injected in a 50 pl voIume into the 
do& tail vein using a 28 gauge needle. 
Mice were immunized by the i.p. route with recombinant bgai (Sigma ChemicaIs, St 
Louis, MO), either as a soluble protein in phosphate-buffered dine (PBS) or adsorbed to 
the aluminum hydroxide geI adjuvant, alhydrogef (Superfos Biosector, Vedbaek, Denmarlc) 
as adjuvant. For the alhydrogel prepation, the required amount of protein was mixed with 
alhydrogel and then lefi for two hours at ambient temperature to allow the protein to adsorb. 
An equal volume of PBS was added to the mixture and 200 pl was injected into each mouse. 
Injections of purified recombinant influema nucIeoprutein as desm'bed in the section 
2.20, were also performed by the i.p. route a f ta  adsorption of the protein to aluminum 
hydroxide gel adjuvant as described. Mice were immunized initially at six wk of age with 25 
pg of p d e d  protein and boosted an additional three times with 10 pg of protein at two 
week intervals, starting four weeks after the initid immunization. 
In the experiment in which the lFNyresponse to Ieistrmania parasite was determined, 
BALBIc mice were injected with approxhkIy 1000 L. major strain MHOM parasites 
subcutaneously into the footpad. 
2.4 BCG Antigen Preparation 
Bactaia were grown until they reached approximately 4x107 cfulml. They were 
pelleted by spinning for 20 minutes at 8000 g, resuspended in 0.05% Tween 80 in saline, 
and washed twice more in this sohation. The b a d  were resuspended in 5 ml of ice-cold 
0.05% Tween 80 in saline, and sonicated for 14 cycIes of one minute each in a Branson 
Sonifier, Model 450, according to the manufactureis instructions for disrupting 
mywbacteria The suspension was held in an ice bath during sonication and between cycles 
to prevent overfieating which would destroy some antigen components. In each case, protein 
concentration was determined by the bicinchoninic acid (BCA) protein assay reagent (Pierce, 
Rochford, Illinois) using bovine serwn albumin (MA) as a standard. The antigen was 
stored at -70°C. This sonicated suspension was used as antigen in the enzyme-linked 
immunospot (ELISPOT) assay, the bioassays, and the enzyme immunoassay (EIA). For 
stimulation of splenocytes in the ELISPOT assay and the bioassays, this antigen preparation 
was used at 3.33 pghnl, the concentration detamined to be optimal for stimulating the 
production of cytokines by BCG-primed spleen ceUs 
2.5 SDS-PAGE and Immunoblotting 
Discontinuous sodium dodecyl dphate-po~yaclylamide gel electrophoresis (SDS- 
PAGE) was performed using the B i d  Mini-Protean II electrophoresis system according to 
the instructions provided by the mandktum. Gels containing 12% acrylamide (30:0.8 ratio 
of acrylamide to bisacrylamide) with 4% stacking gels were nm in all cases under denaturing 
conditions. Pre-stained molecular weight standards (Biorad or New England Biolabs, 
Mississauga, ON) were nm on each gel. 
Proteins were trauskred to Biorad PVDF membranes using the Biorad Trans-Blot 
SD semi-dry transfer system. For immuaostaining of protein, blots were h t  placed in a 
blocking solution of I-% wlv polyvinylpyrrotidone (Aldrich Chemical, Milwaukee,WI), 
0.05% Tween 20, in Tris-buffered saline (TBS) for one hour. After rinsing with TBS 
containing 0.05% Tween 20 ('ITBS), the primary antlady was added in a solution of TBS 
containing 2% bovine serum albumh (BSA) and 2% Tween 20. For staining of p-gal, a 
monoclonal mouse anti-&gal a n t i i y  (Sigma Chemical, St. Louis, MO) was used at a 
111000 dilution. Staining of the HisaTag-nucleoprotein fusion was performed with an anti- 
6xHis monoclonal antiiy (Clontech Laboratories, Inc., Palo Alto, CA) at a 114000 
dilution. Lysates h m  rBCG transformed with the pMV361::NP vector were stained with 
serum diluted 11100 h m  mice immunized with purified recombinant nucleoprotein (NP) 
prepared as descriied. After a one hour incubation and washing with ?TBS, the secondary 
anhibody, a h h e  phosphatase-conjugated F(ab'), goat anti-mouse IgG (Jackson 
Immunoresearch Laboratories, West Grove, PA), was applied at 112000 dilution in TBS 
with 2% BSA and 2% Tween 8 4  and incubated for 1 h. The blots were stained with 
NBT/BCIP color development solution (Biorad) in 0.1 M Tris-HCI, pH 9.5, containing 
0.5mM MgCI2. 
2.6 Preparation of Spleen Cells for Immunoassays 
Mice were killed by m*d dislocation and their spteens were removed 
aseptically. 'The spteens were placed in LO mi of Liebovitz media and single cell 
suspensions of the splenocytes were prepared by passing them through a stainless steel 
mesh. The cells were centrifuged and resuspended in complete RPMI medium (RPMI 
I640 supplemented with L-gIu'te ,  containing 1PA heat-inactivated fetal bovine saum 
(Gibco-BRL), penicillin (100 Ufml) and streptomycin (100 &nl) and SxlO-' M fl- 
mercaptoethanol). V i l e  leukocytes were counted using trypan blue exclusion and a 
haemacytometer. Cells were kept on ice until they were aliqwted for the ELISPOT 
assays or bioassays. 
ELISPOT Assay for Detection and Enumeration of  
Antigen-Dependent IFNy- and IL4Secreting Cells 
96-well nitrocellulose-bottomed plates (Polyfiltronics, Rockland. Mass) were 
coated with purified anti-IFNy a n t i  (R4-6A2) or anti-a-4 antilmdy (1 lB11) 
(Phanningen, San Diego, Calif.) by incubating the plates overnight at 4°C with 100 
@/well of anh'body at 1.25 pghl in 50 mM carbonate buffer, pH 9.6. Spots appeared to 
be of highest quality when the coating buffer was between pH 9 and 10. The plates then 
were emptied and rinsed once with 200 pl of complete RPM medium. To reduce non- 
specific binding of proteins at later stages in the assay, the plates were incubated for at 
least one and up to thee hours with an a d d i t i d  200 pl of complete RPMI, which was 
discarded immediately prior to the addition of spleen cells. 
The spleen cells h m  experimental mice were added to the wells at densities 
ranging fkom 1 .2Sx10s to 1x106 splenic leukocytes per well. When required, additional 
spleen cells h m  unimmunized mice were added to wells in an additional 100 pl of 
medium to bring the number of splenic leukocytes up to a total of approximately 106/we11. 
Wells without additional feeder cells received an additional 100 pl of complete RPMI. 
The antigen, when required, was added to the wells with the feeder cells or addi t id  
medium as d e s c r i i  above. For stimdation of cells in the ELISPOT, BCG antigen was 
used at a concentration of 0.66 pglwelI, Ieishmania antigen (Power et al., 1999) was used 
at a concentration of 3 pglwell, and d u b l e  &gaI was used at 1 pg/welI. The assay was 
petformed in triplicate wells with and without antigen stimulation for each cell density in 
ail experiments. The seeded plates were placed undisturbed in a 37°C incubator for 8 h. I 
have compared the ELISPOT results after incubation of cells in the ELISPOT plates for 8, 
16 and 24 h. There was no significant difference between the number of antigen-specific 
IFNy-spots generated by spleen cells at these times. However, the longer incubation 
times resulted in an increase of non-specific spots in wells containing no antigen 
(unpublished data). AAer incubation, the plates were rinsed once with distilled water and 
washed thoroughly with PBS containing 0.05% Tween 20 (PBST). Biotinylated anti- 
lFNy (XMG1.2) or anti-ll-4 (BVD6-24G2) anthdies, (Phanningen) at 1.25 pghl in 
PBST were added to plates at 100 pihell and incubated at 4°C overnight. The plates 
were washed again with PBST and 100 pl o f f  phosphatase strepavidin (Jackson 
Immunoresearch Laboratories lac., West Grove, Pa)  at a concentration of 0.2 pg/ml in 
PBST was added to each well and incubated at room temperature for 1.5 h. The pIates 
were washed by repeated submersion in reverse osmosed deionized water (rdHzO). 
Spots were developed by the addition of 100 pllwell of NBTIBCIP substrate 
(Boehringer-Mannheim, Germany) in substfate buffer (100 mM Tris-HC1 pH 9.5, 100 
mM NaCI, 0.05 M M a  prepared according to the manufacturer's instructions. AAa 
spot development, the plates were emptied, rinsed thoroughly with dH20 and allowed to 
dry. Spots were counted with the aid of a dissecting microscope. Only the mrmber of 
antigendependent cytokine-producing c 4 s  is reported in each case. This number is 
assessed by determining the number of spots in wells that have been stimulated with 
antigen and subtracting the number of spots obtaiued tiurn wells in the absence of 
antigen. In a11 ELISPOT assays, spleen cells from mimmunized mice were run to ensure 
that spot formation in the assay required previous immunization with antigen. 
I use the termfeeder cells to refer to spleen cells from unimmunized mice which 
are added to wells containing spleen cells from antigen primed mice to increase the overall 
cell density in the well. These feeder cells are required to achieve optimum sensitivity in 
the assay if the immune cells are seeded at densities lower than lo6 celIs/well. For the 
experiments in which BALBJc mice were used, the feeder cells consisted of splenic 
Ieukocytes h m  syngeneic non-antigen-primed mice prepared in the same manner as the 
spleen cells h m  the immunized mice. For the experiments in which the B 10 and the 
MHC-congenic B1O.A mice were used, the feeder cells consisted of tither B I 0 or B 1 0 A 
spleen cells, which were prepared as above and further depleted of T cells by incubation 
with anti-Thy-1 a n t i i y  and complement. This was done to eliminate the possibility of 
the feeder cells responding to the allogeneic MHC-molecdes of the immune cells. 
The ELISPOT was also perfonned on Thy-l'depleted immune cells to ensure that 
the IFNy spots were indeed produced by T cells. In some cases, the assay was 
performed on 04'- and CD8+depleted cells and the results were compared to results 
obtained with rmdepleted cells to determine the phenotype of the cytokineproducing cells. 
The T cell depletions were carried out as indicated below. 
2.8 Complement-Mediated Depletion of T h y-l', C D4', and 
CD8' Cells 
Spleen cells were suspended at 10~hnl in complete WMI medium. Ascitic fluid 
containing the anti-Thy-1 2 (TIB 99), anti- (GK1 .a, or anti-CD8 (TIB99) antibodies 
(ATCC, Rockville Maryland), was added to the cell suspension at a dilution of ID00 and 
the cells were incubated on ice, After 15 h, rabbit complement (Cedariane Laboratories, 
Homby, Ontario, Canada) was added at 1/10 the volume of the cells and the mixture was 
incubated at 37°C for 45 min. The cells were washed twice with complete RPMI medium 
and resuspended in fksh medium. The number of viable wbite cells was counted once 
again to check the percentage of Iysis. In procedures where complement mediated lysis of 
celh was perftted, cells were added to the assay based on the cell counts obtained 
before the depletion. 
2.9 Interferon-y Assay 
2.9.1 Preparation of Cellular Supernatant Fluid 
Spleen c d s  fiom BCG-infected and control mice were plated at a concentration of 
4x106 cells/well in 24 well trays in complete RPMI medium. Cells from each mouse were 
incubated both with antigen and without antigen to ensure that cytokine production was 
antigen-dependent. When present, antigen was added to the wells at a concentration of 
33pg/ml. AAer incubation at 37OC for 48 h, the supernatant fluid was collected Cells and 
d d a r  debris were removed by centrifuging at 500 g for 20 minutes. The samples were 
stored at -20°C until use. 
2.9.2 Interferon-y Bioassay 
IFNy present in spIeeu cell cuIture supernatants was quantitated using a viral 
cybpathic reduction assay emp1oying the murine ~ b l a s t i c  ceII line L929 and 
endomyocafditis virus (Familletti et ai., 198 1)- The reduction in viral cytopathogenicity was 
invariably due to interferon as confirmed by its abrogation upon adding the lFNy 
neutdkhg monoclonal anthdy XMGI.2 (Chawinski et al., 1987). The assay was 
standatdized employing recombinant mutine iFNy of known activity, as specified by the 
(htennedico, Markham, ON). All assays were done in triplicate. The 
production of my is given as units per 106 cultured white spleen cells. One ng of lFNy is 
equal to 5 units according to the standard assay procedure. 
2.10 Analysis of Anti-Mycobacterial or Anti-P-gal Antibody 
by Enzyme Immunoassay 
Blood h m  n o d  or infected mice was collected by tail bleeding into serum 
separator tubes (Becton Dickinson, Rutherford, NJ). After allowing the samples to clot for 
at least several hours, individual serum samples were harvested by centrifugation at 
approximately 5000 g for 60 seconds. Sera were stored at -70°C until use. The IgG1 and 
IgG2a serum antibody titers were determined using an EIA (Hornbeck, 1994). Immuion- 
4 96 well polystyrene plates (Dynatech Laboratories, Chantilly, VA) were coated with 
either BCG antigen or with soluble bgal antigen at a concentration of 1 pglwell in t 00 pl 
of PBS. Serum samples were diluted 11100 in PBS containing 2% BSA and 2% Tween- 
20 (assay diluent) and two-fold serial dilutions were prepared in the EIA plate. The plates 
were incubated at 31°C for 2 hr and washed thoroughly with rdH2O. Horse-radish 
perolddaselabeled rat anti-mouse monodonal antr'body against mouse [gGl Qr IgG2a 
(Southern Biotechnology Associates, Birmingham, AL) was added to the wells at a 
dilution of 113000 in assay diluent, 100 pl per well, and incubated at 370C for two hours. 
AAer washing, ABTS (22'--azino-di[3-ethyl-benzthiazohe sulphonate (6)J) substrate 
solution (Kirkegaard and Perry, Gaithembur& MA) was added to the wells and incubated 
for 20 minutes betbre reading the plates on a Biorad (Hercules, CA) Model 2550 EIA 
Reader. Pooled serum fiom normal mice was used as a control. Titers were determined m 
one of two ways. For the d t s  presented in Chapter 4, the titer is presented as the last 
dilution factor to give aa optical density m the assay twice the value of the resuIt for a pool 
of sera h m  unimmtmized control mice. At the suggestion of my supervisory committee, 
I used a differe~lt method to determine titer in subsequent experiments. For d t s  
presented in Chapter 5, optical density was plotted against the log of the dilution factor for 
each sample. The endpoint titer was assigned as the point on the line at which the optical 
density was 0.5 above the value for wells in which no serum was added (conjugate blank). 
2.11 Establishment and Assessment of Cell-Mediated immune 
Deviation 
Mice were inoculated intravenously in the tail vein or intradermally on the abdomen 
with the number of cfu indicated in the text, and were later challenged with a high number 
of BCG cfu given intradennally. The number of mywbacterial antigen-specific IFNy- and 
IL4pduc ing  cells in the spleen of these high dose challenged mice was assessed by the 
ELISPOT assay. The number ofmJycproducing cells and number of IL4producing cells 
were taken as measures of the ThI- and Th2-components of the immune response 
respectively. 
2.12 Isolrtion of plasmid DNA from E. coli 
Plasmid isolation was carried out using two methods. In most cases, plasmid 
DNA minipreps were prepared by the boiling method (Sambrook et aI., 1989). In some 
cases, when DNA of higher purity was required, DNA midipreps were prepared using a 
co~tlfnercial kit (Qiagen, Mississauga, ON,). In the latter case, the concentration was 
estimated spectrophotometrically by absorbance at 280 nm wavelength. 
2.13 Mycobrcterial Expression Vectors 
Dr. Mark Hanson of Medlmmune, Gaithersberg, MA, kindly provided two 
mycobacted expression vectors, phN26 I and pMV36I. Both plasmids contain the E 
coli repticon hrn pUC19 which supports replication in E. coli, the b y c i n  resistance 
gene, and the regulatory sequences ofthe BCG heat shock protein hsp60. The regulatory 
sequence contains a mycobacted promoter, a mdtiple cloning site including ten unique 
restriction sites, and a tmmiptionaI terminator rmABt. The extrachromosomal plasmid 
vector pMV261 (Figure 2-1) contains a 1.8 kb segment of DNA tiom pAL5000, a natural 
plasmid obtained hrn M.fomincm, which includes a mycobactecial origin of replication 
(oriM) to support plasmid replication in mycobacteria, pMV361 (Figure 2-2) is an 
integrative vector constructed by replacing tbe oriM sequence of pMV261 with DNA 
encoding the attachment site and integrase gene of mycobacteriophage L5. In both cases, 
inserted genes are expressed as a fusion protein with the first six amino acids of the 
mycobacterial hsp60. Vectors pMV261 and pMV361 containing genes for pgal 
(pMV361:ficZ) and the gag protein of HIV (pMV361::Hgag) were also provided by 
Medlmmune. 
2.14 Growth md Purification of Influenza V i s  
Thirty-five lo-day old chicken embryos were inoculated in the allantoic sac with 
100 pi of influenza A/PR/8/34 virus stock (local laboratory stock, hemagglutination titer 
of 11256) according to the method of Rovozzo and Burke (1973). The eggs were 
incubated for 3 days at 37' C, and tumed eacb day. On the third day, the embtyonated 
eggs were pIaced in the figeratot overnight. The virus-containing allantoic fluid was 
collected, pied and centrifbged at 1 OOO g fbr 10 min to m o v e  particulate matter. The 
titer of the subsequent v i m  stock was U256 as assessed by virus hemaggIutination of 
chicken red blood cells. The virus was hrher purified by the method of Laver (1969). 
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Figure 2-1 Stmcttm of plasmid pMV261. 
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The virus infected allantoic fluid was cmtdbged at 2000 g for I5 min to remove 
wculate matter. The supernatant fluid was chilied to 0°C in an ice-water bath. Chicken 
blood cells were collected in Elsevers solution as anticoagulant. The cells were washed 
in PBS and also chilled in the ice bath. A 5% vlv of packed red blood d s  was added to 
the dantoic fluid and the mixture was s t .  gently for one hour while kept in the ice- 
bath. The supernatant fluid was then removed and discarded. The aggIutinated cells were 
washed once with icecold saline, and then resuspended in a volume of warm saline equal 
to 1/10 of the original volume of allantoic fluid. The virus was then allowed to elute for 
one hour at 37°C. The cells were removed by centrifugation and the supematant fluid 
containing the virus was collected and stored at -70°C. 
2.15 Isolation of Viral RNA 
The purified virus was pelleted by centifugation at 100,000 g for I6 h. The viral 
RNA was extracted by the following method. The virus pellet was suspended in 0.5 mf 
of RNA buffer (0.5 M NaCI, 0.2 M Tris-Ha, pH 7.6, 10 mM e t h y I e n e d i a r n i n ~ * c  
acid (EDTA), and 1% SDS. A 0.5 ml volume of pheno1:chloroform:isoamyl alcohol at a 
ratio of 25241, which had been eqltilt'brated with RNA buff= (without SDS), was 
added. The mixture was vortexed at high speed for 1 min and then centrilged for 30 
sec. The aqueous phase was removed and treated with an equal volume of the 
pheno1:chloroform mixture and centrifuged at high speed to separate the phases. The 
aqueous pbase was transfecred to a clean tube and 1 ml of ice-cold 100% ethanol was 
added to this tube, which was then spun at high speed for 1 min to pellet the RNA, The 
pellet was rinsed once with 150 pl of 70% ethanol, resuspended in I00 pI of rdH,O, and 
stored at -70°C. AU r8I,O used in this extraction method was treated with 
diethy1pyrocarbOnate and autoclad before use. 
2.16 Preparation of Viral cDNA 
First strand cDNA was prepared using the Superscript kit (Glbco Scientific, 
Burlington, ON) according to the instructions provided Primer PRS- I (ACG AAA AGC 
AGG) prepared by integrated DNA Technologies (Coralville, IA, USA) was used for 
first strand cDNA preparation. This procedm provides cDNA of all eight influenza gene 
segments as the primer is compIimentary to a sequence common to all segments. 
2.17 Amplification of the Nudeoprotein Gene by 
Polymerase Chain Reaction (PCU) 
To amplify the nudmprotein gene segment, two NP specific primers were used, 
NP-1 (5'-CGA A n  CAT GGC GTC CCA AGG CAC C-3') and NP-2 (5'-CCA TCG 
A T  AAT TGT CGT ACT CCT CTG-3'). To facilitate cioning of the PCR product into 
the various vectors, the primers contained 5' extensions coding for restriction enzyme 
sites: Eco R[ in NP-I and Cla I in NP-2. As the primers anneal to templates without these 
extensions at a lower temperature than to those with extensions, the PCR was carried out 
in two phases. The denaturing time and temperature were 94°C for one min and the 
extension conditions were 72"c for 2 minutes throughout the procedure. In the tint three 
rounds of amplifim-on, the annealing conditions were 44°C for one min. The 
temperature was then ramped b m  44°C to 72OC at a rate of O.S°C per min. followed by 
the one minute extension at 72OC. Subsequently, the annealing temperature was raised to 
53°C fbr another 30 rounds of amplification. 
The NP gene segment was cloned into the Em EU and Cla I sites of pBluescript 
SKI1 vector (lnvimgen, San Diego, CAI. The construct was used to transfii DH5a E. 
coli cell he and miniprep DNA of transformed colonies was prepared. Sequencing was 
cazried out using the 'I7 DNA sequencing kit (Pharmacia, Piscatawy, NJ). The sequence 
of the cloned nucleopmein gene was compared to the ori@ published sequence for this 
strain of virus (Winter and Fields, 198 I). 
2 .18 Cloning of the Nucieoprotein Gene into E. c d i  
Expression Vector pTrcEis 
The NP gene was cloned into pTrcHis (Invitrogen Corp, San Diego, CA). For 
the purpose of cloning into this plasmid, the pBIuescipt construct containing the NP gene 
was digested with the restriction enzyme Xho I which lies downstream h m  the Clo I site 
at the 3' end of the NP gene, and a Xho I-Eco RI linker was ligated into this site. This 
provided a NP gene insert that has au Eco lU restriction site at either end of the gene to 
b 5 W e  cloning into vectors containing a single Eco RI site within the multiple cloning 
site. This hgment was then ligated into the Eco RI site of pTrcHis for expression of the 
NP gene. After transformation of DHSa cells, miniprep DNA prepared h r n  individual 
colonies were screened for appropriatety sized plasmids. Those containing the fragment 
in the appropriate orientation were sdected based on hgment size after restriction digest 
2.19 Trmsformation of E. coli 
Transformation of E. coli was performed using the E. coli pulser eiectroporator 
(BioRad) according to the manufiicturer's instructions. 
2.20 Expression and Purification of Recombhaat NP from 
E. coli 
The pTrcHis pIasmid contains a HisoTag, a sequence of six histidine residues in 
sequence, immediatdy dowmtrem firom the plasmid encoded ATG sbrt site. The NP 
gene was inserted in h e  with this sequence so that the expressed protein would be a 
firion protein with t&e HisoTag. The HisoTag has a very high afihity for the nickel ion 
which allows purification of the h i o n  protein fiom the cell lysate with an afkity media 
Purification was carried out using the Novagen HisoBind metal chelation resin columns 
(Novagen, Madison, WL) using the directions for denamring conditions (Novagen, 
1995)- Purity was assessed by SDS-PAGE. 
2.21 Cloning of the NP Gene into the Mycobacterial 
Expression Vectors pMV261 and pMV361 
The NP gene was cut out of pBluescneScnpt SKII by restriction digest with Eco Ri 
and Ch I and ligated into pMV361 and pMV261 plasmids digested with these same 
enzymes. The ligation reaction product was used to transform E. coli strain DHSa. 
TfaZlSformed cells were plated on L e ~ o x  broth agar (US Biologicals Swampscott, MA) 
plates containing 50 pg/ml of kanamycin as a seIective marker. Miniprep DNA was 
prepared h m  cultures of selected colonies and screened for the appropriate plasmid size. 
DNA sequencing of the pIasmid/insert junction was performed to ensure that the insert 
was in b e  with the plasmid encoded portion (6rst six amino acids of hsp60) of the 
h i o n  protein gene. 
2.22 Preparation of Electroporrtion-Competent BCG 
The method of Parish and Stoker (1995) was used to prepare electroporation- 
competent BCG. A 200 ml aliquot of MiddIebmok 7H9 medium (Difco, Detroit, MI) 
containing OADC supplement @ifco, Detroit, MI) and 0.05% Tween 80 was inoculated 
with 1 ml of a 5 day cdture of M. boxis and cultured for 12 days. Glycine was added to 
the culture to a final concentration of 1.5% for the last two days of culture. At the end of 
the culture period, the mycobacteria were incubated on ice for 1.5 hr before harvesting. 
They were peIleted by centrifugation at 8000 g for 30 min at 4°C. The d t i n g  pellet 
was washed by repeated wspemion and cdfbgation (8000 g, 4OC) in reducing 
volumes of an ice cold solution of 10% giycerol, first in 100 ml, then in 25 ml and lastly 
in 5 ml. After the final centrihgation, the bacteria were suspended in 2 ml of ice cold 
glycerol, dispensed into 100 pl aliquots in eppendorf tubes, and flash hzen by 
immersion in an ethanol bath containing dry ice. The tubes were stored at -70°C. 
2.23 Trmslormation of Competent M. bovis BCG 
Tran&ormation of competent BCG was performed by electroporation using the 
Gene Pulser I1 (BioRad). BCG were removed h m  the W e r  and immediately placed 
on ice. One microgram of plasmid midiprep DNA was added to the tube and the contents 
were mixed and placed on ice for ten min. The mixture was transferred to a chilled, 2 mm 
gap electroporation cwene (WNR scientific, Toronto, ON). The bacteria were subjected 
to a pulse of 3.5 kV, 25 pF, at a resistance of 1000 Q (Parish and Stoker, 1995). The 
cuvette was incubated on ice for ten minutes before the contents were transferred to a 
separate tube and diluted with 3 ml of Middlebrook 7H9 media (Difco, Detroit, MI) with 
0.5% Tween 80 and OADC supplement @ifm). The mixture was incubated at 37°C for 3 
h to allow for antiiotic expression. Cells were harvested by centrifugation at 3000 g for 
ten min and plated on Middlebrook 7H10 agar plates with OADC and 10 pghI of 
kanamycin (Parish and Stoker, 1995). The plates were sealed with parafh and 
incubated at 37°C for 2 1-28 days to allow cobnies to grow. 
A Valid ELISPOT Assay for Enumeration of Antigea- 
Dependent Cytokine-producing Cells 
3.1 Introduction 
The ELISPOT assay for the enumeration of cytokine-producing cells was first 
d e s c r i i  over a decade ago (Czerkinsky et al., 1988). Since that time, various 
modifications and applications of this technique have been described. Many reports on 
conditions for optimization of the ELISPOT assay have used T cell clones, (Czerkinsky et 
al., 1988; Hutchings et al., 1989; Miyahira et al., 1995) or mitogen- (Okamoto et al., 
1998; Taguchi et al., 1990), or anti-CD3- (Favre et aI., 1997; Hutchings et al., 1989) 
stimulated cells as a source of cytokine-producing cells. T cell clones or mitogen- 
stimulated ceUs are convenient for designing ELISPOT assays because they provide an 
efficient and consistent source of cytokine-producing cells. These investigations have 
defined certain parameters of the assay, such as the identification of appropriate anti- 
cytokine antibody pairs and the standardization of reagents. However, these experimental 
models do not necessariiy optimize the conditions for detecting antigen-specific cytokine- 
producing lymphocytes present in an immune individud. The requirements for triggering 
antigen-specific cytokine production by a population of polyclonaI lymphocytes in vitro 
may be different h m  those causing cytokine release h m  cells belonging to a T all 
clone. Anti-CD3 and some forms of mitogen stimulation of T cells do not require antigen 
presentation and, therefore, are not good models for antigen-specific cytokine production. 
To obtain an optimaIIy sensitive assay for detecting single, antigen-specific cytokine 
producing cells, the effects of varying parameters such as the antigen concentration, the 
numbers and types of ceh in the ELISPOT well and the time required for stimulation 
must be assessed. 
The enumeration of antigen-dependent cytokine-producing cells in b b l y  isolated 
lymphocytes by ELISPOT assay has been problematic. Many report a requiranent for a 
period of pre-incubation of the lymphocytes with antigen, h m  ovanight to 72 hours or 
more (Hutchings et al., 1989; Xu et al., 199 1; Muller et al., 1994; Sarawar and Doherty, 
1994; Milligan and Bemstein, 1995), to optimize detection of cytokine-producing cells. 
Although very short-term restimulation with antigen may be acceptable, the activity of 
cells after longer term incubation with antigen in vitro may not reflect the ex-vivo state of 
the cells, the assessment of which is usually the primary purpose of the assay. The 
addition of extraneous cytokines during a pre-incubation step is inadvisable, as this will 
compound the difficulties of relating the observations to the in vivo state of the cells. 
If the goal is to measure the magnitude of the immune response in an individual by 
estimating the number of antigendependent cytokine-producing cells in a particular 
immune compartment, it is necessary to make such an estimate as soon as possl%le after 
removing the cells h m  the individual, without long incubation periods or pre-exposure 
to extraneous cytokines. I descni a short-term ELISPOT assay technique for detection 
of antigen-specific IFNyproducing mrrrine splenic T ails. Although the results presented 
in this chapter concentrate on IFNyproduciag T cells, I have used similar expetiments to 
show the validity of this method for enumerating antigen-specltic L4producing T celIs. 
This method differs h m  most descnibed in that the cells are placed directly ex-vivo into 
the EMSPOT plate without the need for a sepslrate step involving pre-incubation with 
antigen. Optimal sensitivity is obtained in this assay by incubating the cells at high 
densities in the ELISPOT tray wells. The results presented here have shown that very 
high cell densities are required to provide effective antigen-presenting cell- (APC) 
fuaction to the T cells. Therefore, when Iowa numbers of immune ceh  are used, spleen 
cells h m  n o d  syngeneic mice can be used to provide this APC function. 
3.2 Results 
In coflaboration with others in Dr. Bretscher's lab, I have developed a very 
sensitive ELISPOT technique for detection of antigen-specific T cells which is performed 
on cells immediately after their removal fiom the mouse without the requirement for a 
separate step involving the incubation of the cells with the antigen. Sensitivity of the 
assay is dependent upon a high density of cells in the wells of the ELISPOT plate while 
they are being stimulated with antigen. In an optimally functional and valid assay, 1 expect 
that the number of cytokine-producing cells detected (spots) to be proportional to the 
number of immune cells in the well. Therefore, for each two-fold dilution of immune 
cells in the well, the number of spots should decrease by half. For the ideal assay, a plot 
of number of immune cells vs. the number of spots should result in a straight line that 
intersects the y axis at the origin. Figures 3-1 to 3-3 demonstrate the requirement for high 
cell density in tbe assay regardless of the antigen used. In the experiments shown in 
Figures 3-1 and 3-2, the assay was performed with two-fold serial dilutions of immune 
cells h m  mice that received approximately 10' BCG cfb by the intradennal route, ten 
weeks earlier. When the serially diluted immune cells alone were incubated with antigen 
in the ELISPOT plate wells, the resulting number of spots at the lower dilutions was not 
proportional to the number of immune spleen cells added to the well. However, when the 
same assay was performed with the addition of feeder cells to bring the total number of 
cells in each well to approximately 10" the number of spots was approximately 
proportional to the number of immune cells plated at all dilutions. 
Figure 3-3 demonstrates a similar d t  using another antigen system, the 
leishmania parasite. The reauIts of the ELISPOT assay for spleen cells h m  two 
individual mice infected with leishmania parasites are shown. When dilutions of these 
cells are used in the EWSPOT alone, the resulting number of spots is not relative to the 
number of cells, i.e., a plot of spots vs. the number of immune cells is not linear. 
Figure 3-1 Representative weUs h m  the ELISPOT assay performed with and 
without added f& cells. The ELISPOT technique was performed as indicated in the 
Mataials and Methods section on sensend dilutions of spleen cells fbm BCG immunized 
BALBIc mice. The weUs contained 5x1@ (A and D), 2.5~1 o5 (B and E), and 1.25~1 O5 
(C and F) immuue spleen ceWweU. The w e b  shown in A, B and C contained immune 
cells only whereas syngeneic spleen cells from UnimmMized mice were added to the 
wells depicted in D, E and F to bring the total number of spleen cewwell to approx. 1 06. 
NO. OF PRIMED CELLS I WELL (x 10 - 5) 
Figure 3-2 Effect of feeder cells on the sensitivity of the IFNy ELISPOT assay 
performed on spleen cells fiom BCG immunized mice. Mice were injected by the 
intradermal mute with approximately 10' BCG cfu The ELISPOT assay was paformed 
on sexid two-fold dilutions of splenocytes pooled fhm 3 BCG immlmized mice. The 
immune cells were incubated in the ELISPOT plate either alone (A) or with spleen cetls 
fiom syngeneic unhnunized mice (0) to bring the total number of celWweIl to 10'. The 
number of antigen-- spots is determined by subtracting the numbex of spots (in all 
cases < 10 spotdl0 spleen cells) m wells without added antigen. Each point represents 
the mean number of antigen-specific spots m 3 assay welIs +/- SD. 
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Figure 3-3 Effect of feeder cells on the sensitivity of the IFNy ELISPOT assay 
performed on spleen cells firom L major-immunized mice. The ELISPOT assay was 
performed separately on seriaI two-foId dilutions of splenocytes k m  two L major- 
immunized mice (0,O) as indicated. The immune cells were incubated in the ELISPOT 
plate hr 8 hours either alone (dashed line) or with spleen cetls h m  uahmunized 
syngeneic mice to bring the total number of ceWvel.I to lo6 (solid line). Each point 
r~pnscnts the mean number of spots in 3 assay wells af€er subiracting background spots 
in wells without antigen (in all cases < 10 spatsi106 spleen cells) +I- standard deviation 
(SD). 
However, with the addition of feeder cells, the resulting number of spots is always 
proportionai to the number of plated immune celis, i.e., the results are linear. Tfie same 
conclusion has been made by N. Ismail with sp1m cells h m  mice immmhd with red 
blood ceUs (Power et al., 1999). In pteliminary experiments, 10' ceWwell was shown 
to be optimum for spot detection m the BCG and leishmania antigen systems, as higher 
densities resulted in increased background without significant increases in sensitivity 
(unpublished data). It should be noted that the feeder cells do not signifiwntly contniute 
to the nmber of spots produced, as 10' feeder cewwell alone produce negiigible 
numbers of spots when stimulated with antigen. These results indicate that the ELISPOT 
assay as descnied, is an efficient method to detect cytokine responses to a vanvanety of 
antigens and that the requitement for high cell density to achieve maximum sensitivity in 
the ELISPOT assay is independent of the antigen used. 
In ELISPOT assays for IL4producing cells, sensitivity was much less dependent 
on the density of cells in the weIl. Although increased cell density increased detection of 
IL4producing cells marginally, the difference was much less dramatic than that in the 
IFNy assay. 
I hypothesized that high oell density is necessary to allow T cell - T cell 
interactions to OCCLK, to condition the media by providing some soluble hctor mpired for 
optimal fimction of the T cells, or to provide adequate antigen presentation to the immune 
T cek. The experiments shown in Figure 3-4 were conducted to address this question of 
feeder cell function. In three separate experiments, I petformed the ELISPOT assay on 
immune cells fhm B C G - i m m d  mice. In each case, immune spleen cells h m  these 
mice were incubated either alone, or with T celldepleted feeder ceIls from syngeneic mice 
or h m  MHC-congenic mice. [n all cases, MIIC-matched feeder cells were requid to 
ensure optimal functioning of the assay. A11 spots were produced by antigmqecific T 
cells, as spIeen cek h m  u n i m m a  mice did not produce significant spots under the 
Figure 3-4 MHC-matched feeder tens are requhd for enhanced sensitivity observed 
at high cell density. Serial dilutions of white splenocytes from BCG-immunized mice 
were used in the ELISPOT assay. These immune cells were incubated in the ELISPOT 
plate wells either alone (A), or with T cell Mleted feeda cells h m  syageneic (U) or 
MEiC-congenic (0) unimmunized mice. A and B represent two independent 
experiments in which the immune spleen cells were from B LO mice (H-2*) and the MHC- 
cimgenic feeder cells were from B Z 0.A mice (H-27. C shows the reverse experiment m 
which the immune cells were fima B IOA mice and the feeder ceUs wexe taken h m  B I0 
mice. All points represent the mean number of spots m 3 assay wells +/- SD. T 
Iym@cyte depIetion of immune ceIls aiminllted spot farmation. 
same d t i o n s  and T cell depletion of spleen cells from immunized mice eliminated spot 
formation (unpublished data). These observations show hat  the major function of the 
feeder cells is MHC-restricted. I S i r  that the increase in spot formation is due to an 
increase in the number of antigen-presenting cells in immediate contact with the T cells, 
providing improved antigen presentation and thereby enhanced stimulation of the T cells. 
Complement depletions performed with anti-CD4- and anti-CD8- a n t i i e s  
demonstrated that m BCGimmunized mice, approximately 75% of IFNyproducing & 
were CD4' while 25% were of the CD8' phenotype. BCG-specific tL4producing cells 
were of the C W  phenotypetype 
I also compared the iFNy ELISPOT assay to the bioassay for antigendependent 
production of IFNy that is used in Dr. Btetscher's laboratory. The results are shown in 
Figure 3-5. There is a high conelation between the two assays. However, the ELISPOT 
assay is a more sensitive assay as IFNy spot-forming cells can be detected when IFNy 
was rrndetecmble by the bioassay. This may simply be due to differences in the 
sensitivity of detection between the two methods. Alternatively, it may be a result of the 
iong term cutture system used in the IFNy bioassay. Drrring this culture period, the cells 
rn actively metabolizing so some of the IFNy that is produced may be either collsumed 
by cells, or broken down by proteases in the medium. 
INF? SPOTS 1 lo6 SPLEEN CELLS A 
3.3 Discussion 
Enumeration of cytobpducing ceIls by ELISPOT provides an efEcient 
method for measuring the effector response of a cell population to a specific antigen. I 
wished to use this technique in the laboratory to determine the a d  number of antigen- 
s p d c  cytokinaproducing cells in a given immune compartment such as the spleen. 
This requires that the assay be performed upon cells immediately after their removaI h m  
the animal, without long in vitro restimulation that can lead to antigen-dependent and 
antigen-independent changes in the T cell population, including alterations in their 
cytokine-producing profiles. Accordingly, I undertook to define the parameters that are 
required for optimal sensitivity of the ELISPOT assay when ex-vivo lymphocytes are 
used. 
When spleen cells h m  immunized mice were stimulated with antigen only during 
the UISPOT assay, the sensitivity of k assay varied depending on the nmber of cells 
in the well. The bighest sensitivity was observed at high cell densities, and the sensitivity 
decreased progressively as the number of cells/well was reduced. I found h t  the 
sensitivity could be maintained when the immune cells were used at low density by 
supplementing with spleen cells h m  no& mice. These supplemental cells did not 
contribute significautly to the number of spots observed because lo6 feeder cells alone 
produced a negligible number of spats when stimulated with antigen. 
The results show that the cornlation between the assay sensitivity and cell density 
is due to the requirement for adequate antigen presentation. The close cell to cell contact 
that occurs at high cell density allows fw intimate contact between the T cells and antigen- 
presenting cells providing efficient antigen presentation and stimulation. Previous assays 
have used in vim antigen-restimdation for varying intervals before the cells were used in 
the ELISPOT to increase the d t y  of the assay ( Hutchings et al., 1989; Xu et aI., 
1991; Muller et al., 1994; Sarawar and Doherty, 1994; De Franc0 et al., 1995; Milligan 
and Bemstein, 1995). This method eliminntff the need for this additional step by 
incubating the cells in the ELJSPOT assay at high density, and I believe that the results 
obtained by this method represent the in vivo situation more accurately. Furthennore, by 
eliminating the necessity for the a d d i t i d  step, this direct assay reduces time and cost. 
The assay d e s c n i  is also advantageous when the number of immune cells that 
can be used must be restricted. If the immune response in the animal is very high, the 
assay must be performed using fewer irmnuue celldwell so that the spots can be counted 
reliably. AItematively, when the assay is being performed on peripheral blood 
lymphocytes or on cells h m  murine lymph nodes, then the number of immune cells 
available may be limited. In each of these situations, spleen cells h m  syngeneic mice can 
be added to increase the density of celldwell, thereby maintaining the sensitivity of the 
assay even when fewer than an optimal number of immune cells is used. 
These findings indicate that the current ELISPOT protocol offers an efficient, 
convenient and very sensitive alternative to other ELISPOT methods, and I have identified 
eficient antigen-presentation as crucial requirement in establishing maximal sensitivity in 
any ELISPOT technique. Furthermore, the jmameters needed to achieve optimal 
sensitivity seem to be virtualIy identical in the different antigen systems employed, namely 
BCG, leishmania parasites and xenogenic red blood cells (XRBC) (Power et al., 1999). 
Immunization of Mice with a Low Dose of BCG 
Induces A Thl Response that is Stable upon Challenge 
with r High Dose of BCG 
4.1 Introduction 
The influence of immunizing dose has been documented in other antigen systems, 
both with non-replicating (Salvin, 1958; Parish, 1972; Hernandez-Pando et al., 1997; 
Ismail and Bretscher, 1999) and replicating antigens (Bmtscher et al., 1992; Menon and 
Bretscher, 1998), demonstrating that low doses in these systems initiated Thl responses 
while high doses initiated mixed ThllTM or predominantly Th2 responses. Never the 
less, it is not generally accepted that antigen dose can be a major factor in determining the 
type of immunity that is generated in response to an antigen. The experiments detailed 
below were performed to determine how the dose of BCG administered to mice via the 
i.d. and i.v. routes of administration influences the T h l m  nature of the immune 
response. Two types of experiments were performed. In initial experiments, mice were 
immunized with BCG and the primary immuue response to BCG antigen was determined 
ten wk pi, by ELISPOT assay and by EIA for anti'body production. In the second group 
of experiments, the ability of low dose BCG immunization to establish immune deviation 
towards the Thl pole was examined in mice subsequently challenged with a high dose of 
BCG. 
4.2 Results 
Figures 4-1 and 4-2 and Table 4-1 show the response to primary infection with various 
doses of BCG . . by the id. (Fig. 4- 1 and 4-2) and the i.v. route (Table 4-1). 
Figure 4-1 ~ u r n b e r ~  o f ~ ~ ~ s p e c i i i c  cytoi ine-producing ce~s/106 spleen cells as 
measured by ELISPOT in mice immunized intradefmaliy with differe~lt numbers of BCG 
cfu Spleens of individual mice were assayed at the indicated times poststididon. OlJen 
bars represent the number of IFNy spots and hatched bars of IL-4 spots. Control mice 
received sahe only. * Indicates number of spots < 5 per lo6 spleen cells. 
Figure 4-2 S e m  antiiy titers (IgGl and IgG2a1 of mice 11 weeks after i.d. 
imrmmi;Lation with varying doses of BCG. Open bars represent IgGl and hatched bars 
IgG2a titers. * Indicates an antibody titer of 100 or Iess. Negligible titers were observed 
at 3 weeks post-inoculation. OnIy immunization with the highest dose induced significant 
antiiy a 7 weeks post-infection. Sera of mice were tested up to 1 I months post- 
infection and no BCG-specific antiiy was de!ectd m the sera of mice which received 
2x1 d BCG during this the .  
Table 4- 1 Immune response for individual mice 1 1 wk after immunization by the i.v. 
route with different numbers of viable BCG mywbacteria. 
Cytokine-producing Cell$ 
Per lo6 SpIeen Cells S e m  Anti iesc  
Mouse IL-4 I@ IgG2a 
"Mice were given dine (C), approx. 2x10' BCG cfb (L), or approx. 2x106BCG dL 
(HI. 
The ELISPOT assay was used to quantitate cytokine-producing cells. 
' A n h i y  titers were determined by enzyme immunoassay and the titer is defined as the 
last dilution to give a positive result Prebleed sera had titers of < 100. 
* Antibody titer 400. 
In the experiment shown in Figure 4-1, groups of mice were immunized with three 
different doses of BCG; 2x103, 2x1@, and 2x10' administered intradermally. A control 
group was given only saline. The immune response in the spleens of three mice h m  
each group was deteRniLled by the ELISPOT assay at 3,7, and 11 wk post-infection. Fig 
4-1 demonstrates that the low dose of 3x103 BCG administered i.d. induced T cek 
pmducing IFNy, but few IL4producing cells. The intermediate dose resulted in some 
IL4producing cells, but the IFNyproducing cells still predominated In mice that 
received the highest dose, strong and equally potent IL-4 and IFNy responses were 
observed in all three mice. These results demonstrate that while high doses of BCG 
induce both IFNy- and IL4production by T cells, low doses induce only [my- 
producing cells. 
The IgGl and IgG2a subclasses of a n t i i y  were also examined in the same 
mice. These two subclasses of antibody were chosen for examination because they are 
indicative of different types of immune response. IL-4 and IFNy have differentia1 effeds 
on a n t i i y  heavy chain class switching with IL-4 promoting switching to IgGl and 
IFNy favouring IgG2a production (Coffinan et al., 1993). As seen in Figure 4-2, the 
lower dose of BCG did not induce antiiy production in any of the three mice at 1 1 wk 
pi while the higher dose induced a strong a n t i i y  response at 1 1 wk pi. 
Table 4-1 shows similar results upon primary i.v. infection with BCG. In this 
experiment, mice were given saline or either a low dose or a high dose of BCG, by i.v. 
injection in the tail vein. AIthough, on average, the IFNy response was strongest in the 
high dose immunized mice, IL-4 was equally high in this group. However, the low dose 
immunized mice had a signitlcant IFNy response without the high IL-4 response seen in 
the high dose innntmized mice. Once again, in the mice that received the higher dose of 
rnyabactmia, there was a very strong mtiiody response while low dose immunized mice 
and the controls had very hale anti-BCG anti'body. G. Wei, using low dose vaccination 
by the S.C. raute, has achieved results similar to those shown here power et al., 1998). 
These results show that the immunizing dose has a signifitant impact on the 
immune response generated to BCG. Further experiments were designed to determine the 
stability of the immune response generated upon primary exposure to a low dose of 
mycobacteria, when the same mice were challenged with a significantly higher dose 
which induces a Th2 response in previously unexposed mice. Groups of mice were 
injected with d i f f l t  doses of BCG intradennally on the abdomen. A contml group was 
injected similarly with saline. AAer eight months, the mice were challenged with a higher 
dose of BCG, one which normally induces a mixed Thlm response in normal mice. 
Ten weeks Iater, mice were killed and the BCG-wfi~ cytokne response in the spleens 
of mice was determined by UISPOT assay. Figure 4-3 shows the results of this 
experiment. Mice that initially had been given lower doses of BCG showed a 
predominant FNy response even upon challenge with the high dose. However, those 
mice that had been given saline or rhe higher doses of BCG originally, had a mixed 
response upon challenge with the higher number of BCG. Similar results have been 
achieved by G. Wei afta s.c. vaccination with BCG (Bretscher et al., unpublished 
observations). The BCG-specific antibody titen as determined by EIA are presented in 
Figure 4-4. In this case, most mice had an a n t t i y  response after the challenge. 
However, the IFNydependent IgG2a antibodies predominated in the mice that received 
lower vaccine doses, while IgGl predominated in those mice that were given higher 
doses initially. The d t s  presented in Figures 4-3 and 4-4 are important in that they 
demonstrate that low dose vaccination is not ody capable of inducing a Thl response, but 
that under appropriate conditions, this Thl response is maintained even under conditions 
that would normally hwur a mixed T h l m  response. 
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Figure 4-3 Number of IFNy and Il4prodnCing BCG-specific cells present in the 
spleen of mice 10 weeks post-challenge with a high dose of BCG (2 xlOb) givea 
i n m y .  Each group of mice had been pre-expsed 8 months earlier to a differat 
dose of BCG admim'stered intn&mally as indicated in the abscissas. Open bars 
qmseat IFNy spots and hatched bars IL-4 spots of individual mice. * Indicates number 
of spots c 5 per 106 spleen cells. 
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Figure 4 4  Antibody titers in normal mice and mice p ~ x p o s e d  to BCG 
intradermally, 10 wk following an id. challenge with a bigh dose (2 x10) of BCG. Each 
group of mice had bcm prrcrposed 8 monh earlier to a different dose of BCG 
administered intradedy as indicated in the abscissas. Open bars repmxnt IgGl aud 
hatched bars IgG2a titers. * indicates MP of 100 or less. 
It should be noted that unimmunized mice sometimes &%it a weak antr'body 
response to BCG as they age. I believe that these mice have been exposed to 
mywbacterial species in their environment and that anb'bodies produced in response to 
these environmental mycobacteria cross-react with the BCG antigen used in the EIA. 
Indeed, the TB lab of the Department of Microbiology and Immunology has isolated a 
saprophytic mycobacted species, M. gordonii limn samples of the drinlang water of 
mice in the animal colony. I compared irnmunogtobuIin titers in mice immunized with a 
low dose of BCG with those of unimmunized control mice. The results are shown in 
Table 4-2. Although the distinction is not absolute, the data suggest that the low dose 
BCG vaccination has had an e f f i  in reducing the both the number of animaIs 
seroconvdg, as well as the amount of antiidy produced by these animals. 
Table 4-2 Smnversion rates and anthdy titas to mycobacterial antigens in low 
dose BCG-immunized and control mice. 
. . b 
Mean Titer of 
E.&Bmm Treatment No. Smposltrve ollositivq 
1 Control 11/16 400 
Low dose" 5/16 250 
2 Control 41 10 1600 
Low dose 1/10 400 
"Mice received approx. 4x 1 O3 BCG by id. injectioa All mice were 6 8  weeks of age at the 
time of irmnunization and serum antibody was measured by enzyme immunoassay at 10-1 6 
weeks post-immunization. The probability of semconversion was significantly greata 
among the conmI mice than among the low dose vaccinated mice (Chi-square d u e  = 6.47, 
DF = 1, p < 0.02) 
4.3 Discussion 
These results show the significant impact which vaccine dose has on the 
development of the immune response to BCG. Although there are many variables that 
can contriiute to the determidon of Th d fate and thus the nature of the immune 
response to mywbacteria, I betieve tbat controlling a single variable, namely dose, wiU 
reduce or eliminate the influence of many other variables. Consider the factor of genetic 
variability in a population. Different strains of mice mount very different types of 
immune responses to the same dose of BCG antigen. BALB/c mice generate a Th2 
response at a much lower dose than C57BL (Power and Bretscher, unpublished 
observations). Individuals among the human population, like inbred mouse strains, are 
likely to show similar differences due to genetic diversity. This seems to be an 
insurmountable problem. How can we ensure an & d v e  immune response in all 
individuals regardless of genetic diversity? A solution to this problem has been proposed 
by Bretscher (1992b). This hypothesis is based on the ability of live BCG organisms to 
replicate once injected as a vaccine. A suitably low dose of BCG will induce a Thl 
response in those individuals that are prone to respond to such a low dose. In other 
individuals, a low dose wilI not induce any inrmune response initially, but because the 
organism is alive and capable of replicating in the host, it will eventually reach a dose 
which will be deteaable by the immune system, at which point it will induce a Thl 
response. Thus, by immunizing with a suitably low dose of BCG, it may be possible to 
induce an appropriate Thl response in the majority of individuals vaccinated, regardless 
of their genetic predisposition. 
Another factor that has the potential to interfere with the efficacy of BCG 
vaccination is previous exposure to environmental mywbacteria Immune priming to 
mycobacterial antigens that cross-react with BCG has the potential to affect the response 
to subsequent BCG vaccination or exposure to M. tuberculosis. In the mouse colony, 1 
have noticed that it is more di£ficult to establish immune deviation in older mice. 
Furthermore, dose dependence to primary BCG vaccination is not as clear in older mice. I 
hypothesize that this is due to exposure of these mice to mycobacteria in their environment 
that estabtishes a non-exclusive Thl response (i.e., having a significant Th2 component) 
and subsequently prevents the low dose vaccine from establishing a Thl response. Based 
on the findings presented, I hypothesized that a low dose vaccine given at an early age 
may establish a Thl response that subsequently prevents the development of a Th2 
response upon natural exposure to environmental mycobacteria. If this were the case, I 
expect to see fewer of the mice given the low dose BCG vaccination developing antibody 
titas to BCG antigen than in the control group. Indeed, this is what we observed. The 
fact that low dose immunization at an early age seems to prevent seroconversion of mice 
naturally exposed to mycobactaia is a significant finding, in that it suggests an approach 
by which the negative influence of such exposure could be overcome. Because early 
exposure to BCG administered parenterally to mice reduces the chance of them 
developing a possibly harmful Th2 response, vaccination of infants with low doses of 
BCG may be a mechanism by which the negative influence of enviromental 
mycobacteria could be eIiminated or reduced. Establishing a bendcia1 immune imprint 
before the negative effect of exposure to enviroumental mycobacteria can occur may offer 
a solution to the problem. These results support neonatal BCG vaccination as an 
approach to circumvent any negative influences of exposure to environmental 
mycobactecid. 
It remains to be determined whether Iow dose vaccination with BCG will provide 
greater protection than the standard dose, or whether id. immunization can provide 
protection by natural challenge via the respiratory route. Many tines of &deuce suggest 
that it will. In animal studies, BCG administered by parenteral routes provides some 
protection to respiratory challenge with virulent M. tuberculosis, indicating that this 
method of immmkation provides a degree of protection at mucosaI sites. Secondty, 
some studies in humans have shown that BCG offers a high rate of protection h m  
development of TB after na- exposure to M. tubmculosis (Aronson et al., 1958; 
Ferguson, 1955; Hart and Sutherland, 1977). Thus, the standard means of vaccination is 
capable of inducing effective immune response at the site of idkction at least in some 
populations. Finally, in studies in cattIe, low dose immunization given subcutaneously 
was able to provide significant protection h m  challenge that mimicked natural infection 
(Buddle et al., 1995a; 199%). The results of these studies, together with the 
immunological evidence presented here, indicates that effective low dose vaccination of 
humans is a possibility. The Saskatchewan Research Centre for Elimination of 
Tuberdosis is initiating a human trial of the 6 c a c y  of neonatal low dose BCG 
vaccination here in Saskatchewan. 
I have previousfy suggested that individuals may develop TB as a result of two 
distinct types of failure by the immune system. Although this may be the case, iow dose 
vaccination wouId be appropriate for individuds prone to develop either type of disease. 
For those who wodd develop TB as a result of indicient Thl immunity, a low dose 
vaccine would induce an appropriate response so that upon exposure to M. tuberculosis, 
a stmnger ThI and more rapid response would be induced before the infection could 
s p d .  For those prone to develop a Th2 response upon infection with M. tuberculosis, 
Thl imprinting with low dose BCG vaccination would prevent the development of the 
damaging Th2 response. A single vaccination ptocol wodd be appropriate for both 
groups, eliminating the necessity to distinguish between them. 
Antigen load or dose is not a static parameter, and is dependent on several 
variables. For non-replicating organisms such as killed organisms, xenogenic red blood 
cells, or protein antigens ariministered by an immtmoIogist, the administered dose alone 
determines the immune response. For Iive vaccines, another facbr comes into play. the 
replication rate of the organism once it is introduced into the vaccinated host. For 
relatively sIow growing orgmkm such as leishmania parasites and BCG, the replication 
rate is not a problem, and small di fbaces in replication rate between strains can be 
overcome by varying the immuniziug dose. However, in the case of more rapidly 
dividing organisms such as Plasmodium sp., the replication rate is a concern. In this 
case, regardless of the number of otganisms administered, the rapid growth of the 
parasite results in a large number of organisms within a very short time (Taylor-Robinson 
and Phillips, 1998). This eflective dose results in a Tli2 response regardless of the 
i m m d g  dose. Thus, the low-dose vatxidon strategy will be an effective method 
for achieving a Thl response only when it is used with non-replicating or slowly 
replicating antigens. 
In most natural infections, the replication rate of the organism is likely to be the 
most prominent determinant of antigen load and hence of the resulting immune response, 
as initial infections are Likely to resdt from Iimited numbers of organisms. In an 
interesting set of experiments, North and Izzo demonstrated that one indicator of 
mycobacterial virulence is the initial in vivo replication rate. AU virulent strains of 
mywbacteria tested had an initial rapid rate of replication in vivo while avirulent BCG did 
not (North and Izzo, 1993). Therefore, it is possible that a rapid in vivo reptication rate is 
important formycobacterial pathogenicity by quickly establishing a Th2 response so that 
the mycobactaial species can escspe effective immune control. 
The results of experiments presented here have also shown that low doses of 
BCG can genetate an ''immune imprint1' such that, upon challenge with a dose that 
normally induces Th2 cells, a predominant Thl response is maintained. This immune 
deviation is a requirement if such a mcckdion strategy is to have any utility for 
vaccinating against organisms that are best contained by cell-mediated immunity. If the 
protective ThI response is not maintained upon natural challenge with the pathogen, then 
the vaccine will not be effective. Therefore, it is an important observation that a low dose 
of BCG not onIy induces a Thl response, but given sufficient time between vaccination 
and challenge, such an immune response becomes stable so that it can resist the influence 
of subsequent conditions which would n d y  lead to the development of a humoral 
response. 
The development of a stable immune response requires a considerable amount of 
time between vaccination with BCG and subsequent high dose challenge (3-4 months for 
BCG Montreal strain in BALBlc mice), before the immune response upon challenge is 
locked into a Thl mode. ChalIenging mice with a high dose before this time does not 
result in immune deviation, and the immune response is of a mixedThl/Th2 or 
predominant Th2 type (unpublished observation). I believe that the time required for 
establishment of stability in the immune response is necessary for the development of 
antigen-specific cells that can actually inhibit the a n t i i y  response. Current theories 
suggest that a simple T h l m  dichotomy is responsiible for establishing the exclusivity of 
the response. Once a strong ThI response is established, Thl cytokines such as INFy 
iuhiiit the generation of cells of the Th2 type* and vice versa. However, a study by 
Ramshaw et al. (1977) found that under conditions that favour generation of a DTH 
response, CDS' cells were generated that had the capacity to suppress anti'body responses 
to the same antigen upon adoptive h-ansfer to syngeneic mice. These results suggested 
that CD8" cells may be involved in establishing, and maintaining the stable Thl response 
and suppressing the Th2 response at the time of challenge. 
Characterization of the immune Response to a Foreign 
Protein Expressed in BCG 
5.1 introduction 
This chapter exmines the immune response in mice immunized with rBCG 
expressing the kgal protein. The purpose of this work was to evaluate the potential use 
of low dose vaccination with rBCG as a method to immunize against diseases for which a 
Thl response is protective. bgai was chosen as a candidate protein because it is known 
to be expressed in mycobacteia at levels which can induce an immune response. 
Furthermore, purified kgal is easily obtained from a commacia1 source at a reasonable 
cost and anti-ggal antifbodies could also be easily obtained. Mice were immunized with 
various doses of rBCG expressing the PgaI protein or with a high dose of BCG 
transformed with a control vector containing the gene for h e  HIV gag protein. The 
immune response to BCG antigen and to the kgal protein were assessed by ELISPOT 
and ELISA at lOwk post immunization. To dekmhe the stability of the immune 
response to the recombinant BCG, some mice were challenged with a high dose of rBCG 
16 wk after the initial i m m a o n  and their immune responses were assessed after an 
additional 16 wk as d e s c r i i  in the Materials and Methods section. 
5.2 Results 
It was necessary to ensure that pgal was indeed expressed in the mycobacteria 
that were transformed with the pMV361::lacZ plasmid. The western blot shown in 
Figure 5-1 demonstrates the expression of E. coli Pgal in BCG mycobactaia transfected 
with the pMV361:*acZ pIm*d. The protein content of the BCG lysate was estimated at 
2000 pg/ml by BCA protein assay, and 10 pl (approx. 20 pg of protein) was loaded. 
Staining of the fbgal band in lane 1 is estimated to be at least twice the intensity of that in 
lane 3. Therefore, @gal expression is expected to be approximately 2-3% of the total 
protein production in the rBCG. 
Figures 5-2 through 5-5 tepresent a preliminary experiment in which the immune 
response to rBCG expressing Pgal was assessed Figures 5-2 and 5-3 show the number 
of BCG- and bgal-specific IFNypducing cells in the spleens of mice 9 wk after 
immunization with different doses of rBCG. As predicted, immunization with both low 
and high doses of rBCG induced not only BCG-specific, but also pgal-specific IFNy- 
producing cells. This is encouraging because it indicates that not only is the bgai 
expressed in vivo, but also that expression is at a significant level to induce an immune 
response. Unfortunately, for this experiment, the results of the L-4 assay are not 
available due to a technicaI problem. However, a surrogate marker for a Th2 response is 
s m  anti'body, and as serum was collected, antt'body titers were determined for these 
mice. These results are shown m Figures 5-4. Regardless of the route of immunization, 
prominent a n t i i y  responses were only observed m the high dose immunized mice. I 
concluded that high doses of BCG induced a mixed Thl/TM response to both the BCG 
Figure 5-1. &gal is expressed in BCG transfected with pMV361:LacZ as detected by 
immunoblot. Lanes 1 and 2 contain I0 pl of lysate prepared h m  recombinant BCG 
expressing &gal (rBCGpgal) and BCG respectively as d e s c n i  in the Materials and 
Methods section. The protein content of the sonicate is estimated to be about 2000 p@mI 
as determined by BCA protein assay. Lane 3 contains 0.1 pg of a wrnmercid preparation 
of purified Pgal of approximate molecular weight, II6,OOO (Sigma Chemicals). 
Molecular weight markets are indicated by the atrowheads at the left, from top to bottom: 
maltose-binding protein-ggal(175kDa), maItose-binding protein-paramyosin (83 kDa), 
gIutamic dehydrogenase (62 kDa), aIdolase (47.5 kDa), triosephosphate isomerase (32.5 
kDa), and &lactogIobuIin A (25 Da). 
Figure 5-2. Number of IFNyproducing ails m the spleens of idviduai mice 
inrmunized with difExent numbers of rBCGPgaI by the i.d- route at 10 wk post- 
imrrrrmizadon, The values for salineinjected control mice are also shown. Open bars 
indicate the number of BCG responsive d s  while the black bars represent &gal 
responsive ceIls. 
Figure 5-3. Number of FNy-producing cells in the spleens of individual mice 
i m r n d  with diffetent numbers of rBCG$gaI by the i-v. route at 10 wk post- 
irmnunization. Opa bars iodie~a the number of BCG responsive cells while the black 
bars qresent &gal responsive cells. 
itself and to the pH, as this dose induced both' IFNy-producing T eels and a n t i i e s  to 
the BCG and the incorporated Mice given the lower doses of rBCG did not 
produce significant amounts of a n t i i e s  to either BCG or B-gal, but did have spleen 
cells that produced M y  in response to both of these antigens. These observations 
indicate that the mice receiving a low dose had ody a Thl response to the BCG as weIl as 
to the @ foreign protein. I proceeded to determine if the Thl response induced by 
the low dose of rBCG wodd be stable upon a subsequent challenge with a high dose of 
rBCG, which would induce a Th2 response in normal mice. The results of an experiment 
in which rBCG were given initially by the i.d. route and subsequently challenged by the 
same route are shown in Figure 5-5. In mice initially immunized with the tow dose of 
rBCG, a predominantly Thl response is maintained even after the chalIenge dose is 
given. In comparison, the control mice that received only the challenge dose have a much 
more prominent Th2 component to their immune response, as do those mice that were 
given a high dose of BCG initially. All mice immunized by the i.v. mute developed a 
mixed response in the spieen when Wenged with ahigh dose of rBCG by i.d. injedion 
(data not shown). Thus, it appears that low dose i.d. immunization provides a stable 
hmnune response when mice are challenged by this route. Intravenous immunization 
provides a strong Thl response when mice are given a low dose vaccination by this route; 
however1 this Thl response appears to be more easily deviated to Tb2 upon challenge by 
the heteroiogous route. 
To codinn these observations, a second experiment was carried out following a 
similar protocol. The results of this experiment are given in Figures 5-6 through 5-16. 
Figures 5-6 and 5-7 show the immune response to different doses of rBCG given by i-v. 
(Figure 5-6) and i d  (Figure 5-7) immunization. Once again, regardless of the route? 
high doses ofrBCG induce a mixed Thlm (both lFNy and IL-4) response, while 
Figure 514. IgGl and IgG2a anti'body response to pgal in serum of mice receiving 
2x10' rBCG by the i.v. aad i.& routes. These are the same mice depicted in Figures 5-2 
and 5-3. NegIigiile antiiy titers were observed in mice receiving lower doses. 
Anh'body titers were determined by enzyme immmoassay. IgGI (open bars) and IgG2a 
(black bars) 
2x1 o4 BCGBgal i.d. 
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Figure 5-5. IFNy and IL.4 responses to BCG and kgal of mice h n m d  with 
different numbers of rBCGPgal by the i.d. route and then challenged intdemdy with a 
high dose (2x10') ofrBCG. Mice were 6rst immunized with the number of BCG du as 
indicated under each graph. Afier 4 months, all mice were challenged with the high dose 
of rBCG. The control p u p  received the challenge dose only. in each case, the number 
of BCG and bgal qxd ic  IFNy and L4producing cells was determiwd by ELISPOT 
. - 
sixteen wk after adrrrrmstra . . tion of the challenge dose. Open bars - IFNy response to 
BCG; Black bars - IFNy response to pgal; Hatched bars - IL-4 response to BCG; 
Stippledbars - IL-4 response m p-gal. Where values are off the chart, the value and SD 
(in brackets) are given above the bar. 
iower dosa induce a pr&&tly 'I711 (IFNr) response to both BCG and the expressed 
pgal antigen. Mice immrmized witb BCG transformed with a control vector not 
expressing Pgal (Figwe 5-6) show no response to bgal while cells h m  control mice 
shown in Figure 5-7 do not respond to BCG-lysate antigen or bgal antigen. Figures 5-8 
and 5-9 show the IgGl and IgG2a titers to kgal d g e n  in the same p u p s  of mice. 
Oaly mice irnmrmized with the high doses of rBCG have significant titers to pgal 
indicating that the anhibody response is indeed attributable to immlrnization with 
recombinant BCG, and hat ody higher doses will induce a n t i i y  production. For 
comparison, the a n t i y  responses to BCG antigen in these same mice are incIuded in 
Figures 5-10 and 5-1 1. Once again, high doses of BCG are required for a n t i i  
production. 
Mice from each group were challenged four months after imrnrrnization with a 
high dose of rBCGPgal given i.d. to detamjlle the stability of the Thl response induced 
by the low dose vaccination. The immune response was assayed at 16 wk post-chalIenge, 
as opposed to 10 wk postchallenge as in previous experiments. Mice were assayed at a 
later time, not by design, but due to the unavailability of the ELISPOT plates. 
Mice that were immunized with low doses by the id. route (Figure 5-12) 
possessed a strong and stable Thl response to BCG antigen and to Pgal after the 
challenge with a high dose and the immune profile of these mice was distinct hrn that of 
the conml mice that received ody the challenge dose. However, results hrn mice that 
were chailaged by the i.d, mute a h  i.v. i m m ~ o n  were perplexing (Figure 5-13). 
Mice that were given the Iowest dose (2x103 dearly demonstrated no immune deviation 
as they showed a strong and even dominant IL-4 response, indicating that Thl immune 
Figure 5-6. immune response of individual mice after i.v. immunization with different 
doses of recombinant BCG (rBCG). Mice were hnmlrnized as indicated under each 
graph. Mer 9 wk, the mice were killed and the number of pgal- and BCG-specific 
IFNy- aad IL4podudng cells in their splaas was determined by ELISPOT assay. The 
response in mice given a high dose of BCG transfomed with a contml vector containing 
the HIV gag sequence is also shown. Opn bars - IFNy response to BCG; Black bars - 
IFNy response to Bgd; Hatched bars - IL4 response to BCG; Stippled bars - IL-4 
response to PgaL Where values are off the chart, the value and SD (in brackets) are given 
above the bar- 
Figure 5-7. Immune mpow of individual mice after i d .  immunization with different 
doses of recombinant KG. Mice were immuuized as indicated under each graph. After 9 
ark, the mice were Wed aud the number of @gal- and BCG-speific m y -  aud U.4 
producing alls in mdr sp1eens was demmined by E L I S P M  assay. The response in 
lrnimmunized control mice is also shown- Opm bars - IFNy rrspome to BCG; Black bars 
- IFNy response m w; Hatched bars - I L 4  response to BCG; Stippled ban- IL-4 
response to Where vdm are off thc chuS the d u e  and SD (in brackets) are given 
above the bar. 
Figure 54. Senrm a n t i i  responses of mice to bgal9 wk after immuni7ation with 
difkrent doses of K G  by the i x  route. Results for mice immunized with a high dose 
of BCG t r i i e d  with a control vector ate also shown. Open bars show IgGl titers 
while black bars depict I f i2a  tit-. 
lam 1 
- 
2x t o3 BCGBgJ i.d. 
Figure 519. Senan antl'body responses of mice to pgal9 wk after immuuization with 
diffkrent doses of r3CG by the i.d mute. The resalts for ~mimmrmized, age-matched 
controI mice are also shown Open bars show IgGI titers while black bars depict IgG2a 
titers. 
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Figure 5-10. Senrm a n t i i y  responses of mice to BCG antigen 9 wk after 
immunization with different doses of rBCG by the i.v. route. Results for mice immunized 
with a high dose of BCG mdiormed with a contro1 vector are also shown. Open bars 
show igGI titers while black bars depict IgG2a titers. 
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2x 1 03 BCG8gal hd. Cmrml. 
Figwe 5-11. Serum a n t ~ i y  responses of mice to BCG antigen 9 wk a f ta  
imm&atiou with diffaent doses of BCG by the i.d. mute. The Ciesults for 
unmwnmized, age-matched control mice are also shown. Open bars show IgGI titers 
whiIe black bars depict IgG2a titers. 
110 
Control 
Figure 5-12. Immune response of individual mice vaccinated with d i f i t  doses of 
rBCGpgal Pfta subsequent id. challenge with a high dose of rBCGpgal. Each group of 
mice was hdriany giwn an i.d. d o n  d o e  of rBCGpgd as indicated under afb 
graph. After 4 months, the mice were challenged with approximakly 2 xio7 rBCGPgal 
cfu given i.d- A h  an additional 16 w 4  the mice were killed and the number of PgaL 
aud BCG-qesific IFNy- and IL4producing cells in their spleens was dasmined by 
ELISPOT assay. Control mice rsdved th challenge dose only. O p  bars - IFNy 
~ t o B C G ; B l a c k b a r s - I F N y r e s p o ~ l s e t o  f3-gaI;Hatchedbars-IL4rrsponsem 
BCG; Stippled bars - IL4  respow m Bgd. Whae values are off the chart, the d u e  
and SD (in brackets) are givm above the bar. 
Figure 5-U. Immune response of individual mice vaccinated i.v. with diffueat doses 
of rBCG a f k  subsequent id.  challenge with a high dose of rBCGbgal. Each p u p  of 
mice was initially given an i.v. vaccination dose of a rBCG mdin as indicated under arb 
graph. After 4 months, the mice were challen@ wit6 a approximately 2 x10' rBCG$gal 
EfY 8iVQ i.b Ahz an additional 16 wk, the lnice w a c  killed and the number of bgd- 
and BCG-specific my- and IL4pmdudog cells m their spleens was determined by 
ELISPOT pssay. Opn bars - tFNy response to BCG; Black bars - IFNy response to B- 
gal; Hatched bars - IL-4 response to BCG; Stippled bsn - R4 response to PgaL 
imprinting in this p u p  was unsuccessll. The response from mice that were inrmunized 
with 2x1d tBCGBgal i.v. and then challenged with 2x10' rBCG$gal are strikingly 
different. These mice appear to have a very small T cell response to both antigens, a 
response qyite diff't from the control animals that were similady challenged. The 
reason for this is unknown. Perhaps at this dose, these mice developed an effective 
immune response and thus, were able to clear the challenge dose rapidly, leaving few 
remaining effector T cells at the time of testing, i.e., 16 wk instead of ten. 
The anti-ggal serum anh'body titers h m  the mice of Figures 5- 12 and 5-13 are 
shown in Figures 5 4  4 and 5-1 5 respectively. Note the prominence of IgG2a a n t i i y  in 
the serum of mice immunized with a low dose of rBCG before challenge, compared to the 
contro I. 
I wished to compare the immune response to kgal in mice imrnuaized with 
rBCGBgai and in mice immunized with purified fbgiil by other methods that would be 
acceptable for immunization of humans. Figure 5-1 6 shows the immune response in mice 
inrm- with purified &gal given as a soluble protein in saline or in alum as an 
adjuvant, the onIy adjuvant approved for use in humans. In both cases, immrrnization 
was by the i.p. mute. Soluble bgal did not induce a significant immune response in any 
of the mice immunized with this preparation. bgai in alum, however, induced a 
predominantly Th2 response in mice at even the low dose used. This is not unexpected as 
alum is particularly effective at inducing Th2 responses. However, these results 
exemplifjr potential problems in achieving a Thl response in humans with current 
vaccination procedures. 
Figure 5-14. Serum aut i iy  responses of mice to PgaI a f k  immtmization with 
different doses of rBCG by the i.d. route, and subsequent challenge with a high dose of 
rBCG by the same route. The results for unimmunized, age-matched control mice are also 
shown. Mice were irnmuuized initially with the dose of rBCG indicated below each 
graph. Mer 16 wk., all groups were challenged with 2x10' rBCG given intradendy. 
Saum was collected at the time the mice were killed, 16 wk after the challenge. Open bars 
show igG1 titers while black bars depict IgG2a titers. 
Figure 5-15. Serum a n b i y  responses of mice to bgal after immunization with 
different doses ofrBCG by the i.v. route, and subsequent challenge with a high dose of 
rBCG by the i.d, route. Results for mice immMited with a high dose of BCG 
transformed with a control vector are also shown. Mice were immunized initially with the 
dose of rBCG indicated below each graph After 16 wk, all groups were challenged with 
2x10' rBCG given mtradamaUy. Senrm was 001Iected at the time the mice were killed, 
16 wk after the challenge. Open bars show IgGl titers while black bars depict Igma 
titers. See Figure 5-14 for the response of n d  mice given only the challenge dose 
(Control), 
Figure 5-16. Number of IFNy- and IL4ptoducing ceiIs in mice immunized 
intraprkmeally with soluble bgal (A) and bgal adsorbed to alum as an adjwant (B). 
Soluble Pgal was i&mmted . - twice five days apart, while f)-gaVdum was administered 
only once. Mice were killed 11 days after the initial injection, and antigen-specific 
cytokine-producing spIeen cells were enumerated by ELISPOT assay. Open bars 
w e n t  IFNy spots and hatched bars represent IL-4 spbk 
5.3 Discussion 
These results demonstrate that @gal is expressed at significant levels after 
transformation of the BCG Montreal strain with pMV36k::pgal. Expression of bgal is 
much higher than that initially reported by Stover et al. (1991), who developed this 
plasmid and initially expresd &gal. No doubt this is due to BCG strain diffefences as 
has been reported previously (Burlei- et al., 1994). 1 have not estimated the in vivo 
expression of p g d  after injection; however, one study found that the activity of the 
hsp60 promoter in intracellular mywbacteria growing in cultured macrophages was 
similar to that of bacteria grown in broth culture (DelIagostin et al.. 1995). 
The dramatic effect that a simple variation in dose can have on the immune 
response to BCG is evident. I have shown, as have others, that rBCG is an efficient 
method for delivering antigen to mice. Not only do these results demonstrate a significant 
immune response to the recombinant protein, but unlike previous studies, they show that 
an ahnost purely Th1 response can be generated to the recombinant antigen by giving the 
rBCG at low doses. This is a very effective method for achieving this type of response in 
mice. Compare the immune response in mice immunized with soluble &gal, either in 
saline or adsorbed to alum, with that in mice immunized with low doses of rBCG$gal. 
Perhaps not unexpectedly, the mice did not mount an immune response when given the 
solubIe protein in saline, and they mounted a Th2 dominated response when given the 
aIum preparation. Assuming that vaccination with the recombinant BCG is able to induce 
a similar pattem of response in humans, low dose vaccination with tBCG will be a very 
efficient mechanism for achieving effective vaccination for diseases for which a Thl 
response is desired. 
There runain many diseases for which an effective vaccine is required. Some of 
these diseases remain a problem because cell-mediated immunity is r q u k d  to contain 
infection, and vaccines that induce stable and effective CMI have not been established. 
The use of rBCG as a vaccine vector for immunizing against such diseases has been 
pursued for some time. However, the use of low doses of rBCG to ensure a Thl 
response to the recombinant protein and subsequently upon exposure to a pathogen is 
novel and offers promise as a strategy to vaccinate against this type of organism. Three 
pathogens for which induction of a cell-mediated immune response by a low dose of 
rBCG o f f a  promise are influenza, HIV,  and Leishmania 
In consultation with my supervisor, Dr. Qualtiere, I decided that the infIuenza 
virus would be an appropriate model to assess the protective efficacy of low dose rBCG 
vaccination. The relative roles which a n h i y  and cell-mediated immunity play in 
immunity to viruses are dependent on the s p d c  virus. It is generally believed that 
antibody is more important for protection against cytopathic viruses while cytotoxic T 
cells are required for immunity to non-cytopathic viruses (Zinkemagel et al., 1996). In 
influenza virus infections, antibody is effective at limiting viral infiion and in preventing 
reinfection with a homologous virus, but not against viruses with heterologous surface 
giycoproteins, hemagglutinitn (HA) and neuraminidase (NA). The internai structural 
proteins of influenza, NP and matrix protein (MA) are highly conserved among viruses of 
the same type but due to their location within the virus membrane, antibodies against these 
proteins have no effect in viral clearance. The role of cell-mediated immunity and in 
particular CTLs in protection against and clearance of influenza infktions is poorly 
characterized. It is unclear whether a purely CMI response to this cytopathic virus will 
Iimit infection to a virus challenge. The most convincing evidence that cell-mediated 
immunity to influenza nucleoprotein is able to control an influenza infection comes h m  a 
paper by UImer et al. (1993). In experiments descn'bed in this paper, immunization of 
BALB/c mice with au influenza nucleoprotein DNA vaccine resulted m generation of both 
antiies and CTLs. Mice immunized in this way were protected against normally lethal 
chdenge with a heterologous virus. Furthermore, virus titers h m  lungs of imm- 
mice challenged with a sublethal dose of virus were dramatically Iower than those of 
unimmrmized mice. Transfer of antibodies &om immrmized to mimmunized mice could 
not provide any protection h m  heterntypic challenge in recipient mice. Subsequently, 
other studies have shown similar results (Bot et al., 1996; Fu et al., 1997). These results 
indicate that, at least under some conditions, CMI to conserved influenza proteins can 
provide protection against heterotypic virus challenge. Thus, antibodies recognizing 
conserved d c e  epitopes can provide protection against homotypic influenza challenge, 
but CTL. recognizing internal viral proteins can also provide protection from heterotypic 
viruses. 
However, infection with in€luenza virus does not always provide protection 
against viruses with antigenically different d a c e  glycopmteins, even though they have 
nearly identicd nucleoproteins and matrix proteins. I believe that this is due to the nature 
of the immune response that is generated upon exposure to influenza v i m .  If cell- 
mediated immunity but not a n t i i e s  can provide heterotypic immunity to influenza 
infedion, then conditions of immuukatioa that promote cell-rnediated immunity will be 
protective against heterotypic challenge, while those that induce an a n t i i y  response will 
be ineffective. Thl cells are more &cient inducers of CTL responses Than Th2 cells 
and firrthennore, Th2 cells inhibit the promotion of CTL. activity by Thl cells (Palladino 
et al., 1991). The &kt is likely mediated by IL-4 as this cytokine has been shown to 
reduce viral dearnee in influenza infx-ted mice when produced locally in the Iung in 
transgenic mice (Bot et a!., 2000) or after i-v. injection (Motan et al., 1996). Thl cells, 
on the other hand, are potent inducers of CTL. In mice, the ThllTb2 nature of the 
immune response to iduenza virus depends on a number of pameters including the 
strain of mouse used (Graham et al, 1998); the age of the mouse at the time of exposure 
(Bot et al., 1997) and the type of antigen exposure, i.e., Iive virus, inactivated virus or 
subunit vaccines. It has been suggested that live virus idkcti011 induces a prefaecltidy 
Thl response in mice whiIe, inactivated virus, which is currently used as the hrrman 
vaccine is bought to be more efficient for inducing a Th2 response (Moran et d., 1999). 
This may be me under standard conditions employed. However, d k t  comparisons 
between live and inactivated vinrs have not been made using a range of doses and similar 
routes of administration. 
I propose that, in those who become ill after infection with influenza, a response 
with a Th2 component that is predominantly directed against the surface proteins HA and 
NA, results in induction of a humoral immune response to these proteins. This Th2 
response inhibits the Thl response to the virus and deviates the immune response away 
h m  the internal proteins. I hypothesize that this occurs for several reasons. The first is 
related to the replication of the v im,  influ- being a very rapidly replicating cytopathic 
virus. The remlts presented here and the work of others (Lagrange et al., 1974; Parish, 
1972) have demonstrated that antigen dose has a dramtic e m  on the outcome of an 
encounter with antigen. postdate that the high antigen Ioad that the rapidly replicating 
influenza virus puts on the immune system results in immune deviation away h m  Thl, 
cell-mediated immunity towards a Tb2, hum& response. The imrnunodominant d c e  
proteins on the intact v i m  are also very efficient at stimulating B cells through the B cell 
receptor. The resulting humoral rqmnse is effective in neutralizing the virus. However, 
the anthody response to the d c e  glycoproteins is  probably induced at the expense of 
the CTL response to internal proteins. Cytokines produced during a strong Th2 response 
have been shown to counteract the Tht cytokines (Lehn et al., 1989; Sher et al., 1992). 
Studies of the CTL response to influenza in natural infection have identified CTLs specific 
for a number of epitopes of influenza proteins after infection with influenza, many of 
which are specific for NP. However, detection of cytolytic activity by these CTZs 
requkes in vitro restimulation with antigen (Yewdell and Hackett, 1989). This suggests 
that although NP-specific CTLs are present afta infection, their numbers or activity may 
not be at a signiscant level. Other studies have shown that Th clones specific for NP help 
in an m vivo a n t i  response to HA, but not for NP when T celldeficient nude mice 
are huuized with intact inauenza virus (Scherle and Gerhard, 1986). Similarly, T 
cells primed to internal components of influenza virus by immMization with influenza 
vErus particles from which the HA and NA spike proteins have been removed, are able to 
help in the antibody response to HA (Russell and Liew, 1979) when mice are i m m d  
with intact virus. This is because these proteins are on the surface of the vinrs, allowing 
than to bind to B cell receptors and activate HA-specific B cells. Once the virus is 
internalized and degraded, NP epitopes presented on MHC-class II-molecules of the B 
ceU, allow NP-specific Th cells to provide help to the HA-specific B cell. Internal 
proteins of intact viruses are unable to bind B cell receptors. Thus, the immune response 
is deviated not only towards Th2, but a h  towards the dominant HA and NA srafilce 
glycoproteins. 
The manner in which the immune system responds on first contact with the virus 
sets the stage for future encounters with heterotypic influenza viruses due to the 
phenomenon of "original antigenic sin" (Fazekas-de-St.-Groth and Webster, 1 966). 
Upon secondary exposure to the virus, the same type of immune response wii be 
generated as in the primary infection due to the recall response to conserved regions in the 
d a c e  glywproteins. Evidence suggests that this phenomenon may also fimction in the 
Cl"L response to viruses as well ( K I e n e r m ~ ~  and Zinkemagel, 1998). I propose that a 
cell-mediated immune response to internal virus proteins such as NP, is capable of 
providing protection against heterotypic viruses. Due to the dominance of the Th2 
response to HA and NA both in natrrml infection and in vaccination tesponses, the Thl 
and CTL memory responses are not strong enough to provide protection to surface 
glycoprotein variant viruses. I reason, therefore, that an immunization protocol that 
induces a Thl immuue response to c o m e d  influenza proteins would be effective in 
providing heterotypic immunity to influenza 1 believe that a recombinant BCG virus 
could accomplish this end. 
An effective HIV vaccine has yet to be developed. This virus, like influenza, hEts 
variant d a c e  glywproteins that mutate over time, and this diversity wntniutes to the 
ability of the virus to escape the na tdk ing  effects of anti'body. Unlike influenza, the 
virus can live for many years withia an infected host accumulating mutations within an 
iodividuai rather than a population, allowing the virus to escape successive waves of 
immune response. Vaccines that induce a humoral response to HIV are Wrely to be 
unsuccessful, because in order to prevent an infection, they must provide sterilizing 
immunity at the site of infection, an immune state that is very difficult to achieve. 
There is much evidence to support a strong role for cell-mediated responses in 
providing protection against HIV (Cao et al., 1995; Rowland-Jones and McMichaeL 
1995; Fowke et al., 1996). As in the case of influenza, a rBCG expressing conserved 
HIV proteins may achieve this end (Salk et al., 1993). 
The importance of the cell-mediated immune response in leishmania inf'tions has 
been established (Locksley and Scott, 1991; Locksley et al., 1999). BALBk mice are 
susceptiile to leishmania infdons with high numbers of parasites because they generate 
a Th2 response to this organism iastesd of the protective Thl response. CBA mice are 
resistant to infection because they generate a Thl response even at higher doses. 
However, when BALBIc mice are given a low dose of live leishmania parasites, they 
generate a protective Thl response and are subsequently immune to further infections 
with much higher doses of the parasite (Bretscher et al., 1992; Menon and Bretscher, 
1998). These experiments demonstrate the exquisite effectiveness of the low dose 
immunization strategy in another model system. 
However, vaccination of humans with live leishmania parasites is not a 
practicality, and a safer method that achieves similar resuits must be developed for 
v accinating people. Low dose vaccination with rBCG that express leishmania proteins is 
a promising alternative. In me expaiment, BALBIc and CBA mice were immunized with 
BCG expressing leishmania gp63, and then chalIenged with L Major promastigotes 
(Connell et aI., 1993). CBA mice spontaneously heal lesions, but some additional 
protection was provided by the rBCG vaa5mtion as lesions m these mice were smaller 
and healed faster thau in control mice. BAWc mice were not protected from challenge 
by the L. major promastigotes. I predict that Iow dose vaccination with the recombinant 
BCGgp63 would be much more effective in inducing immunity to leishmania in BALBlc 
mice than the dose that was used in this study, just as a low number of leishmania 
parasites provides protection where a high dose does not. I believe that BCG expressing 
leishmania parasite-antigens will be a safe and effective alternative to low dose vaccination 
with the parasite itself 
Cloning and Expression of Influenza Nucleoprotein in 
E. coli and BCG 
6.1 Introduction 
In an effort to determine if low dose vaccination with rBCG expressing the 
idueaza nucleoprotein could protect mice fiom subsequent infection with influenza 
virus, 1 attempted to clone the NP gene h m  influenza strain A/PR/8/34 and express it in 
BCG using the pMV361 plasmid. My intention of was to examine the immune response 
as well as the protective effect of NP expressed as a cytoplasmic protein in BCG. The 
plasmid pMV361 was chosen because it is a plasmid which integrates into the 
rnycobacterial genome, thereby ensuring stable expression of the foreign gene. 
6.2 Results 
The gene was successfully cloned h m  purified viral RNA and sequenced. 
Figure 6-1 shows the amino acid sequence of the NP protein as predicted fiom the cDNA 
sequence. By comparison with the original published sequence of this strain (Winter and 
Fields, 1981), five nucleotide differences existed between the two sequences. Oniy three 
of these resulted in amino acid substitutions as indicated in Figure 6-1. Cloning of the 
gene into an E. coli expression vector pTrcHis enabIed expression of recombinant NP as 
a h i o n  protein with a HiseTag in E. coli. Figure 6-2 shows lysate of E. coli 
trsnsfmed with pTrcHis::NP nm on imrnunoblot and stained with a monoclonai 
antiiy which recognizes the HisaTag. This figure shows that the fulI-length protein is 
Figure 6-1. Amino acid sequence of the cloned influenza rmcIeop10tein~ Shaded boxes 
indicate the amino acid differences between tbe original published sequence and 
Fields, 198 1) and the newly cioned gene, Open boxes indicate the position of adjacent 
arginine pairs. Underlined areas are regions containing T cell epitopes for BALB/c mice 
(Brett et al., 1991). 
Figure 6-2. Immtmoblot of E. coli iysate stained with a monoclonal a n h i y  that 
recognizes the HismTag on the NP protein. Lane 1 contains Ipte  h m  E. coli 
tmsfbmed with pTrcHis::NP. Lane 2 contains Iysate of E. coli Wormed  with the 
parent pIasmid done. The fd length product is ViSI'bIe m h e  1; however, many other 
d e r  protein products are a h  stained Molecnlat weight markers are indicated by the 
anowheads at the left, firom top to bottom: phosphoryhse B (97.4 ma), bovine s e m  
albumin (66 kDa), ovamumin (45 Da), d x m i c  axhydrase (3 1 kDa), soybean trypsin 
inhiitor (1 8.4 kDa), lysoyme (12.5 ma). 
produced, but that many other smaller p d u @  are also stained with the anti- HisoTag 
monoclonal anti'body. No bands are visi'ble in immmoblot of lysate from untraasforrned 
bacteria (Fig. 6-2), suggesting that the smaller protein products are truncated versions of 
the NP protein. Analysis of the cDNA sequence of the virus shown in Figure 6- I rweaIs 
a series of arginine residues throughout the sequence, In particular, five pairs of adjacent 
arginines are located within the ki t  200 amino acids of the gene. Analysis of codon 
usage in E. coli indicates that transfer RNAs (tRNAs) for arginjne are rare and, therefore, 
these arginine pairs (and perhaps other rare codons) may be responsible for n'bosome 
stalling resulting in incomplete protein products (Hormeache and Khan, 1996). Of 
course, another explanation for the truncated NP proteins is that they are the result of 
proteolysis. However, preparation of the lysate in conditions designed to limit pmteolytic 
cleavage, i-e., in the presence of protease inhibitors and at low temperature. did not 
change the banding pattern of the product, suggesting that proteolytic cleavage is not 
respomble for the multiple bands observed. Because the codom for arginine used in this 
gene require tRNAs that are rare in mywbacteria as well (Andersson and Sharp, 1996), 
this could present a problem for expressioa of the NP gene in BCG also. 
The NP gene was cloned into the mycobacterial expression vectors pMV261 and 
pMV361. Figure 6-3 shows the sequence of the junction between the Ew RI &don 
site in the pMV361 vector and the NP gene hgment The fragment is in frame, but 
expression of NP from BCG transformed with expression vectors containing the NP gene 
proved difficult BCG Wormed with pMV26I::NP did not form colonies suggesting 
that the NP protein may be toxic to the cells. Similar resuIts have been found for other 
proteins expressed in BCG. Colonies were formed when BCG was trandocmed with the 
genome integrating vector pMV361::NP; however, no significant expression of the gene 
could be detected either by immmobIot of the rBCG lysate or by an immune response to 
NP in mice after immunization with a higb dose of the rBCG. Thus, it seems that the NP 
protein is toxic to BCG and that the transformed organisms can only grow when the 
protein is not expressed, or expressed at very low levels. 
A C G T  
ATG GCC AAG ACA ATT GCG GAT CCA 
GCT GCA GAG TTC ATG GCG TCC CAA 
GGC ACC AAA CGG TCT TAC GAA . . . . 
Figure 6-3. Sequence of the junction between the pMV361 plasmid and the NP gene. 
A. Sequencing gel showing the junction between the plasmid and the NP gene insert at 
the Em RI restriction site (arrow). B. The NP gene is in h m e  with the ATG 
staa of the first six amino acids of the Hsp60. The Eco RI site is underlined. 
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6.3 Discussion 
These findings put some Iimitations on the ability to use low dose rBCG to 
vaccinate against influenza. Firstly, it appears that NP is not expressed efiiciently in 
BCG, at least fiom the vector of choice, pMV361. This may be due in part to codon 
usage. As in E. coli, tRNAs recognizing the codons for many of the arginine residues are 
rare in mywbaderia (Andasson and Sharp, 1996). This problem could be alIeviated by 
site-directed mutagenesis to change the offending codons. However, this wodd simply 
cause another problem since the expressed protein appears to be toxic to the mycobacteria 
To elimiaate the toxicity problem, there are several approaches one could take. First, by 
creating deletion mutants of the NP protein, one could try to determine the areas that are 
toxic to the bacteria Analysis of the functional domains of the protein may have some 
predictive value in determining these (Kobayashi et d., 1994). The influenza NP binds to 
iduenza RNA gene segments without sequence specificity (Baudin et al., 1994). It is 
IikeIy that the NP protein, when expressed in mycobacteria, will bind to the bacterial 
RNA inhiiiting n d  hction within the cell. Thus, ebnating portions of the gene 
coding for RNA binding portions of the protein might prevent the problem of toxicity. 
However, the areas of the NP protein which are responsible for RNA binding, the first 
200 amino acids (Kobayashi et d., 1994), are aIso immunologically important areas (see 
Figure 6-1). In particular, for BALB/c mice, which are H-2d. the only class I-restricted 
epitope lies within this area (Brett et id., 1991). Eliminating immunologidy important 
areas could significantly alter the ability of the immune system to respond 
Certaidy for human ncchtion purposes, it is preferable to have a recombinant 
vaccine that contains the entire NP sequence, as this wil l  have the greatest chance of 
containing qitopes recognized by T cells of all members ofthe popidation. This is what I 
attempted to do initially, but it m y  not be possi'bk For experimental purposes, it may be 
more practical to choose certain @topes of immunological impmtauce to a particular 
mouse strain such as BALBlc, and to express these peptides as a fusion protein with a 
protein that is well tolerated and expressed at reasonabIe Iewels by BCG. This would 
allow the testing of various hypotheses of the low dose rBCG vacdnation strategy, 
presumably without the complications of dealing with the intact protein. If this work is to 
continue, I suggest h t  this is the next logical step. However, for practical purposes of 
vaccinating humans, it would be interesting to explore the use of BCG vectors encoding a 
truncated form of NP, perhaps in combination with other conserved hflueaza proteins 
such as the matrix protein. 
7 General Discussion 
7 . 1  Implications of the Experimental Observations for 
Immune Class Regulation 
7.1.1 Dose as a Determinant of Immune Class 
The resuIts presented here should be of interest to those studying basic 
inrmuuological mechanisms in several respects. First of all, as in previous studies h 
this laboratory (Bretscher et al., 1992; Menon and Bretscher, 1996; Menon and 
Bretscher, 1 W), they demonstrate important characteristics of immune regulation that are 
not commonly recognized. The immune system seems to follow some very simple rules 
in responding to antigen. These simple rules dominate decision making by the immune 
system and it seems that many other variables, which have been determined to be 
important in immune class regulation, may be at least parhally secondary to antigen dose. 
The k t  that the immune system can respond to complex and simple antigens in simiIar 
ways, and that merely changing the dose of antigen administered can dramatically change 
the irmnunological outcome of antigen exposure, suggests that the physiochemical nature 
of the antigen is of less importance than the dose. In numerous vaccination studies using 
antigens of varied levels of complexity, b m  simple proteins to complex pathogens 
(Asherson and Stone, 1962; Parish, 1972; Bretscher et al., 1992; Bancroft et al., 1994; 
Menacci et al., 1996; Menon and Bretscher, 1998; Power et al., 1998), dose has proven 
to be the determining hctor in the type of immune response generated, with low doses 
inducing predominantly type I responses and higher doses inducing either type 2 
responses or mixed type Iltype 2 responses, A low dose of a protein antigen induces a 
DTH response, while higher doses result in antibody production (Parish, 1972). 
Similarly, admin&ation of relatively low numbers of XRBC (Ismail and Bretscher, 
1999; Lagrange et al., 1974), heat-killed Mycobactenurn vaccae (Rook et al., 198 1) or 
slowly replicating viable organisms such as BCG mycobacteria (this work and Power et 
al., 1998), or leishmania parasites (Menon and Bretscher, 1996; Menon and Bretscher, 
1998) initiates a Thl response while higher numbers induce either a mixed Thl/Th2 or 
predominantly Th2 response. Thus, the naturp and complexity of the antigen are 
subordinate to the dose of antigen administered in determining the class of immune 
response generated. This is not to say that the physiochemical nature of antigens is not an 
important factor in immune class regulation. This is evidenced by the tact that although 
low doses of both BCG and leishmania induce ThI responses, high numbers of 
leishmania parasites induce almost exclusive Th2 response while high numbers of 
mywbacteria induce a mixed response. This is most likely due to the preseuce of many 
immunomoduiatory molecules within the mycobacteria that exert their effects more 
strongly at high doses. However, the simple fact that low doses of many antigens can 
almost always induce a Thl response suggests that dose is dominant over the nature of 
the antigen. 
Similarly, dose of antigen appears to be dominant over the route of exposure as a 
k t o r  in determining the class of immunity that is generated in an immune response. In 
the various routes that have been assayed, i.v., S.C. and i-d., the type of response 
generated could be controlled simply by varying the dose of antigen, suggesting that the 
low dose strategy works independently of the route of administration. However, among 
the various routes, the antigen dose range differed- With i.v. administration of BCG, a 
low dose was in the range of 10'-lo3, while for the i.d. route it was at least ten fold 
higher. This is not unexpected as previous work has demonstrated that antigens are more 
effective immunogens when administered by some routes than by others (Lagrange et al., 
1974), most likely because the antigens have greater access to secondary Iymphoid 
organs. None the less, in all experiments reported here, a refatively low dose produced a 
predominant Thl response and a relativdy high dose induce a mixed ThliTh.2 response. 
This observation highti@ the importance of looking at the response to a fdl range of 
doses before discussing the ability of a parti& mute of immunization to induce a 
particular type of response. 
It must be noted that low dose Vaccinatioa to achieve a stable Thl imprint works 
only with non-replicating antigens when administered repeatedly over a number of weeks, 
or with an infection of a very slowly replicating organism. This is because it takes dme 
for the stable immune response to develop, and chronic, low level stimulation of the 
immune system is required during this time to prevent the development of a Th2 
response. 
Why should the immune system respond to [ow doses of antigen with the 
generation of a relatively exclusive Thl response? Consider that the irmnune system of 
mammals has co-evolved with various infectious pathogens. The immune system must 
have evolved not only mechanisms to deal with the various diverse pathogens, but also an 
ability to decide which mechanism is -ate for dealing with each organism t 
encounters. As it is impossible for a species to develop a mechanism for dealing with 
each particular pathogen @articularly before encountering it), the immune system must 
have developed a set of general d e s  to d o w  it to respond to the largest number of 
potential pathogens most effectively. In order to do this, the immune system must take its 
cues h m  the infecting organism in determining how it will respond These cues must be 
general properties shared by large numbers of organisms &at provide the immune system 
with clues about how to initiate an effective response. The clues are likely to be simple 
characteristics of the pathogen such as the site of infection, the site of replication of the 
organism (intraceUuIar vs. extrctcelldar), as well as the rate of replication of the organism. 
En some sites, catain classes of immunity dominate the response, i.e., at mucusal 
sites, immu11oglobutin-a (I@) production by B cells is strongly favoured- k, any 
antigen that is presented at a mucosal surface favours an IgA response regradless of the 
nature of the antigen. This makes sense because, regardless of the mture of the antigen, 
binding of IgA will allow it to be neutralized without the generation of a more damaging 
inflammatory response. None the less, wen in the jysfmintestinal tract, dose of antigen 
has a role to play in determining the T h l m  nature of the immune response (Bancroft et 
d., 1994). 
Similarly, the location where a pathogen resides in vivo has a significant influence 
on the type of immune response it induces. Intracellular pathogens are much more 
effective at inducing MHC-class I-restricted T cells than those that reside extracellularly. 
Protein antigens which are introduced into this compartment are also effective inducers of 
class I-restricted T cells (Moore et al., 1988). Thus, it is a characteristic of the organism, 
the Iocation in which it resides in vivo, which determines the efficiency of induction of 
this class of immunity. 
I believe that the immune system has evolved mechanisms for detamining which 
type of T helper response is appropriate for a given infection, and that the decision is 
based, to a large extent, on the amount of antigen which is "perceived" by the responding 
immune ceils. There is evidence to suggest that immuue responses follow a particular 
pattern, with Thlld-mediated immunity being induced first, followed hereafler by the 
Th2/humod response (Salvin, 1958). However, in many cases an exclusive Thllcell- 
mediated immune response is induced. I believe that the signal that tells the immune 
system to mount a Th2 response is a higher antigen load. There is a logical explanation as  
to why this should occur. In an initial infection, low antigen dose induces the initial Thl, 
cell-mediated response. If the infecting organism is a slow-growing organism, then the 
antigen load remains low and the immune response remains a cell-mediated one. Cd- 
mediated responses can be particularly effective for eliminating infecting organisms, but 
in the process, they can be very destructive to host tissues. When the number of infkchg 
organisms is small, the body can handle a limited amouut of tissue destruction in favour 
of elimirrllting the infection, a small sacrifice to ensure that the infection is contained. 
However, with an increased pathogen load, the tissue damage caused by a cell-mediated 
response becomes a much more serious problem, as the damage caused by the immune 
response may be detrimental or lethal to the host, a sacrifice too great for the benefits. 
Thus, at higher antigen loads, a humoral response which is less destructive to host tissues 
would be prefdle .  
Why should such dmc t ive  cell-mediated mechanisms exist if the humoral 
responses can eliminate an infection? The answer is related to the functional ability of the 
two different arms of the immune system. Cell-mediated responses can function at very 
low IeveIs of antigen stimulation. A T cell can be activated to perform same functions at 
extremely low levels of T cell-receptor (TCR) occupancy, while antibody-dependent 
complement-mediated cell lysis, for example, requires approximately 1 OS IgG molecules 
bound to a cell in order to be effective (Humphrey and Domashkin, 1969). This 
number is required to ensure the likelihood that two of them will be sufficiently close to 
allow for cross-linking of, for example Clq, the initiating component of complement. 
Thus, at low antigen load, cell-mediated immunity would be a functional effector 
mechanism, while at higher antigen loads a humoral response would be operational and 
far less damaging. 
7.1.2 Coherence 
The experimental results presented here and elsewhere (Bretscher et al., 1992; 
Menon and Bretscher, 1998; Power et aI., 1998; Ismail and Bretscher, 1999) also 
demonstrate another little com*dered characteristic of the immune system. The Th cell 
response to all epitopes physically associated with a discreet entity, be it a protein, a virus 
particle, a bacterium or parasite, will be regulated such that all responding cells wiII tend 
to have a similar helper phenotype. Such regulation is referred to as coherence 
(Bretscher, 1994) and I believe that it reflects the need to ensure that the host is able to 
mount a directed and effective immune response. If the immune system did not have such 
a mechanism to coordinate the immune response, I would expect that the response to each 
individual proteiu or @de of BCG would be different, i.e., thae would be both Thl 
cells and Th2 cells responding to each of the various epitopes in a protein and each of the 
proteins within the organism. This is not the case, as in mice immunized with a low dose 
of rBCG we see a predominantly, if not exclusive, Thl response to the expressed foreign 
protein bgal, indicating that a m m  to maintain a coherent response to each epitope 
of an individual protein must exist, Furthermore, as shown m chapters 4 and 5, the 
immune response to all proteins that are physically Linked as part of one entity, such as 
BCG, are coordinately regulated such that the Th cells responding to all individual 
epitopes of individual proteins tend to be of the same type. 
There are rational arguments as to why such a mechanism should exist. Consider 
an individual who is infected with a complex organism such as M. nrberculosis. This 
intracellular organism can be wntrolled by cell-mediated immunity, but a humoral 
response is ineffectual in ehinahg an infection. Furthermore, cytokines produced by 
Th2 celIs may stctually counteract the &ect of the ThI cytokines, thereby inhibiting the 
&kt of the srpptopriate immune response. Studies have also shown that the Ti12 
cytokine, IL-4, alters the function of the Thl cytokine TNF, mgking it more d-ctive to 
host tissues (Hernandez-Pando and Rook, 1994; Hernandez-Pando et at., 1997). Thus, 
it is imperative that the immune system is able to mount an appropriate type of response to 
all possiile epitopes of an dkting organism to ensure efficient clearance of that 
organism with the Ieast possi'ble damage to the host. If such a mechanism did not exist, it 
is hard to imagine how a directed and e&ctive immune response could be generated to 
any infectious organism. Understanding how coherence is maintained is aiticai to 
understanding hnmuue regulation. One theory suggests that coherence is established 
through T cell-T dl cooperation, and experimed evidence supports this theory 
(Bretscher, 1994). 
7.2 Factors that Influence T helper Responses 
The class of immunity that emerges in an encounter with antigen can be influenced 
by numerous variabies acting throughout the dedopment of the immune response. As 
the class of inrmAty often determines the efficacy of the immune response, an 
uadersbnding of immune class regulation is essential for effectual immune intenention in 
infectious diseases. This work demonstrates that mycobacterid dose is a significant factor 
in determining the ThllTb2 aature of the subsequent immune response. Knowledge of 
other fictors involved in the ThllIh2 he of ceUs, their mechanism of action and their 
relative importance at various stages of the immune response to pathogens, will provide a 
better understanding of disease pathoIogy and will ensure effective disease interventions. 
The following sections discuss some of these variables. 
7.2.1 Genetic Factors which Predispose individuals to 
Develop Polarized Immme Responses 
Inbred mouse strains demonstrate great variability in the type of immune response 
they generate upon exposure to Ieishmania parasites, an intraceIIular parasite that can only 
be controlled by a Thl response. BALM mice deveIop a Th2 dominated response and 
are unable to control infection when infected with relatively high n u m b  of parasites and 
are considered a susceptiile strain (reviewed in Locksley et al., 1999). Other strains are 
resistant to leishmania because they generate a Thl response and controI the infection 
when administered a similar number of parasites (Locksley et al., 1999). The genetic 
predisposition to develop poIarized Th respanses rdects the mbined effects of multiple 
genetic loci rather than a single gene (Bix et J., 1998; Cofhan and Beebe, 1998). 
Genes involved in the ThlRh2 decision following Ieishmania infkdion in mice include 
MHC-genes (Roberts et al., 1997), and those affectiag cytokine production (Bix et al., 
1998) and the ability to respond to cytddne signals (Gorbam et al., 1996). In humans, 
wceptiiility to mycobactexial infections has similar genetic associations (Altare et al., 
1998b; B o W e y ,  1999; Bothamley et al., 1989). 
In the leishmania model, genetic suscephibility or resistance are not absolute baits 
since curing Thl- or non-curing Tb2dominated responses can be generated in both 
"sus~ible" BALWc mice and "mistant" CBA mice simply by varying the dose of 
parasite administered (Bretscher et al., 1992; Menon and Bretscher, 1996; Menon and 
Bretscha, 1998). Therefore, a genetically diverse mouse or human population 
demonstrates considerable variability in the T h l m  nature of the response generated 
upon infection. However, it is probable that the large majority of individuals could mount 
either a Thl or Th2 dominated response depending on the conditions of exposure to the 
organism. 
7.2.2 The Cytokine Environment of T Cella 
IL-12 is the main differentiating cytokine for Thl cells (Abbas et al., 1996; 
O'Garra, 1998). Early exposure of activated Th ceils to IL-12 affects the regulatory 
elements of the IFNy promoter, d t i n g  in increased transcription of the IFNy gene 
((Zhang et al., 1998). Thus IL-12 produced by antigen-presenting cells can significantly 
increase the production of IFNy h m  T cells, and stimulate Thl cell differentiation- 
However, IL- 12 deficient mice are able to mount a Thl type response to virus infixtiom 
(Oxenius et al., 1999) and IFN-regulatory factor-1 genedisrupted mice which do not 
produce either LL-I 2 or interleukin 18 (IL-18) can m o m  a Thl response upon infection 
with plasmodium (Feng et al, 1999a). These studies suggest that while IL-12 is a potent 
inducer of Thl, it is not an absolute requirement for the development of the ThI 
phenotype, 
IL-4 is required for the differentiation of newly activated precursor T heIper cells 
@Th) cells to the stable IL4ptoducing, Th2 phenotype (Abbas et al., 1996; Bix et d., 
1998; OIGarra, 1998). Consequently, several groups have sought a non-T cell source of 
IL4 that could prime newly activated T celIs to produce IL-4 (OIGarra, 1998). However, 
simply because IL-4 activity is requid for development of cells with a stable Th2 
phenotype does not mean that newly activated Th cells require L-4 stimulation before 
they can produce L-4. ladeed, the newly activated T!I cell itself can be a source of IL-4 
that acts in an a u t o h e  manner to drive Th2 differentiation (Schmitz et al., 1994; Rincon 
et al., 1997; Bix et al., 1998; Coffinaa and von der Weid, 1999). Thus, IL-4 h m  an 
extraneous source is not obIigatory for Th2 differentiation. 
The mechanism by which IL-12 and IL-4 promote Thl and Th2 responses, 
tespectively, is as yet unclear. Whether such cytokines induce diffmtiation of pTh cells 
into polarized subsets or simply promote expansion of polarized clones is a topic 
receiving considerable attention (Cofian and Reiner, 1999; Reiner and Seder, 1999). It 
is probable that both mechanisms are involved. 
There are several situations in which the cytokiae environment is likely to play a 
significant role in the Thl/lQ nature of the immune response. 
i. Some pathogens, particularly bacteria, possess factors that directly 
stimulate cells to produce cytokines. These factors include bacterial cell wall 
components such as lipopolysaccharide (LPS) and mycobacterial lipoproteins 
(Brightbill et al., 1999; Watanabe et al., 1999), bacterial DNA CpG motifs 
(Bendigs et al., 1999, Cowdery et al., 1999), and toxins such as choIera toxin 
(Foss et al., 1999). LPS and a 19 kDa mycobacterial lipoprotein stimulate IL-12 
production in macrophages by binding to Toll-like receptors on these cells 
(Brightbill et al., 1999). Microbial DNA containing CpG motifi is a potent 
inducer of inflammatory responses, inducing production of IL-12 by cek of the 
monocyte lineage (Cowdery et al., 1999). Recent results have demonstrated that 
these sequences can also have direct effects on T cells, inducing lFNy (Iho et al., 
1999), as well as IL-2 production aud proIifaation (Bendigs et al., 1999). These 
immediate responses to pathogen components probably rdect employment by the 
immune system of an innate defense mechanism, and the early cytokine 
production could potentially iafluence the fate of Th cells. 
ii. Conversely, many pathogens are able to escape immune detection through 
their ability to exert negative influences on the immune response. Macrophages 
infected with mywbactaia demonstrate reduced ability to respond to IFNy- 
signaling (Hussain et al., 1999; T i g  et al., 1999). RetroviraI infection inhibits 
a-12 production by mouse dendritic ceUs or human peripheral blood 
mononuclear cells (Kelleher et al., 1999; Marshall et al., 1999) and a similar 
function has been demonstrated for leishmania phosphoglycans (Piedrafita et al., 
1999). In addition, LPS and its lipid A moiety have been shown to directly inhiit 
IL-4 pmduction in T cells (Watanabe et al., t 999). In such cases, the absence of 
differentiating cytokines could act to sway the immune response away fbm a 
protective one. 
iii. In an ongoing immune response or a secondary response to a pathogen, 
poIarized effector Th cells (em) are likely to be present during the initial ac?ivation 
of pTh ceils. Cytokines produced by these eTh cells could influence the fate of the 
newly activated cells maintaining a coherent response to the pathogen. Similarly, 
the lineage of APC involved in activating Th cells can influence their fite 
(Maldonado-Lopez et al., 1999; PuIendran et al., 1999; Rissoan et al., 1999; Saha 
et al., 1999; Stumbles et al., 1998). Generation of these different dendritic cell 
subsets involves exposure to distinct cytokines dtaing maturation, and results in 
cells with vastly different cytokine profiles (Kalinski et al., 1999; MaIdonado- 
Lopez et aL, 1999) and mrhce markers (Stumbles et al., 1998), which can, m 
turn, help to polarize Th cells. 
iv. Infections with pathogens such as Toxoplasmu gondii (Santiago et d., 
1999) result in very potent cytokine responses. It is probable that the cytokines 
produced by these cells influence the fkte of Th cells responding to non-cross- 
reacting antigens (see section 7.2.6). 
7.2.3 Streagth of Signal Model and Cell Cycle Control o f  
Cytokine Expression 
In many situations, the ThlA'h2 fate of cells is determined in the initial absence of 
exogenous polarizing cytokines such as IL-12, IFNy and IL-4. A model that descriies 
how the fate of Th c e k  is determined m such cases is necessary for developing a b e t t ~  
understanding of imrnune class regulation. The "strength of signal" model suggests that 
higher TCR occupancy and wstimulation are required to induce a Th2 response than a 
Thl response. Many experimental observations support such a model (Bretscher et al., 
1992; Cony et al., 1994; Brown et al., 1997; Power et al., 1998; Saha et al., 1998). 
Recent studies by Reins (Bird et at., 1998) and Hodgkin (Gett and Hodglun, 
1998) have suggested a mechanism by which ten cyde controI of cytokine expression 
could detamine ThlAlL? differentiation. Upon activation of pTh cells, initial expression 
of cytokines varies depending on ceIl cycle and cell division (Bird et al., 1998; Gett and 
Hodgkin, 1998). Upon stimuIation of naive CD4' cells, K-2 is produced before the ceil 
enters cell cycle, whiIe IFNyproduction requires progression of the cell into S phase. IL- 
4 is not produced mtiI ceUs have gone through three or mote rounds of replication even if 
IL4 is present in tk culture (Bid et al., 1998)- It has been suggested that chromatin 
restructuring, necemry to allow for subsequent traasaiption of some qtokine genes, 
takes place during cell division (Bird et al., 1998; Reiner and Seder, 1999). 
I espouse a model in which IL-4 production by T cells does not d e c t  a 
requirement for a definitive number of cell divisions, but rather a minimum rate of 
replication. For cells that do not meet this minimum rate of cell division, the defdt is a 
ThI phenotype while those that divide at or above this minimum rate of division begin to 
produce IL-4. At low levels of stimulation (TCR occupancy, wstimulation), the pTh cell 
is weakly stimulated and cell division progresses slowly. However, L-2 and IFNy are 
produced and IFNy stimulates IL-12 production by antigen-presenting ceIls. At low 
levels of stimulation, the Th cell does not reach the critical rate of cell division required for 
IL-4 production. Meanwhile, autocrine IFNy has a negative influence on the ability of the 
cell to produce IL-4, possibly through epigenetic modification of the L-4 gene andlor 
though regulation of transcription factors (Lederer et al., 1996). Under conditions of 
high antigen stimulation, the Th cell divides rapidly, quickly acquiring the ability to 
produce IL-4, which acts in an autocrine fashion to stimulate Th2 cell differentiation, 
7.2.4 The Dose and Nature of Antigen and Route of Infection 
In support of the strength of signal model, the initial dose of a simple antigen or 
complex organism administered to an anirnd has a significant effect on the outcome of an 
immune response, as discussed throughout this thesis and in many publications on the 
topic. None the less, results of dose response studies which have used transgenic mice 
are often opposed to the results discussed above, with high doses of peptide mediating a 
Thl response and low doses mediating Th2 responses (Grakoui et id., 1999; Rogers and 
Croft, 1999). Experiments involving urn-transgenic mice and intact antigens at 
physiologic concentrations are more likely to reflect the situation observed in n a r d  
iafectious. However, the differences between these two models deserve explanation. An 
attempt has been made to reconcile these obsenred differences (Rogers and Cro4 1999). 
7.2.5 Number of T cells Available to Respond 
The number of Th cells available to respond to a particular antigen is a central 
W r  in determining the fate of the responding Th cells (Mitchell et al., 1981; Powrie et 
al., 1994). BALBIc mice are susceptile to infection with leishmania when inoculated 
with a relatively high dose of the parasite. Nude mice reconstituted with I q e  nmbers of 
BALBfc lymphocytes are also susceptible. However, nude mice reconstituted with low 
numbers of BALBfc lymphocytes produce a h d n g  Th 1 response (Mitchell et al., 198 1 ; 
Powrie et al., 1994). These results suggest that more responding Th cells are required for 
devetopment of a Th2 response, whereas fewer Th cells favor development of Thl MIS. 
Similar d t s  have been achieved using XRBC as an antigen (Ismail and Bretscher 
1999). Reconstitution of M a t e d  mice with high numbers of syngeneic spleen cells 
results in a Th2 response upon immunization with a large inoculum of XRBC, while 
ceconstitution with lower numbers results in a Thl response. However, mice 
reconstituted with the higher number of lymphocytes developed Thl dominated responses 
when immunized with a low number of XRBC (Ismail N and Bretscher PA, unpubhshed 
data). Thus, Th celI fate is demmined by an interplay between the number of T cells 
available to respond and the amount of antigen to which they are responding, A model 
that explains how the number of responding T cells and the amount of antigen can 
conjointly regulate the Thl1Th2 fate of immune responses has been proposed (Bretscher, 
1996). 
7.2.6 Concurrent Infections 
Myabacteria are potent inducers of immune responses, having 
immunostimulatory properties, which promote Thl responses in particular. Vaccination 
with M. bovis BCG has been shown to sway subsequent immune responses towards the 
Thl pole. Schoolchildren who received BCG vaccination were less likely to develop 
atopic reachreachom t an were those who had not been vaccinated (Shirakawa et al., 1997). 
Similar results were observed in an d- model (Hen et al., 1998). Likewise, 
Toxoplasma gondii infection, which induces a Thl response upon infection of BALBJc 
mice, can prevent the development of a Th2 response and progressive disease upon 
infection with Leishmania major (Santiago et al., 1999). Conversely, helrninth 
infections which tend to induce potent type 2 immunity can divert Thl response towards 
the Th2 pole (Brady et al., 1999; MaIhotra et al., 1999; Stewart et al., 1999). These 
results suggest that a strong, ongoing systemic response can significantly influence the 
Thl1Tb2 nature of the response to an unrelated antigen. None the less, it is possible to 
achieve independent immune responses to non-cross-reacting antigens in the same 
lymphoid organ (Ismail and Bretscher, 1999). Therefore, the influence of these infectious 
agents on immune responses to non-related antigens reflects pathological effects of an 
overwhelming Section rather than a n o d  regulatory mechanism of the innnuue 
system. The mechanisrn(s) by which these potent immune responses exert their effects on 
responses to unrelated antigens remains to be detennind 
7.2.7 Concluding Remarks 
The work presented in this thesis illustrates the effect of vaccination dose on the 
outcome ofthe immune response to mycobactaia The work has important implications 
for both immune class regulation and vaccination. 
The experiments presented in this thesis demonscrate that vaccination dose is a 
dominant factor in deten;aining the Thlm nature of the immune response to BCG. This 
is a sigoificant observation that makes sense with regard to the functions of the various 
classes of immunity. The results aIso demonstrate the property of coherence in the 
immune response to compiex organisms (Bretscher, 1994). The immune system appears 
to have a mechanism for ensuring that the majority of T cells responding to a complex 
organism are of the same Th phenotype. Such a mechanism is important to ensure that an 
effective immune response is generated against the i n f i g  organism, 
Because TB is a disease which appears to be pteventabIe by a cell-mediated 
immune response, these d t s  suggest that BCG vacciaation for TB may be rendered 
more & t v e  by administering the vaccine at a low dose, as such vaccination would 
. . induce a response that is predominantiy of the ThI type. Furthermore, the adnumation 
of low doses of BCG at an eady age appears to reduce the effect of exposure to 
enviromnental mycobacteria on the immune response, suggesting an approach by which 
the probIem of exposure to enviromnental mycobactetia wuId be overcome. Due in part 
to the results presented here, the Saskatchewaa Research Center for the Elimination of 
Tuberculosis is undertaking a study to examine the efficacy of neonatal low dose BCG 
immunization in First Nation children. 
hmunization with recombinant BCG that express proteins of infectious agents 
has been a goal of researchers for some years. The method offers some promise as 
recombinant proteins expressed in BCG g e n d y  induce significant immune responses. 
I have demonstrated that low dose BCG vaccination induces a Thl response to the 
expressed foreign protein while higher doses, in this study and in others, induce a mixed 
Thl/Th2 response. I suggest that low dose inmnmization with rBCG may be a more 
effective alternative for vaccinating against organisms that can only be elbimed by cell- 
mediated immunity, such as HlV and leishmania, than inrmullzitlg with the higher doses 
used in most studies. Moreover, the methd may be useful in other special situations 
where induction of a cell-mediated tmmuue tespom would be beneficial, such as 
immunizing against the conserved proteins of influenza virus to provide hetemtypic viral 
immunity. 
The opportunity also exists to use r3CG expressing a number of proteins h m  
various pathogens as a mdtivalent vaccine. This would &ow for innnunization against 
numerous possiiIe pathogens with a single vaccine dose. As BCG is considered to be the 
safest vaccine in use today, the method may provide a safe means to ensure a potent 
immune response with minimal side effkcts. I m m ~ o n  with rBCG containing 
nmerous foreign proteins may not be necessary initially, as immunization with a low 
dose of non-recombinant BCG should be sufficient to establish immune deviation. 
Vaccination with rBCG expressing proteins from various pathogens could be carried out 
subsequently, as it is expected that the immune response to the recombinant protein would 
be similar to that induced against BCG proteins due to the property of coherence. 
There are many directions that future studies based on the work reported here 
could take. The observations presented here outline a property of the immune system that 
could be exploited in a variety of situations. The method offers promise for influenza 
vim vaccination and hture plans of Dr. Qualtiere include exp-on of portions of the 
NP protein and/or other conserved influenza proteins in BCG to determine the &cacy of 
this method in providing immunity to the virus. This model is intriguing because it offers 
the benefit of an animal model in which to determine protection. 
HIV is another virus for which this vaccination procedure has potential. Assessing 
protection of macaques from infection with simian immunodeficiency vim after 
immunization with rBCG expressing SIV proteins would be an appropriate model for 
assessing the potential of the low dose rBCG vaccination method for HIV (Salk et al., 
1993). Plasmids that express the SIV gag and env proteins have been acquired h m  
MedImmune. 
Expression of the leishmania gp63 surface protein in BCG has been achieved 
previously (Cornell et al., 1993). Immunization of B A W c  mice with rBCGgp63 gave 
IittIe protection against challenge with L w ~ r  promastigotes. In this study, a high dose 
of rBCG was used. I propose that a lower dose of rBCG would be more effective in 
protecting BALWc mice, as it is likely to induce a Thl response to the gp63 protein and 
hence provide protection to leishmania Moreover, if low dose BCG &tion with 
BCGgp63 is effective m deviating the immune response to gp63 towards Thl, it may 
even provide a mechanism for treating leishmania infections. 
There are applications for low dose rBCG vaccination outside of the field of 
infectious diseases. Using rBCG expressing allergens to achieve immune deviation of the 
Th response to these allergens to the Thl type may allow vacciaation against allergy. 
Exposure to BCG has been shown to divert the immune response to other antigens 
toward the Thl pole (Hen et al., 1998; Shirakawa et al., 1997). This is thought to be a 
comeqmce of immune regulatory properties of mycobacteria that can induce potent Th1 
responses. BCG immunized children were less likely to develop allergy thaa those who 
had not been vaccinated (Shirakawa et al., 1997). I believe, as originally suggested by 
Dr. Bretscher, that vaccination with rBCG containing genes for allergenic proteins would 
be extremely effective for preventing allergies. 
There is increasing evidence that many tumors contain tumor-@fit antigens 
(Boon, 1992; Gaugler et al., 1994). Immuaization with low numbers of rBCG 
expressing tumor-specific antigens may provide a means for vaccination against tumors. 
In conclusion, I believe that the experiments presented tmere will have extensive 
apptication and should provide many possibilities for fivther productive research. 
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